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Abstract 
Alzheimer’s disease (AD) is a progressive form of dementia, which currently 
has no cure. The metabolism of the amyloid precursor protein (APP) is an important 
determinant in the development of AD. APP is proteolytically processed either in 
the amyloidogenic pathway, generating the AD-causing amyloid-beta (Aβ) peptide, 
or in the non-amyloidogenic pathway which prevents the generation of Aβ. The role 
of four different proteins, BIN1, contactin 5, neurofascin and Thy-1, in the 
regulation of APP proteolytic processing was investigated. Contactin 5, neurofascin 
and Thy-1 have been shown to interact with APP, whereas BIN1 has been 
genetically related to AD by genome-wide association studies. Over-expression of 
each protein in cell lines showed that BIN1 and contactin 5, but not neurofascin or 
Thy-1, regulate the production of Aβ. Contactin 5 over-expression prevented Aβ 
generation by inhibiting cleavage of APP by the γ-secretase. Western blots of 
human brain samples showed that contactin 5 levels in the brain are not altered 
during aging or in AD. BIN1 over-expression decreased APP levels, and decreased 
Aβ, whereas BIN1 knockdown increased APP, suggesting that BIN1 redirects APP 
from processing in the amyloidogenic pathway to a compartment of the cell where it 
is degraded. BIN1 did not alter either Aβ uptake, or the endocytosis or cell surface 
levels of APP. BIN1 levels were shown to be reduced in the brain during aging and 
in AD. This has led to the hypothesis that during aging and AD, BIN1 levels 
decrease, so more APP is trafficked into the amyloidogenic pathway rather than 
being degraded, resulting in more Aβ generation so increasing the risk of developing 
AD. This is the first time a mechanism for the role of BIN1 in AD has been 
suggested. 
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1 Introduction 
1.1 Discovery of Alzheimer’s disease 
Alzheimer’s disease (AD) is a progressive form of dementia characterised 
by amyloid plaques and neurofibrilary tangles in the brain (figure 1.1) (Hardy 
and Allsop, 1991). It is named after Dr Alois Alzheimer, who discovered the 
disease in 1906. In 1901 Alzheimer observed a 51 year old patient, Auguste 
Deter, who presented symptoms such as loss of memory, delusions, and drastic 
mood swings. In 1906 when Auguste Deter died Alzheimer examined her brain 
and identified the plaques and tangles that are characteristic of the disease, and 
so was the first person to associate the symptoms of the disease with the brain 
pathology. 
1.2 Current therapies for AD 
Dementia affects 33.3 % of people over the age of 65 (figures from 
Alzheimer’s Research UK). AD is the most common form of dementia and 
currently there is no cure or treatment that will slow down or halt the progress of 
the disease: current therapeutics focus on treating just the symptoms of the 
disease. SSRI (selective serotonin re-uptake inhibitors) are frequently used to 
treat depression or anxiety in Alzheimer’s patients, while other psychiatric 
symptoms (such as delusions) are commonly treated with the drug Risperidone. 
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Figure 1.1 Pathological hallmarks of AD. Image showing Alzheimer’s 
pathology in the brain, an amyloid plaque is at the top left of the image 
surrounded by black tau tangles. Image taken from sciencephoto.com. 
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Cholinesterase inhibitors (such as Donepezil and Galantamine) can be used 
to prevent the breakdown of the neurotransmitter acetylcholine, and improve 
general cognition (Citron, 2002). The NMDA (N-methyl-D-aspartate) receptor 
antagonist Memantine has been used in severe AD cases (over-stimulation of 
NMDA receptors has been linked to neuronal death in AD) to improve cognition 
and motor skills (Lleo et al., 2006; Mucke, 2009). Both Donepezil and 
Memantine have been shown to improve cognition in patients with severe AD, 
cholinesterase inhibitors in mild AD, and currently no drugs can benefit 
cognition in patients with mild cognitive impairment (O'Brien and Burns, 2011; 
Howard et al., 2012). Although NMDA receptor agonists and choline esterase 
inhibitors induce a small improvement in cognition, neither of these are disease 
modifying drugs – they cannot alter the pathology of AD and so do not halt or 
slow down progress of the disease. 
1.3 Amyloid-β 
The amyloid plaques that are characteristic of the disease are composed of 
a peptide called amyloid-beta (Aβ) (Masters et al., 1985). Aβ is secreted from 
brain cells throughout life; however in AD, Aβ aggregates to form toxic species 
which kill surrounding neurons. It is the death of neurons leading to the loss of 
synapses and neuronal networks which causes AD. Aβ is secreted from cells in a 
monomeric form, however it can aggregate into oligomers (AβOs), which range 
in size and structure, from dimers and trimers to much larger multimers that can 
be up to 200 nm in size. AβOs can aggregate further forming Aβ fibrils, which 
eventually deposit as the plaques of Aβ seen in AD (Shankar and Walsh, 2009).  
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Aβ is generated from cleavage of a larger membrane spanning protein, 
amyloid precursor protein (APP). APP can be proteolytically processed by one 
of two mutually exclusive pathways (figure 1.2). APP can be cleaved initially by 
α-secretase to generate a secreted N-terminal fragment – soluble APPα (sAPPα), 
and a C-terminal fragment which remains in the membrane – C83/CTFα. The C-
terminal fragment is then cleaved by γ-secretase to generate p3 (a fragment 
which is secreted), and the C-terminal stub called amyloid precursor protein 
intracellular domain (AICD). This is the non-amyloidogenic pathway; 90 % of 
the APP in the cell is processed in the non-amyloidogenic pathway (Gandhi et 
al., 2004). Alternatively APP can be cleaved first by β-secretase, to generate the 
secreted fragment soluble APPβ (sAPPβ) and the β C-terminal fragment – 
C99/CTFβ. The C-terminal fragment is then cleaved by γ-secretase to generate 
Aβ (the toxic fragment implicated in AD), and the C-terminal stub AICD (Evin 
and Weidemann, 2002; Vardy et al., 2005). Under normal circumstances only  
10 % or less of the APP in the cell is processed in the amyloidogenic pathway 
generating Aβ. The exact location of cleavage in C99 by γ-secretase varies 
generating Aβ molecules of varying lengths. The most important Aβ species for 
AD are Aβ40 and Aβ42 (40 and 42 amino acids long, respectively). Longer Aβ 
species are more prone to aggregation and are more toxic (Pike et al., 1995; 
Klein et al., 1999). The proteolytic processing of APP is discussed in further 
detail in section 1.6. 
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 Figure 1.2 Proteolytic processing of APP. APP is processed on either the 
non-amyloidogenic pathway (left) or the amyloidogenic pathway (right). On the 
non-amyloidogenic pathway APP is cleaved initially by α-secretase, generating 
sAPPα and C83/CTFα. CTFα is then cleaved by γ-secretase generating p3 and 
AICD. On the amyloidogenic pathway APP is initially cleaved by β-secretase, 
generating sAPPβ and C99/CTFβ. CTFβ is then cleaved by γ-secretase generating 
Aβ and AICD. The Aβ peptides can build up and aggregate forming the plaques that 
are the hallmark of AD. 
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1.4 The amyloid cascade hypothesis 
The amyloid cascade hypothesis proposes that the primary cause of AD is 
aggregation of the amyloid-β peptide, and has been the most widely accepted theory 
in the field since it was proposed in 1991 by John Hardy and David Allsop (Hardy 
and Allsop, 1991) then updated by John Hardy and Gerry Higgins (Hardy and 
Higgins, 1992). Since then it has been re-appraised several times by John Hardy and 
Dennis Selkoe (Hardy and Selkoe, 2002; Hardy, 2006). There are two forms of AD, 
familial/early onset AD (FAD) and sporadic/late onset AD (SAD). Both FAD and 
SAD are characterised by build up and deposition of amyloid in the brain, but FAD 
occurs earlier in life (around 50 years as opposed to 80). FAD is caused by 
inheritance of dominant mutations in genes which drastically increase the production 
or aggregation of the Aβ peptide (Murrell et al., 1991; Citron et al., 1992; Tomita et 
al., 1997; Su and Ni, 1998). It is this observation that forms the basis of the amyloid 
cascade hypothesis. Hardy, Higgins and Selkoe proposed that in FAD mutations in 
the APP and presenilin genes (the presenilin proteins form part of the γ-secretase 
complex involved in the production of Aβ) cause increased production of Aβ42, 
which then accumulates and aggregates. These aggregates have subtle detrimental 
effects on synapses and activate microglia, which then cause synaptic injury, 
altering signalling pathways in neurons so altering the activities of kinases and 
phosphatases. This leads to, among other things, hyperphosphorylation of tau 
protein. Hyperphosphorylated tau aggregates and is unable to perform its normal 
function: stabilising microtubules. The combined effects of altered signalling 
pathways, hyperphosphorylated tau, and activated microglia causes neuronal death, 
resulting in dementia (figure 1.3) (Hardy and Selkoe, 2002; Ballatore et al., 2007). 
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The amyloid cascade hypothesis is also applied to SAD, though the initial event that 
causes increased levels or increased aggregation of Aβ is yet to be determined. 
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 Figure 1.3 The amyloid cascade hypothesis. Mutations in APP or presenilin 
proteins (in FAD), or an unknown initiating event (in SAD) cause a build up and 
aggregation of the Aβ peptide. The Aβ aggregates are toxic to neurons (shown in 
yellow), causing neuronal death and dystrophy, synaptic loss, and activate microglia 
(the immune system cells of the brain, shown in blue, active microglia are shown in 
red) stimulating an inflammatory response. The activated microglia and Aβ 
aggregates activate stress pathways in neurons altering kinase and phosphorylase 
activity causing the microtubule binding protein tau to become 
hyperphosphorylated. Hyperphosphorylated tau no longer binds to microtubules 
causing them to become de-stabilised, and aggregates to form neurofibrillary tangles 
within the neuron. This causes further damage to the neuron and disrupts transport 
around the cell, causing further neuronal loss and activation of microglia. 
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1.4.1 Critical analysis of the hypothesis 
Since its proposal there has been a lot of criticism of the amyloid cascade 
hypothesis. Many people argue that it is out of date and amyloid toxicity alone 
cannot explain the development of AD. This has lead to several attempts to update 
and modify the amyloid cascade hypothesis making it specific for sporadic AD, and 
to accommodate new findings. For example it has been suggested that amyloid 
deposition along with some initiating injury (such as head trauma, diabetes, life 
stresses or vascular events) cause a chronic inflammatory response in the brain. This 
inflammatory response triggers a shift in cellular physiology re-initiating cell cycle 
proteins (which are normally turned off) putting these neurons at an increased risk of 
death (Chen et al., 2010; Herrup, 2010). However it should be pointed out that the 
initiating injuries proposed to cause cell cylcle re-initiation can also cause chronic 
hypoxia in the brain. Chronic hypoxia has been linked to AD, as it causes an 
increase in generation of Aβ peptides which then dyrupt calcium homeostasis of 
neurons (Webster et al., 2006; Peers et al., 2007; Peers et al., 2009), providing and 
alternative explanation for the link between these “initating injuries” and 
development of AD. 
Many people have also argued that hyperphosphorylated tau aggregates rather 
than Aβ are the primary cause of AD, but there is a significant volume of evidence 
supporting the amyloid cascade hypothesis. For example, mutations in presenilin 
proteins and APP that increase Aβ42 or alter the ratio of Aβ40 and Aβ42 cause familial 
AD (Murrell et al., 1991; Citron et al., 1992; Tomita et al., 1997), and recreating 
these mutations in mice causes amyloid pathology (Masliah et al., 1996; Su and Ni, 
1998) as well as AD-like symptoms (such as memory deficits) demonstrating that 
altered amyloid metabolism alone is sufficient to cause AD. Aβ is an aggregation-
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prone peptide and exists in a natively unfolded conformation – it is well known that 
aggregation-prone molecules can be detrimental to the survival of cells, and Aβ has 
been shown to be toxic in tissue culture models (Lambert et al., 1998; Grace et al., 
2002) suggesting it is the toxic causative species of AD. Mutations in tau do cause 
dementia, but do not cause any amyloid deposition. Tau tangles occur in other 
neurodegenerative diseases suggesting that in AD tau pathology occurs downstream 
from amyloid pathology (Oddo et al., 2003; Bolmont et al., 2007). Furthermore, 
introducing APP mutations into transgenic tau mice increases the number of 
neurofibrillary tangles (NFT) of tau, further confirming that amyloid pathology can 
induce tau hyperphosphorylation and NFT formation (Hardy and Selkoe, 2002; 
Hardy, 2006). Neurons derived from fibroblasts taken from AD patients have been 
reverted back into stem cells, then re-differentiated into neurons. In some cases these 
neurons secrete increased levels of Aβ compared to control cells, and have increased 
levels of phosphorylated tau, confirming the importance of both amyloid and tau 
metabolism in development of AD pathology (Israel et al., 2012). A major criticism 
of the amyloid cascade hypothesis is the existence of non-demented individuals who 
have extensive amyloid and tau pathology in their brains, yet lack any symptoms of 
AD. Recent evidence, though, shows that they do not have oligomeric forms of Aβ 
at the synapses whereas patients with AD pathology and AD symptoms do 
(Bjorklund et al., 2012) suggesting that both the aggregation state and location of Aβ 
is important for the development of the disease. Some of the most convincing 
evidence in support of the amyloid cascade hypothesis comes from the very recent 
discovery of a mutation in APP that is protective against AD. The A673T mutation in 
APP decreases β-cleavage of APP and so decreases Aβ generation (Jonsson et al., 
2012). The mutation was shown to be enriched in a group of people over the age of 
85 without any form of dementia compared to over-85s with AD, demonstrating that 
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preventing Aβ generation can protect against AD in the human brain (Jonsson et al., 
2012). 
However, unanswered questions remain about the amyloid cascade hypothesis. 
Aβ load does not correlate well with severity or progression of AD, Aβ plaques have 
been identified in cognitively normal patients, and although drugs designed to 
reduce Aβ load or Aβ aggregation have been successful in AD mouse models, they 
have not been successful in humans. Despite years of research and drug 
development no amyloid altering drugs have passed clinical trials for AD 
(Pimplikar, 2009), demonstrating that there is still much to learn about the 
development and pathogenesis of AD.  
1.5 The metabolism of amyloid precursor protein 
1.5.1 APP isoforms and homologues 
Aβ is generated from proteolysis of the transmembrane protein APP. APP is 
located on chromosome 21 (21q21) and is highly conserved (Goldgaber et al., 1987; 
Kang et al., 1987; Robakis et al., 1987a; Robakis et al., 1987b) suggesting it carries 
out vital functions in the cell. There are several isoforms of APP; the main isoforms 
are 695, 751 and 770 (695, 751 and 770 amino acid residues long respectively) 
(Ponte et al., 1988). The 751 and 770 isoforms are expressed by most cells, whereas 
the 695 isoform is predominantly neuronal (Weidemann et al., 1989; Kang and 
Muller-Hill, 1990). The 751 and 770 isoforms contains the kunitz inhibitor domain 
(Ponte et al., 1988). APP comes from a superfamily of proteins: there are APP 
homologues in other species as well as the human homologues amyloid precursor-
like protein 1 and amyloid precursor-like protein 2 (APLP1 and APLP2) (Wasco et 
al., 1992; Sprecher et al., 1993; Wasco et al., 1993; Webster et al., 1995). APLP1 
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and two have a similar structure to APP, they have similar alternative splicing 
(Sandbrink et al., 1994), they are phosphorylated and glycosylated in a similar way 
to APP (Suzuki et al., 1997; Eggert et al., 2004), and they undergo similar 
processing events to APP. APLP1 and 2 are cleaved by the APP α-secretases, 
BACE1 and γ-secretase (Gu et al., 2001; Scheinfeld et al., 2002; Walsh et al., 2003; 
Eggert et al., 2004; Li and Sudhof, 2004; Endres et al., 2005; Cong et al., 2011; 
Hogl et al., 2011). γ-secretase cleavage of APLP proteins generates an intracellular 
transcriptionally active fragment which is translocated to the nucleus (Scheinfeld et 
al., 2002; Walsh et al., 2003; Li and Sudhof, 2004), like AICD generated from APP 
(for details about AICD see section 1.7.2). Unlike Aβ, the fragments generated from 
the APLPs following proteolytic processing do not aggregate and are not toxic 
(Eggert et al., 2004; Minogue et al., 2009). The expression of APP, APLP1 and 
APLP2 all overlap in the brain (Crain et al., 1996; McNamara et al., 1998) 
suggesting they have redundant or overlapping functions, however knockout mice 
show subtly different phenotypes, and there are differences in the subcellular 
localisation of APP and APLPs demonstrating that there are differences in their 
functions (Kim et al., 1995; Heber et al., 2000). 
1.5.2 The physiological function of APP 
The normal role of APP in the cell is still unclear, though many functions have 
been proposed. Much of the evidence for physiological functions of APP comes 
from knockout studies of APP homologues in other species. Since the phenotypes 
caused by knockout of APP homologues can often be rescued by expression of 
human APP (Luo et al., 1992) it is reasonable to assume that its functions are 
conserved. It has been suggested that APP may have a role in development – for 
example blocking APP with an anti-APP antibody can prevent induction of neuronal 
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differentiation of embryonic stem cells (Freude et al., 2011), and knockout of the 
Caenorhabditis elegans homologue of APP, APL-1, causes larval death due to 
disrupted development of the larvae (Hornsten et al., 2007). Over-expression of 
human APP and APLP proteins in Drosophila melanogaster affects the development 
of mechano-sensory organs (e.g. the sensory hairs on the insect’s legs) (Merdes et 
al., 2004). APP may also have roles in stem cell differentiation and development of 
neurons (Hiltunen et al., 2009). Knockout and over-expression studies of the 
Drosophila APP homologue APPL have shown that APPL has a role in the 
development of synapses and in the transport of both organelles and proteins along 
axons, indicating APP may be involved in the development and the normal 
functioning of neurons (Torroja et al., 1999; Gunawardena and Goldstein, 2001). 
APP can bind several cell surface proteins, so may perform this function by acting 
as a receptor or through signal transduction. APP has been shown to promote 
synaptogenesis by functioning as an adhesion molecule; Wang et al. (2009) 
proposed that APP has a role in the formation of synapses at the neuromuscular 
junction via direct interaction between APP at the synapse and muscle (Wang et al., 
2009). APP can also bind to glycosaminoglycans and collagens so may be important 
for cell adhesion and neural outgrowth (Evin and Weidemann, 2002).  
APP has been shown to be involved in the regulation of endocytosis of the 
choline transporter. The choline transporter removes choline from the synaptic cleft, 
so APP may regulate acetylcholine metabolism (acetylcholine is a neurotransmitter 
with roles in learning, memory and muscle control) (Wang et al., 2007). APP can 
reduce Cu2+ to Cu+, so may be an anti-oxidant (Evin and Weidemann, 2002). APP 
can also bind Fe2+ and facilitates its oxidation it to Fe3+, and loss of APP expression 
causes iron accumulation so it has been suggested that that APP acts as a ferroxidase 
in neurons (Duce et al., 2010). 
- 14 - 
1.5.3 APP knockout mice 
APP knockout mice have been generated (Zheng et al., 1995; Zheng et al., 
1996). These were shown to be fairly normal: they had normal brain structure, and 
were fertile, however the brains of some mice displayed reactive gliosis (activation 
of microglia which suggests there was some neuronal damage) and all knockout 
mice had decreased body weight, decreased grip strength and decreased locomotor 
activity. Mice with the APP gene disrupted (by insertion of a neomycin resistance 
gene) also show these phenotypes, however unlike the APP knockout mice they did 
not have normal brains – some mice did not have a corpus callosum, and the mutant 
APP mice performed less well than wild type in a Morris water maze test (Muller et 
al., 1994). A possible explanation for the discrepancy between these studies is that 
the neomycin insertion mice were not complete knockouts for APP – they expressed 
very low levels of a truncated form of APP.  
The single knockout studies suggest that either APP does not have a major 
physiological role or that its functions are conserved by another protein. This idea is 
backed up by knockout of other members of the APP protein family. Knockout of 
APLP2 in mice did not cause any drastic phenotypes – the mice were fertile, of 
average size, were not cognitively impaired and displayed normal axon outgrowth. 
However 80% of APP/APLP2 double knockout mice died within a week of birth, 
the mice that survived were decreased in weight and displayed ataxia, trouble self 
righting, and developed gliosis by 9 months of age (von Koch et al., 1997) 
suggesting that APP and APLP2 can substitute for each other functionally in the 
brain. Although there were no gross changes in the phenotype of APP knockout 
mice, later studies identified several subtle deficits such as in increase in sensitivity 
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to seizures (Harper et al., 1998; Steinbach et al., 1998), altered neuron morphology 
and decreased synaptic plasticity (Seabrook et al., 1999),  
1.5.4 APP synthesis and trafficking in the secretory pathway 
APP is a single span transmembrane protein with its C-terminus on the 
cytoplasmic side of the membrane (Dyrks et al., 1988; Yamazaki et al., 1995). It is 
synthesised in the cell body on endoplasmic reticulum ribosomes, then is trafficked 
through the secretory pathway to the cell surface of axons. Once it reaches the cell 
surface APP is endocytosed and either recycled or degraded (figure 1.4) (Tienari et 
al., 1996). APP is synthesized in an immature form, which matures when it is N-
glycosylated in the ER and O-glycosylated in the Golgi (Dyrks et al., 1988; Pahlsson 
et al., 1992; Saito et al., 1993; Graebert et al., 1995; McFarlane et al., 1999) and 
sulphonated, (Schubert et al., 1989) increasing the molecular weight by 4-5 kDa 
(Graebert et al., 1995). Most APP then remains stored in the trans-Golgi network 
(TGN) (Weidemann et al., 1989; Graebert et al., 1995). N- but not O-glycosylation 
is required for cleavage of APP by the secretases and secretion of the soluble APP 
fragments (Yazaki et al., 1996; Tomita et al., 1998; McFarlane et al., 1999) (though 
it is not clear whether N-glycosylation of APP itself, or N-glycosylation of other 
proteins is required for the normal trafficking of APP (Pahlsson and Spitalnik, 
1996)). APP is transported from the Golgi to the cell surface, then endocytosed in a 
clathrin-dependent manner (Culvenor et al., 1995; Jung et al., 1996; Marquez-
Sterling et al., 1997; Cossec et al., 2010). 
The majority of APP is recycled back to the cell surface, but some APP is 
trafficked to endosomes (the acidic compartment where β-cleavage occurs 
(Schrader-Fischer and Paganetti, 1996)), or to lysosomes where it is completely 
degraded (Caporaso et al., 1992; Lai et al., 1995; Yamazaki et al., 1996). γ-cleavage 
- 16 - 
of APP occurs after β-cleavage, and has been reported in a number of subcellular 
locations (Kaether et al., 2006). Very little APP is found at the cell surface at any 
given time – it is either very rapidly endocytosed (70 %) or cleaved by α-secretase 
(30%) (Koo et al., 1996). The half life of APP is relatively short (3.5 hours), APP is 
glycosylated (so becomes the mature form) within two hours of being synthesised, 
and is transported along the axon to the synapse on the fastest wave of axon 
transport, and is degraded within 2-4 hours of glycosylation (Lai et al., 1995; 
Lyckman et al., 1998).  
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 Figure 1.4 Amyloid precursor protein trafficking. APP is synthesized in the 
rough endoplasmic reticulum (ER) then transported to the Golgi where it is 
glycosylated and sulphonated to become the mature form of the peptide (1). Most of 
the APP in the cell resides in the trans-Golgi network (TGN) (2). APP is trafficked 
to the cell surface (3), when it reaches the cell surface some is cleaved by α-
secretase generating sAPPα (4), but most is re-endocytosed (5). After endocytosis 
APP can be transported back to the TGN (6) or is cleaved by β-secretase and γ-
secretase generating sAPPβ and Aβ which are both secreted (7). Some APP is 
completely degraded after it has been endocytosed (8).  
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The trafficking of APP depends on both the correct glycosylation of the 
ectodomain, and also on a signal sequence in the C-terminus (Tienari et al., 1996). 
The GYENPTY and the YSTI motifs in the C-terminus of APP are required for the 
internalisation and then either recycling of APP back to the cell surface or its 
degradation in lysosomes (Lai et al., 1995). The phosphorylation state of residues 
within the C-terminus of APP is important in the regulation of APP endocytosis. 
Phosphorylation of Y682 and Y687 in the GYENPTY motif increases endocytosis of 
APP, and so increases β-cleavage of APP (Rebelo et al., 2007; Barbagallo et al., 
2010). The GYENPTY motif is the most important determinant for APP endocytosis 
(Perez et al., 1999; Cescato et al., 2000) but it, and the YTSI motif, are also 
important for insertion of APP into vesicles of the TGN and transport to the cell 
surface (Rebelo et al., 2008; Vieira et al., 2009). Phosphorylation of proteins that 
bind the C-terminus of APP is also important in regulating its metabolism. For 
example X11L binds the APP C-terminus and stimulates APP endocytosis. X11L 
can be phosphorylated by Src kinase, phospho-X11L stimulates APP endocytosis 
and transport to endosomes and lysosomes, whereas  non-phosphorylated X11L 
stimulates APP endocytosis then recycling back to the cell surface (Chaufty et al., 
2012). The endocytosis of APP and the role of endocytosis in AD are discussed in 
section 1.11. For a review of APP trafficking see Selkoe et al 1996 or Thinakaran 
and Koo 2008 (Selkoe et al., 1996; Thinakaran and Koo, 2008). 
1.5.5 Lipid rafts and the role of cholesterol in APP processing 
Amyloidogenic processing of APP occurs in lipid rafts (Ehehalt et al., 2003). 
Lipid rafts are small nanometer sized domains within the cell membrane which have 
a specific lipid composition – they are typically high in cholesterol and 
sphingolipids (Lingwood and Simons, 2010). Diffusion of proteins located in these 
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microdomains is limited to the individual lipid raft whereas non-raft resident 
proteins are much more mobile and diffuse throughout the cell surface (Giannone et 
al., 2010). It has been suggested that lipid rafts cluster with other lipid rafts 
facilitating the interaction of proteins between rafts, and may act as a way to control 
protein interactions at the cell surface (Simons and Gerl, 2010). This may be one 
way of regulating the proteolytic processing of APP, as amyloidgenic processing (β-
cleavage) occurs in lipid rafts, whereas non-amyloidogenic processing (α-cleavage) 
occurs in non-raft regions of the membrane (Lakshmana et al., 2008). 
APP metabolism is strongly influenced by cholesterol levels. Expression of the 
cholesterol exporting channels ABCA7 and ABCG1 in cells, both of which are 
highly expressed in the hippocampus, have been shown to reduce APP processing 
(Tansley et al., 2007; Chan et al., 2008). Knockout of the cholesterol exporting 
channel ABCA1 in mice followed by treatment with a cholesterol acceptor 
decreased the cholesterol content of cell membranes and decreased Aβ40 secretion 
(Burns et al., 2006). The interaction between APP and BACE1 occurs within lipid 
rafts, so reducing the cholesterol levels reduces the area of lipid rafts, causing APP 
to shift out of lipid rafts and into non-raft areas where it will interact with α-
secretase rather than BACE1, increasing α-cleavage (Kojro et al., 2001; Ehehalt et 
al., 2003). Increasing cholesterol levels increases APP and BACE1 co-localisation 
so increases β-cleavage of APP and Aβ generation (Marquer et al., 2011). APP itself 
binds cholesterol in a 1:1 ratio; this interaction may help partition APP into lipid 
rafts and so increase amyloidogenic processing of APP. Furthermore the cholesterol 
binding site in APP is made up from residues in the transmembrane domain which 
are adjacent to the α-cleavage site. It has been suggested that the binding of APP to 
cholesterol may prevent the α-secretase–APP interaction so promoting 
amyloidogenic processing of APP (Barrett et al., 2012). Cholesterol can also 
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influence the activity and the specificity of γ-secretase, Osenkowski et al  showed 
that increasing the cholesterol composition of liposomes containing purified γ-
secretase increased the generation of Aβ then further increases in cholesterol 
decreased Aβ generation. Cholesterol levels also influenced the length of the Aβ 
produced with higher concentrations of cholesterol increasing production of longer 
Aβ species relative to shorter Aβ (Osenkowski et al., 2008). Many proteins that 
regulate the location of APP (i.e. raft vs. non-raft regions) regulate the processing of 
APP. For example LRP1 (Low density lipoprotein receptor-related protein 1) binds 
the C-terminus of APP and re-locates it to lipid rafts, increasing Aβ and sAPPβ 
generation while decreasing sAPPα production (Lakshmana et al., 2008).  
1.6 The proteolytic processing of APP 
The different proteolytic cleavages of APP occur in distinct subcellular 
locations and are carried out by specific secretases (see figures 1.2 and 1.4).  
1.6.1 α-cleavage 
There are several candidate proteases for α-secretases, all of which are 
members of the ADAMs (A Disintegrin And Metalloprotease) family of proteases: 
ADAM9, 10 and 17. Increasing expression of each of ADAM9, 10 and 17 increases 
sAPPα production, whereas knocking down expression decreases sAPPα production. 
ADAM9, 10 and 17 are all expressed in the brain (Asai et al., 2003; Allinson et al., 
2004). It appears that all of these cleave APP in vivo, and they may be able to 
functionally substitute for each other. For example, knockout of ADAM10 causes a 
reduction in sAPPα, though not complete inhibition (Hartmann et al., 2002; Vardy et 
al., 2005). Although ADAM17 is capable of cleaving APP, its inhibitor profile and 
kinetics do not match with physiological observations for α-secretase (Parvathy et 
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al., 1998), so it is most likely not the main enzyme responsible for α-cleavage of 
APP (Allinson et al., 2003). ADAM17 cleavage of APP is stimulated by protein 
kinase C activation, this occurs at the cell surface and intracellular compartments 
(such as the late Golgi/ TGN), so it maybe involved in stimulated rather than 
constitutive α-cleavage of APP (Jolly-Tornetta and Wolf, 2000). 
1.6.2 β-cleavage 
β-secretase has been identified as BACE1 (β-site APP cleaving enzyme). 
BACE1 was identified in a screen of a cDNA library from HEK (human embryonic 
kidney) cells, when expression of one of the cDNA clones increased generation of 
Aβ (Vassar et al., 1999). Purification of this clone demonstrated that BACE1 had the 
substrate specificity, optimum pH and inhibitor profile for β-secretase. BACE1 is an 
aspartyl protease, with a transmembrane domain and an active site made from two 
separate motifs. It is expressed at low levels by most tissues of the body, including 
the brain. In the brain BACE1 expression is highest in the hippocampus, the cortex 
and cerebellum, whereas expression in glial cells is very low/non-existent (however 
BACE1 expression has been detected in reactive astrocytes surrounding amyloid 
plaques in mouse brain (Rossner et al., 2001)). Expression of HA-tagged BACE in 
HEK cells showed it is localised to the Golgi, and endosomes (where it is at its 
optimum pH), with small amounts in the ER and lysosomes (Sinha et al., 1999; 
Vassar et al., 1999; Yan et al., 1999). BACE1 in the endoplasmic reticulum is in its 
immature form, it is cleaved by a furin in the Golgi to form mature BACE1 
(Benjannet et al., 2001). BACE1 has a transmembrane domain that is required for its 
activity (Yan et al., 2001). Most BACE1 cleavage of APP occurs in the late TGN 
and endosomes (an acid environment is required for activity), however there is some 
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in the ER (Schrader-Fischer and Paganetti, 1996; Benjannet et al., 2001; Yan et al., 
2001). BACE1 as β-secretase is reviewed in (Cole and Vassar, 2007). 
1.6.3 γ-cleavage 
γ-secretase is a complex composed of several sub units: Aph1a, Pen-2, 
nicastrin and either presenilin 1 or 2 (De Strooper, 2003; Vardy et al., 2005) (but it 
can function in the absence of nicastrin) (Zhao et al., 2010). γ-secretase is an 
aspartyl protease, and the presenilin subunit (either PS1 or PS2 can be present) 
provides the catalytic aspartic acid residues. Pen-2 is required for an activating 
cleavage of the presenilin. The other subunits may only be required for stability and 
maturation of the complex (De Strooper, 2003). Mutations in γ-secretase account for 
more than half the FAD cases demonstrating its importance in the generation of Aβ 
in AD (Vardy et al., 2005). γ-secretase cleavage of APP has been reported in a 
number of subcellular locations such as the nuclear envelope, the ER, the trans-
Golgi network (TGN), the cell surface and late endosomes. The majority of γ-
cleavage however, occurs after APP has been transported to the cell surface, then 
endocytosed (Kaether et al., 2006; Hare, 2010). It has also been reported that Aβ40 
and Aβ42 generation occurs in separate subcellular locations (Hartmann et al., 1997; 
Xu et al., 1997).  
There is some variability in the cleavage sites of the secretases on APP. α-
secretase cleaves APP at L17 of Aβ, but other α-cleavage sites have been identified 
around this area (at E11 and Q15). These are called α’, and are thought to be due to 
several different enzymes being responsible for α-cleavage (Simons et al., 1996). 
There is also an additional β-cleavage site, called β’ (the β-cleavage site is D1 of Aβ, 
whereas the β’ site is at E11). Both β and β’ cleavage of APP are carried out by 
BACE1 (Vassar et al., 1999). The γ-secretase cleavage site is not very sequence 
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specific which means a range of different sized Aβ peptides are produced: it can 
vary from 39 to 43 amino acids long (Vardy et al., 2005). It has been hypothesised 
that this is because γ-secretase initially cleaves C99 at the ε-site genereating Aβ48 or 
Aβ49, then continutes “nibbling” at the C-terminus of Aβ sequentially removing two 
or three amino acids at a time resulting in the generation of a range of Aβ species 
(Takami et al., 2009). 
  
- 24 - 
 
 Figure 1.5 Amyloid precursor protein structure and cleavage sites. (A) 
The cleavage points of APP by α- β- and γ-secretase. α and α’ cleavages are carried 
out by α-secretase, β and β’ cleavages are carried out by BACE1, and γ and ε 
cleavages are carried out by the γ-secretase complex. Cleavage at the β- and either 
of the γ-sites generates Aβ (shown in red). Numbering of the residues corresponds to 
the 695 isoform of APP. The yellow box represents the membrane. (B) Scale 
diagram of APP695 isoform. The signal sequence is shown in blue, Aβ in red, and 
motifs important for endocytosis and trafficking in yellow. The pale yellow box 
represents the membrane. “N-linked” represents the N-linked glycosylation on APP. 
“O-linked” represents the complex O-linked glycosylation. The location of the KPI 
and Ox2 domain splice site is shown by the insert.
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1.7 The functions of APP metabolites 
The different proteolytic cleavages of APP result in the generation of a 
number of different fragments, and these have been demonstrated to have different 
roles within the cell. sAPPα has been shown to be neuroprotective, whereas sAPPβ 
is toxic. The intracellular fragment AICD can be transported to the nucleus where 
it is transcriptionally active and alters gene expression. It is unclear what the 
physiological function of Aβ is but it appears to have roles in cell survival, and 
may be involved in modulation of current through ion channels (Plant et al., 2006). 
1.7.1 Neuroprotective functions 
sAPPα is has been demonstrated to be protective against proteosomal stress, 
UV induced stress, excitoxicity (Mattson et al., 1993; Copanaki et al., 2010), and it 
decreases the effects of neuronal injury (Thornton et al., 2006). Over-expression of 
ADAM-10 (α-secretase) in an AD mouse model increases sAPPα, and decreases Aβ 
sAPPβ levels, which improves both LTP (long term potentiation, a process that is 
important in the formation of memories) and learning and memory deficits usually 
associated with these mice (Postina et al., 2004). Addition of sAPPα or sAPPβ to 
primary neurons increases axon growth and decreases the number and growth of 
dendrites (Jin et al., 1994). The axonal growth effects of sAPPα are mediated by 
MAP kinase (Chasseigneaux et al., 2011). sAPPα and sAPPβ have both been shown 
to induce neural differentiation in embryonic stem cells (Freude et al., 2011), 
suggesting they (and APP) may have roles in development. The C-terminal fragment 
produced by α-cleavage of APP may also have neuroprotective functions. CTFα can 
inhibit γ-secretase: it binds γ-secretase but is a poor substrate (this is modulated by 
residues 17-23 of CTFα), so inhibits Aβ production (Tian et al., 2010). Even Aβ in 
its monomeric rather than aggregated form has been shown to be neuroprotective to 
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developing neurons again suggesting a role for APP in development (Giuffrida et al., 
2009). Aβ at low concentrations is neuroprotective and enhances LTP, it is only at 
higher concentrations when it becomes toxic (Puzzo et al., 2012). 
1.7.2 Regulation of gene expression 
The C-terminal fragment of APP can bind to the intracellular protein Fe65, and 
is transported from the cytoplasm to the nucleus of the cell. In the nucleus it binds 
the protein Tip60 and forms the AFT transcriptional complex (so called because it is 
a complex of AICD, Fe65 and Tip60). Nuclear AICD has been shown to regulate the 
expression of several genes including neprilysin, aquaporin, p53, BACE1 and many 
others (Belyaev et al., 2010; Ohkawara et al., 2011; Beckett et al., 2012). There is a 
lot of disagreement in the genes regulated by AICD identified by different groups – 
it has been suggested that this is due to the use of different cell lines and cell culture 
techniques. AICD is proposed to alter gene expression by recruiting the MED12 
subunit of RNA polymerase II to promoter sites (Xu et al., 2011). Only AICD 
generated by βγ-cleavage (not αγ-cleavage) of the 695 isoform of APP is transported 
to the nucleus and alters gene expression (Belyaev et al., 2010).  
1.7.3 Toxicity to cells 
Aβ aggregates are toxic to cells, they cause neuronal dystrophy and death 
when incubated with neurons in culture (Grace et al., 2002). Aβ can exist in a 
number of different forms, it is initially generated from cleavage of APP as a 
monomer, but it has a high propensity to aggregate and can form many oligomeric 
species, as well as large fibrils. Initially it was thought that the large fibrils of Aβ 
which make up the plaques characteristic of AD were the cause of the disease, 
however the toxic species of Aβ is now widely considered to be the oligomeric Aβ 
aggregates. The oligomeric forms of Aβ correlate better with cognitive decline than 
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Aβ filbril load (Tomic et al., 2009). AβOs have been isolated from AD brains 
(demonstrating their physiological relevance). They have been shown to be toxic to 
neuronal cultures, to inhibit LTP and to decrease synaptic density (Walsh and 
Doherty, 1991; Lambert et al., 1998; Wang et al., 2002; Deshpande et al., 2006; 
Shankar and Walsh, 2009). There are a larger number of different oligomeric 
aggregates, with a range of different sizes (from dimers and trimers, to much larger 
protofibrils which can be up to 200 nm in diameter) (Shankar and Walsh, 2009). It 
has been suggested that the toxicity of Aβ oligomers may be caused by aggregates of 
Aβ interacting with cellular proteins disrupting their normal cellular functions 
(Olzscha et al., 2011). 
Aβ can be modified after it has been generated, for example the formation of 
pyroglutamate Aβ. These modified forms of Aβ may be more toxic than un-
modified Aβ, and have also been shown to cause AD-like symptoms in mice, for 
example increased neuronal death, and altered behaviours (Alexandru et al., 2011). 
Once Aβ has begun to aggregate in the brain it has been shown to act as a seed 
inducing further Aβ aggregation. This has been demonstrated by injecting Aβ 
containing extracts from transgenic AD mouse brains into the brains of younger 
transgenic mice which induced amyloid pathology in the brain at a much younger 
age (Langer et al., 2011). 
Tau protein, which becomes hyperphosphorylated and forms the tangles found 
within neurons that are characteristic of AD, may be required for the toxicity of Aβ 
oligomers. Phosphorylation of tau is increased by Aβ, inhibition of GSK-3β (which 
phosphorylates tau) and tau knockout prevents Aβ mediated impairment in long-
term potentiation (Shipton et al., 2011).  
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Besides Aβ, sAPPβ also exherts detrimental effects towards neurons. sAPPβ 
can be further cleaved into 35 and 55 kDa fragments, and once cleaved sAPPβ can 
bind the death receptor DR6. It has been postulated that binding of sAPPβ to the 
death receptor DR6 activates the receptor, stimulating pruning of axons in 
development and cell death following nutrient deprivation (Nikolaev et al., 2009).  
It has been suggested that AICD and not Aβ is the toxic species in AD 
(Nakayama et al., 2008; Ohkawara et al., 2011). Evidence for this comes from 
studies in which AICD, rather than the whole of APP, was over-expressed in mice. 
Over-expression of AICD in mice caused age-dependent neuronal loss in the 
hippocampus and a decrease in working memory of the mice. There was no change 
in Aβ or Aβ plaque levels in the brains of these mice, and AICD over-expression 
caused an age dependent increase in tau pathology. This suggests that AD symptoms 
could be caused solely by increased AICD, rather than Aβ (Ghosal et al., 2009). 
1.8 Proteins that regulate APP processing 
There are many examples of proteins which can regulate APP processing and 
so alter the levels of Aβ, sAPPα, and sAPPβ secreted by cells, and therefore 
provide potential therapeutic targets for AD (reviewed in (Tang and Liou, 2007)). 
Proteins that regulate the processing of APP can be broadly split into two 
categories – proteins that alter the processing of APP by binding to APP or to the 
secretases preventing the APP-secretase interaction (direct modulators) and 
proteins that alter the processing of APP by altering its trafficking and its location 
in the cell (indirect modulators). 
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1.8.1 Direct modulation of APP processing 
An example of a direct modulator of APP processing is the protein BRI2 
(Integral membrane protein 2B). BRI2 is a membrane spanning protein that was 
identified in a screen for APP interacting proteins using the split ubiquitin system 
(Matsuda et al., 2005). It is expressed in the brain and found in the axons of neurons 
(as is APP). BRI2 is found at especially high levels in dystrophic neurites 
surrounding plaques, and mutations in BRI2 cause an AD-like dementia 
(Fotinopoulou et al., 2005). BRI2 co-immunoprecipitates with APP, and expression 
of BRI2 in cell lines causes a decrease in Aβ40, Aβ42, sAPPα and CTFα but increases 
sAPPβ. Expression of BRI2 in mouse models of AD decreases both Aβ40 and Aβ42 
(Fotinopoulou et al., 2005). BRI2 expression also reduces expression from APP 
transactivator genes, suggesting it causes a decrease in the levels of AICD (Matsuda 
et al., 2005). BRI2 can interact with mature, but not immature APP, and can interact 
with CTFβ but not CTFα. A mutant form of BRI2 that is retained in the ER is not 
able to alter APP processing, and APP-BRI2 complexes have been identified on the 
surface of cells suggesting BRI2 binds to APP once it has been trafficked to the cell 
surface (Matsuda et al., 2011). Deletion mutants of APP were created and the 
interaction of these with BRI2 was determined by co-immunoprecipitation of the 
mutants with BRI2. This showed that the 17 amino acids of APP adjacent to the 
membrane spanning domain (on the N-terminal side) are essential for BRI2 binding 
APP. These 17 amino acids are in the N-terminal region of Aβ (Matsuda et al., 
2005). These studies led to the hypothesis that APP and BRI2 are synthesised in the 
ER then trafficked separately through the secretory pathway where they are 
glycosylated to become the mature forms of the proteins. At the cell surface, or 
following endocytosis, BRI2 binds to APP covering the α- and γ-cleavage sites 
preventing access by secretases and so decreasing sAPPα, Aβ, CTFα, and AICD 
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production. The β-cleavage site remains exposed so APP is cleaved by β- rather than 
α-secretase resulting in increased sAPPβ production (Fotinopoulou et al., 2005; 
Matsuda et al., 2005; Matsuda et al., 2011).  
1.8.2 Indirect modulation of APP processing 
One of the most well characterised examples of an indirect modulator of APP 
processing is SORLA (sorting protein-related receptor). SORLA was predicted to be 
involved in transport of proteins between the Golgi and endosomes as it interacts 
with many adaptor proteins that act as shuttles between these compartments. 
SORLA expression is decreased in AD in the frontal cortex suggesting it may have a 
role in AD (Andersen et al., 2005). Expression of SORLA in cell lines caused a 
decrease in Aβ, sAPPα, and sAPPβ secretion from the cell, suggesting it has a role 
in APP processing. Surface plasmon resonance and analytical ultracentrifugation 
studies showed that SORLA binds the 695, 751 and 770 isoforms of APP in a 1:1 
ratio and APP and SORLA co-localise when expressed in cell lines (Andersen et al., 
2005). This interaction caused APP to accumulate in intracellular compartments 
reducing cell surface APP levels, which means it did not come into contact with the 
secretases, and so explains the reduction in APP proteolytic processing caused by 
SORLA expression (Andersen et al., 2005). Expression of a mutant form of SORLA 
that traffics to the cell surface rather than remaining in intracellular vesicles caused 
an accumulation of cell surface APP. To confirm these effects in vivo SORLA 
knockout mice were created, and these mice had increased sAPPα and Aβ 
production. The APP-SORLA interaction was confirmed in vivo by co-localisation 
of SORLA and APP in mouse brain (Andersen et al., 2005). The expression of 
SORLA is regulated by brain-derived neurotrophic factor (BDNF), which is known 
to have protective effects in AD. BDNF increases the expression of SORLA, and so 
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causes a decrease in Aβ production due to the effects of SORLA on APP trafficking 
(Rohe et al., 2009). 
For further examples of proteins that interact with and regulate APP processing 
see table 1.1.  
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Table 1.1 A selection of proteins that regulate APP processing 
Protein Effect Mechanism 
ABCA7 Decreases sAPPα, sAPPβ, 
Aβ, CTFβ, CTFα and 
AICD 
Indirect 
Exports cholesterol from the cell, so 
decreases cholesterol in the 
membrane, though this hasn’t been 
proven (Chan et al., 2008). 
ABCG1 Increases Aβ40, Aβ42, 
sAPPβ and sAPPα 
No mechanism proposed (Tansley 
et al., 2007). 
ApoER2 Increases Aβ, decreases C-
terminal fragments of 
APP,  
Multiple contradictory effects on 
APP processing are reported for 
ApoER2. This is because different 
isoforms of the receptor have 
different effect (Fuentealba et al., 
2007; King (Thesis), 2011). 
BDNF  Decreases Aβ Indirect 
Increases expression of SORLA 
which prevents APP transport into 
early endosomes (Rohe et al., 
2009). 
BRI2 Decreases Aβ, sAPPα and 
AICD, increases sAPPβ 
Direct 
Binds APP preventing access to the 
α- and γ-cleavage sites, but leaving 
the β-cleavage site exposed 
(Fotinopoulou et al., 2005; Matsuda 
et al., 2005; Matsuda et al., 2011). 
Continued overleaf  
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Table 1.1 A selection of proteins that regulate APP processing (continued) 
Protein Effect Mechanism 
CD74 Decreases secreted Aβ (not cytoplasmic Aβ) Indirect 
Re-locates APP to intracellular 
structures preventing amyloidogenic 
cleavage of APP (Matsuda et al., 
2009). 
Cellular prion 
protein (PrPc) 
Decreases Aβ Direct 
PrPc interacts with BACE1 via 
glycosaminoglycans so prevents 
BACE1 from interacting with and 
therefore cleaving APP (Parkin et 
al., 2007). 
Flotillin-2 Increases Aβ Indirect 
Flotillin is required for endocytosis 
of APP so removing flotillin 
decreases APP endocytosis and 
therefore β-processing of APP 
(Schneider et al., 2008). 
F-spondin Decreases β-CTF The mechanism is unknown, but it 
binds to APP, and therefore may 
prevent the APP-BACE1 interaction 
(Ho and Sudhof, 2004). 
Grp94/Grp 78 Decrease sAPPα and 
increase sAPPβ 
Indirect 
Acidosis and ER stress increase 
expression of Grp 78 and 94 which 
bind the KDEL domain of APP 
retaining it in the ER preventing α-
processing and increasing β-
processing (Xiang et al., 2010). 
Continued overleaf  
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Table 1.1 A selection of proteins that regulate APP processing (continued) 
Protein Effect Mechanism 
LRP1 Increases Aβ and sAPPβ, 
decreases sAPPα 
Indirect 
Interacts with the C-terminal of 
APP targeting APP to lipid rafts 
promoting amyloidogenic 
processing, (Lakshmana et al., 
2008). 
LRRTM3 Increases Aβ and sAPPβ Modulates β-cleavage of APP but 
not through altering BACE1 activity 
(Majercak et al., 2006). 
NEEP21 Decreases sAPPα, sAPPβ, 
CTFβ, Aβ, and changes 
the ratio of CTFβ:CTFα. 
The effects of NEEP21 
knockdown on APP 
processing are different in 
different cell lines. 
No mechanism proposed (Norstrom 
et al., 2010). 
Nogo receptor Decreases Aβ, sAPPβ and 
sAPPα 
Direct 
Binds APP and prevents the 
secretases interacting with APP 
decreasing all cleavages of APP 
(Park et al., 2006; Park and 
Strittmatter, 2007). 
Reticulon 
family proteins 
Decrease Aβ and sAPPβ Indirect 
Re-locates BACE1 from the Golgi 
to the ER where it is less active 
resulting in decreased β-cleavage of 
APP (He et al., 2004; Hu et al., 
2007; Shi et al., 2009). 
Continued overleaf  
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Table 1.1 A selection of proteins that regulate APP processing (continued) 
Protein Effect Mechanism 
SNX33 Increases sAPPα Indirect 
Prevents endocytosis so APP 
remains at the cell surface 
preventing cleavage by β-secretase 
and promoting cleavage by α-
secretase (Schobel et al., 2008). 
SORLA Decreases Aβ, sAPPα and 
sAPPβ 
Indirect 
Interacts with APP and retains it in 
the ER preventing it coming into 
contact with the secretases 
decreasing all cleavages of APP 
(Andersen et al., 2005). 
X11 proteins Decrease Aβ, sAPPβ, and 
CTF-β 
Indirect 
X11 proteins bind the GYENTPY 
motif in the C-terminal of APP, and 
have been proposed to prevent its 
lipid rafts location, so reduce β-
processing (Kondo et al., 2010). 
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1.8.3 The in vivo APP interactome 
In 2008 a mouse in vivo brain interactome for APP was published (Bai et al., 
2008). This was performed by perfusing the brains of mice with para-formaldehyde, 
which cross-links proteins in close proximity to each other and so cross-links any 
proteins that are interacting. The brain tissue was then homogenised and APP (along 
with any cross-linked proteins) was immunoprecipitated using antibodies to the C 
and N terminus. Proteins that had been co-purified with APP were identified by 
liquid chromatography and tandem mass spectrometry analysis. Several proteins that 
had already been identified as APP interactors were confirmed, and some of the 
novel interactions were confirmed by co-immuno-precipitation experiments, 
validating the methodology of this approach. The interactomes for APLP1 and 2 
were also investigated and were different from the interactome of APP, which 
demonstrates the specificity of the approach, yet some proteins were found in all 
three interactomes. Many novel APP interacting proteins were identified (though the 
authors point out that these may not necessarily be direct interactions), and different 
groups of proteins were pulled out depending on the APP antibody used in the 
immunoprecipitation step. Antibodies directed to the C-terminus of APP mostly 
identified cytoplasmic proteins (possibly involved in the trafficking of APP through 
the secretory pathway), whereas N-terminal APP antibodies identified many 
extracellular proteins (Bai et al., 2008). 
The in vivo brain interactome is an important step in identification of APP 
interacting proteins, as unlike in vitro interaction studies (such as yeast 2 hybrid) it 
shows proteins which do interact with APP in a physiological setting, rather than 
proteins which can interact with APP in an artificial environment. Three proteins 
identified by Bai et al., (2008), neurofascin, contactin proteins, and Thy-1, were 
- 37 - 
selected, and the role of these protein in APP metabolism was investigated (see 
chapter 3). 
1.8.3.1 Neurofascin 
Neurofascin is a type I membrane protein with six Ig domains and five 
fibronectin type III domains (Hortsch, 1996), and is highly glycosylated with both 
O- and N-linked glycosylation (Volkmer et al., 1992) (figure 1.6). There are a 
number of isoforms of neurofascin which are differentially expressed throughout 
development: isolation of neurofascin mRNA from embryonic chick brains 
identified 50 different neurofascin isoforms (Hassel et al., 1997). Neurofascin 
isoforms have been shown to interact with several proteins, and regulating the 
isoform of neurofascin expressed can modulate these interactions (Pruss et al., 
2006). Different isoforms of neurofascin have distinct functions. For example the 
NF186 isoform (so called because it migrates at a molecular weight of 186 kDa on 
SDS-PAGE) has been shown to inhibit neuronal outgrowth, whereas the NF155 
isoform promoted neurite outgrowth (Koticha et al., 2005). Neurofascin knockout 
mice have been generated, but died 6-7 days after birth. Analysis of the mouse 
brains before six days of age showed that their neurons appeared normal, however 
conduction velocities were decreased compared to wild type mice (Sherman et al., 
2005). 
Neurofascin is involved in saltatory conduction. This is a method of rapid 
nerve impulse conduction, which requires myelination of axons. Axons are 
myelinated by Schwann cells (glial cells), myelination causes formation of nodes of 
Ranvier on axons, these form at the points where axons and the myelinating glia 
interact. Neurofascin has a role in assembling and recruiting proteins to the node and 
paranode, and also mediates the neuron – glia interaction. NF155 on the Schwann 
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cell interacts with contactin on the neuron, and NF186 on the neuron interacts with 
gliomedin on the Schwann cell (Sherman et al., 2005). The role of the NF186 
isoform in APP proteolytic processing is further investigated in chapter 3. 
1.8.3.2 Contactins 
The contactins are a subgroup of six proteins (contactins 1-6) all of which 
are glycosyl phosphatidylinositol (GPI) anchored proteins from the Ig superfamily, 
with four fibronectin type III domains followed by six Ig domains (Shimoda and 
Watanabe, 2009) (figure 1.6). The six contactins have 40-60% identity (Kamei et al., 
2000), and are highly expressed in the brain and CNS (a contactin precursor was 
identified as one of the major glycoproteins in the brain (Huang et al., 2004)) with 
different expression patterns for different contactins (Reid et al., 1994; Watanabe et 
al., 1995; Kamei et al., 2000). The contactins have been implicated in neuronal 
outgrowth and cell-to-cell interactions: contactin 1 is located at synaptic sites and 
addition of a soluble form of contactin 1 to dorsal root ganglia cultures increased the 
proportion of neurons extending processes (Durbec et al., 1992; Berglund and 
Ranscht, 1994). Contactin knockout mice have been generated, and knockout of the 
different contactins cause different phenotypes. Contactin 1 knockout mice, 
although normal at birth, develop ataxia and do not survive for longer than 18 days. 
Furthermore the cerebellum of contactin 1 knockout mice is 17 % smaller than that 
of wild type mice (Berglund et al., 1999). Contactin 2 and contactin 5 knockout 
mice, on the other hand, did not have any major deleterious phenotype (Fukamauchi 
et al., 2001; Li et al., 2003).  
There are several reasons to believe that contactins may have an important role 
in AD. A study aiming to identify potential biomarkers for AD found a 1.9-fold 
increase in isoform 1 of contactin 1 and a 2.4-fold increase in contactin 2 in the CNS 
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of AD patients compared to controls (Yin et al., 2009). Expression of contactin 1 
was decreased in hippocampus and cerebellum of rats aged over 30 months 
(Shimazaki et al., 1998), and contactin 2 expression was decreased in the 
hippocampus of 8 and 20 month old mice compared to 8 week old mice (Tachi et al., 
2010). Contactin 1 has been shown to bind the notch receptor and caused γ-secretase 
dependent generation and nuclear localisation of notch intracellular domain (Hu et 
al., 2003; Hu et al., 2004), so contactins may also have a role in γ-secretase 
dependent release of AICD. Contactins 2, 3, and 4 have been shown to bind APP, 
and contactin 5 to bind APLP1 (Ma et al., 2008; Osterfield et al., 2008). Expression 
of contactin 2 in cell culture caused an increase in CTFα, CTFβ and a γ-secretase 
dependent increase in AICD showing that contactin 2 could be involved in 
regulation of APP proteolysis (Ma et al., 2008). Contactin 4 has also been shown to 
increase both APP and CTF-α when over-expressed in cell culture (the increase in 
CTFα was greater than that of APP), demonstrating that contactin 4 may also have a 
role in regulating APP proteolysis (Osterfield et al., 2008). Contactins may also have 
a genetic link to AD: contactin 5 was one of 13 genes showing an association with 
AD in a genome wide association study (Harold et al., 2009). An association of 
contactin 5 with neuroimaging measures for AD (such as white matter lesion volume 
and entorhinal cortex thickness) has also been reported (Biffi et al., 2010). The role 
of contactin 5 in the proteolytic processing of APP was investigated in chapter 3. 
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Figure 1.6 The structure of the proteins contactin 5, neurofascin 186, and  
Thy-1. The transmembrane anchors, the N- and O-glycosylation and the fibronectin 
type III domains and Ig domains of contactin 5, neurofascin, and thy-1.  
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1.8.3.3 Thy-1 
Thy-1 (also called CD90) is another GPI anchored membrane protein and is 
also a member of the Ig superfamily of proteins (Walsh and Doherty, 1991) (figure 
1.6). Thy-1 has been implicated in many cellular functions. It is important in cell-to-
cell and cell-to-matrix interactions, it may act as a tumor suppressor in certain 
cancers, it may have a role in apoptosis, and has immunological functions (Rege and 
Hagood, 2006). Thy-1 is expressed in mature but not in developing neurons, and in 
continually branching axons Thy-1 expression is only found in areas of the axon 
where growth is complete (Xue et al., 1991). The GPI anchor of Thy-1 also means it 
is localised to lipid rafts, where amyloidogenic processing takes place. Thy-1 can be 
shed from its GPI anchor, and its GPI anchor is thought to be important for cell 
signalling (Haeryfar and Hoskin, 2004). Its expression and location at the cell 
surface has also been demonstrated in several neuroblastoma cell lines (Kemshead et 
al., 1982). 
Thy-1 has been previously implicated in AD. Distribution of Thy-1 in neurons 
was found to be altered in AD brains compared to age-matched control brains. 
Additionally there was decreased Thy-1 staining in AD brains, though it is not clear 
whether this reflects loss of Thy-1 expressing neurons, or decreased Thy-1 
expression in neurons (Leifer and Kowall, 1992). 
1.9 Genome-wide association studies 
Initial genetic research into AD was driven by identification of mutations that 
caused familial AD, but the vast majority of AD cases (95%) are sporadic AD, and 
these are not caused by dominant mutations in genes such as APP and the 
presenilins (Pimplikar, 2009). There is, however, a genetic component to sporadic 
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AD, and recent advances in technology have allowed genome-wide association 
studies (GWAS) with large enough sample numbers to detect single nucleotide 
polymorphisms (SNPs) that are related to sporadic AD. Several genes have been 
related to sporadic AD in this way, and different studies have identified different 
genes. Genes that have been consistently identified by several GWAS include CLU 
(encodes the protein clusterin), BIN1 (bridging integrator 1), PICALM (phosphatidyl 
inositol clathrin associated lymphoid myeloid), CD2AP (CD2 associated protein), 
EPHA1 (ephrin receptor A1), CR1 (complement receptor 1), ABCA7 (ATP binding 
cassette transporter A7), CD33, and the MS4A gene cluster (Harold et al., 2009; 
Bertram and Tanzi, 2010; Seshadri et al., 2010; Carrasquillo et al., 2011; 
Hollingworth et al., 2011; Hu et al., 2011; Wijsman et al., 2011). It has been 
estimated that these nine genes could explain up to 50% of sporadic AD genetics 
(Morgan, 2011). 
Hollingworth and collegues grouped the genes that have been linked to 
sporadic AD into groups of related functions, and suggests that this gives us an 
insight into processes involved in sporadic AD (Hollingworth et al., 2011). The 
proteins CLU, CR1, ABCA7, CD33 and EPHA1 all have roles in immune system 
function, PICALM, BIN1, CD33 and CD2AP are involved in processes occurring at 
the cell membrane, while APOE, CLU and ABCA7 are involved in lipid processing. 
No function has been assigned for the MS4A4 gene cluster so these do not yet fit 
into any group (Harold et al., 2009; Bertram and Tanzi, 2010; Seshadri et al., 2010; 
Hollingworth et al., 2011). 
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1.10 The importance of endocytosis in the development of 
Alzheimer’s disease 
Several of the genes identified from SAD GWAS are involved in endocytosis 
(BIN1, PICALM, and CD2AP) suggesting alterations in endocytic pathways have 
a role in the development of AD. Endocytosis has an important role in AD 
pathology, and is involved in Aβ generation (Koo and Squazzo, 1994), Aβ toxicity 
to neurons (Song et al., 2011), and Aβ clearance from the brain by transport of Aβ 
across the blood brain barrier (Mackic et al., 1998). Other studies have also 
implicated endocytic proteins as contributors to AD. In 2011 using a yeast model 
of Aβ toxicity Treusch et al., screened a library of yeast open reading frames 
(approximately 90% of the yeast genes) for modulators of Aβ toxicity (Treusch et 
al., 2011). Twelve of the modulators identified had human homologues, three of 
which were endocytosis related genes, including the yeast homologue of PICALM, 
and the yeast homologue of synaptojanin (which interacts with BIN1) (Treusch et 
al., 2011). Furthermore, defects in endocytic pathways have been demonstrated in 
several models of AD. 
1.10.1 Evidence for endocytosis disruptions in Alzheimer’s disease 
Slices from sporadic AD but not familial AD brains have enlarged early 
endosomes, suggesting the endocytic pathway is up-regulated in sporadic AD 
(Cataldo et al., 2000). These changes in endosome size were also observed in 
regions of the brain where there was not yet any detectable amyloid deposition 
showing that defects in the endocytic pathway occur early in AD pathogenesis. 
Alterations in endosome size are not seen during normal aging or in other 
neurodegenerative diseases, suggesting defects in endocytosis are a specific factor 
for AD (Cataldo et al., 2000). The clathrin mediated endocytosis proteins clathrin, 
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dynamin and PICALM have been shown to be up-regulated in the cortex of aged 
AD model mice (Thomas et al., 2011). Levels of endocytic proteins (dynamin, 
synaptophysin, and AP180) have been shown to be decreased in AD brains and in 
an AD mouse model. Levels of dynamin and synaptophysin were decreased in the 
brains of rats injected with Aβ42, and this significantly reduced the performance of 
these rats in the Morris water maze test demonstrating that this treatment resulted 
in cognitive defects (Yao and Coleman, 1998; Yao et al., 1999; Cao et al., 2010). 
Treatment of hippocampal neurons with Aβ has been shown to decrease 
endocytosis of a fluorescent dye showing Aβ can disrupt endocytic pathways (Cao 
et al., 2010; Bate and Williams, 2011). Aβ has been shown to alter clathrin 
distribution and decrease endocytosis in a yeast model of AD (Treusch et al., 
2011). APPswe (an FAD causing mutant of APP) expressing neurons grown in 
culture gradually accumulate intracellular Aβ, and endosome trafficking and 
synapses become altered suggesting that Aβ can cause abnormalities in the 
endocytic pathway in neurons (Tampellini et al., 2011). Endocytosis is important 
in three main areas of Aβ toxicity in AD; Aβ generation, Aβ uptake by cells, and 
Aβ clearance from the brain. 
1.10.2 The role of endocytosis in Aβ generation 
APP is transported to the cell surface, then endocytosed back into the cell, so 
most APP is found in intracellular vesicles (Cossec et al., 2010). β-cleavage of APP 
occurs in endosomes, where the β-secretase (BACE1) is located and the 
environment is acidic providing the optimum pH for BACE1 activity (Vassar et al., 
1999). Endocytosis has been shown to be required for Aβ generation both in vitro 
using cell lines (Koo and Squazzo, 1994), and in vivo in mouse brains. Inhibition of 
endocytosis decreases Aβ generation (Koo and Squazzo, 1994; Ehehalt et al., 2003; 
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Cirrito et al., 2008; Schneider et al., 2008; Goodger et al., 2009), and has been 
shown to increase α-cleavage of APP (which precludes Aβ formation) (Schobel et 
al., 2008) in cultured cell lines. γ-cleavage of APP has been shown to occur in a 
recycling compartment of cells, rather than in the secretory pathway, therefore Aβ 
generation must occur after APP has reached the cell surface and been endocytosed 
(Kaether et al., 2006; Hare, 2010). Endocytosis is required for synaptic activity, and 
the concentration and deposition of Aβ in the brain is highest in areas where 
synaptic activity of neurons is highest (Bero et al., 2011). Synaptic activity also 
enhances the binding of AβOs to synapses, so endocytosis may have a role in 
targeting the AβOs to synapses, by causing zinc release from neurons (Deshpande et 
al., 2009). Endocytosis has been shown to be required for synaptic activity-
dependent Aβ secretion (Cirrito et al., 2008). As well as being generated within 
endosomes, Aβ can aggregate into toxic AβOs inside endosomes (Takahashi et al., 
2004). 
1.10.3 The role of endocytosis in Aβ toxicity to cells  
There is a significant volume of evidence that Aβ is endocytosed by neurons, 
and that this is required for its toxicity. Aβ42 added to rat cortical neurons was taken 
up by, and accumulated in, the cells. This was prevented by both general 
endocytosis inhibitors and inhibition of clathrin-mediated endocytosis demonstrating 
that Aβ can be endocytosed in a clathrin-dependent way (Yu et al., 2010a; Cizas et 
al., 2011; Song et al., 2011). Cells with high levels of internalised Aβ42 showed 
increased lysosomal and endosomal activity, and re-location of the endosomal 
protein cathepsin D throughout the cell, demonstrating that Aβ alters the endosomal 
pathway. Cortical neurons treated with Aβ42 undergo apoptosis, however this was 
prevented by general endocytosis inhibitors showing that endocytosis is important 
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for AβO toxicity (Song et al., 2011). A high concentration of AβOs was used in this 
study (10 µM), however, AβOs have been shown to decrease cell viability at more 
physiological concentrations (500 nM) and this has been prevented by Ca2+ chelators 
and treatment with methyl-β-cyclodextrin, both of which inhibit endocytosis (Cizas 
et al., 2011). However, not all reports confirm that the endocytosis of AβOs is 
clathrin dependent. Yu et al., (2010) showed that although endocytosis of AβOs was 
required for toxicity in a neuroblastoma cell line, this was not prevented by 
inhibiting clathrin-mediated endocytosis, whereas general endocytosis inhibitors and 
inhibitors of clathrin-independent endocytosis were able to reduce the toxic effects 
of AβO treatment (Yu et al., 2010a). AβOs taken up by cells co-localised with 
transferrin demonstrating that they are taken up by endocytosis (again this was 
prevented by inhibiting endocytosis). Unlike transferrin, AβOs are transported to 
lysosomes and accumulate rather than being degraded which suggests a potential 
mechanism for their toxicity (Chafekar et al., 2008). Finally it has been suggested 
that amyloid oligomers may exert their toxicity by aggregating with cellular 
proteins, which would require their uptake into the cytosol (Olzscha et al., 2011). 
1.10.4 The role of endocytosis in Aβ clearance from brains  
A major mechanism of clearance of Aβ from the brain is its rapid transport 
across the blood brain barrier (Shibata et al., 2000). Most Aβ injected to mouse 
brains is removed by this mechanism, very little is degraded in the brain (it can then 
be degraded in blood and removed from the body by the liver) (Shibata et al., 2000; 
Zlokovic, 2011). Aβ was rapidly taken up by human brain microvascular endothelial 
cells in an in vitro model of the blood brain barrier, and this uptake was prevented 
by endocytosis inhibitors (Mackic et al., 1998) suggesting that endocytosis also has 
a role in transcytosis of Aβ across the blood brain barrier. Aβ clearance from the 
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central nervous system (CNS) has been shown to be decreased in sporadic AD 
(Mawuenyega et al., 2010). Aβ has been shown to bind to the protein p75NTR, a 
receptor on the cell surface. Binding of ligands to the p75NTR receptor can 
stimulate clathrin-dependent endocytosis, and the high expression of p75NTR in 
smooth muscle and endothelial cells of the choroid plexus suggests it may have a 
role in the transcytosis of Aβ from the brain to the blood, as well as in the 
degradation of Aβ (Zhou and Wang, 2011). Defects in endocytosis of p75NTR not 
only prevented the removal and degradation of Aβ, but also stimulated its 
aggregation acting as a seed for Aβ aggregation (Aβ aggregates are high in areas of 
the brain where p75NTR is expressed) (Zhou and Wang, 2011). Aβ has been shown 
to be internalised by human primary smooth muscle cells into endosomes, and this is 
inhibited by pre-treatment with trypsin suggesting receptor-mediated endocytosis is 
responsible for the uptake. Uptake was also inhibited by incubating cells with a lipid 
deficient serum, implicating the involvement of a receptor from the low-density-
lipoprotein receptor family (Urmoneit et al., 1997). For example anti-LRP1 (low 
density lipoprotein receptor-related protein 1) antibodies decrease Aβ clearance 
from brain, and LRP-1 expression levels are high in brain microvessels and decrease 
with age (Shibata et al., 2000). Several other membrane receptors have been 
implicated in Aβ trancytosis across the blood brain barrier.  
1.10.5 BIN1 
Chapter 4 of this thesis focuses on investigation of BIN1 in APP and Aβ 
metabolism. BIN1 was identified as a sporadic AD linked gene by GWAS, and is 
involved in endocytosis, therefore is likely to have a role in either Aβ production, 
up-take or clearance.  
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1.10.5.1 The splicing and expression of BIN1 
BIN1 was first identified in a yeast 2-hybrid screen which aimed to identify 
myc interactors. It is located at chromosome 2q14 (Negorev et al., 1996) and is 
localised to the nucleus. When its gene was mapped, BIN1 was found to be close 
to other oncogenes which, along with its ability to bind myc, suggested it has roles 
in cancer and regulation of the cell cycle (Negorev et al., 1996). Meanwhile, 
analysis of rat brain homogenates identified a protein that was highly homologous 
to the protein amphiphysin and had a role in clathrin-mediated endocytosis, so it 
was named amphiphysin II (Tsutsui et al., 1997). Several groups have shown that 
amphiphysin II is actually an alternatively spliced form of BIN1 (Ramjaun et al., 
1997; Tsutsui et al., 1997). There are several alternative splicings of the BIN1 
gene, and different isoforms are expressed by different tissues (Tsutsui et al., 
1997). The widely expressed isoform of BIN1 consists of a BAR 
(BIN1/Amphiphysin/RVS167 related) domain, a region unique to BIN1, a nuclear 
localisation sequence followed by another region unique to BIN1, and its C-
terminus contains regions involved in protein-protein interactions (a myc binding 
domain and an SH3 (src homology) domain). The brain specific isoform of BIN1 
lacks the nuclear localisation signal, and contains four extra brain-specific domains 
(figure 1.7) (Wechsler-Reya et al., 1997). This has led to the suggestion that the 
widely expressed isoform of BIN1 is located in the nucleus, where it has functions 
relating to cell cycle regulation and cancer, whereas the brain-specific isoform is 
located in axons and at nodes of Ranvier (Butler et al., 1997) and has a different 
function.  
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 Figure 1.7 The non-neuronal and brain specific isoforms of BIN1. The 
different splice-forms of non-neuronal and brain specific BIN1. BAR is 
BIN1/Amphiphysin/RVS167 related domain, U1 and U2 are region unique to BIN1, 
NLS is the nuclear localisation sequence, MBD is the myc binding domain, SH3 is 
the src homology domain. The brain-specific isoform contains four brain-specific 
exons shown in blue.  
  
BAR U1 U2 SH3MBD
BAR U1 U2 SH3MBD
NLS
Brain-specific isoform
Non-neuronal isoform
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1.10.5.2 The functions of BIN1 
 Immuno-fluorescence staining of rat brains showed a punctuate distribution 
of BIN1 in neurons suggesting it is located at synapses. Further evidence for this 
synaptic location was the co-localisation of BIN1 staining with staining for the 
protein synaptophysin which is localised at synaptic terminals (Ramjaun et al., 
1997). The highest levels of BIN1 were found in cerebellum, hippocampus CA1 
and CA3 regions, and pontine nucleus. BIN1 staining was very similar to 
amphiphysin I staining, suggesting it may have a very similar role in endocytosis 
to amphiphysin I. Immuno-electron microscopy has located BIN1 even more 
precisely to the outer surface of synaptic vesicles providing further support for a 
role in endocytosis (Wigge et al., 1997). Furthermore, generation of an 
amphiphysin I knockout mouse resulted in not only the absence of amphiphysin I 
but also BIN1. This mouse had defects in synaptic vesicle recycling suggesting that 
BIN1 functions with amphiphysin I during endocytosis (Di Paolo et al., 2002). 
BIN1, like amphiphysin I, has been shown to bind dynamin, clathrin, and the 
adaptor protein AP2: these molecules are required for clathrin-mediated 
endocytosis (Ramjaun et al., 1997). BIN1 and amphiphysin I can form a 
heterodimer, which can bind two dynamin molecules. As a heterodimer BIN1 and 
amphiphysin I are able to increase the rate of guanosine triphosphate (GTP) 
hydrolysis which provides the required energy for endocytosis (the monomeric 
forms are unable to do this) suggesting that the heterodimer may initiate dynamin 
oligomerisation then assists in the conformational changes required for fission of 
the vesicle (Wigge et al., 1997). The importance of amphiphysin for endocytosis 
was demonstrated by amphiphysin I knockout mice. The amphiphysin I knockout 
mice had decreased synaptic vesicle recycling, and only 50 % of the mice survived 
to 10 months of age. They also performed significantly worse in the Morris water 
- 51 - 
maze test than wild type animals. Interestingly, when amphiphysin I was knocked 
out levels of BIN1 were also reduced (shown by immuno-fluorescence and western 
blot) despite BIN1 mRNA levels being unaltered suggesting amphiphysin I is 
required for the stability of the BIN1 protein (Di Paolo et al., 2002). A BIN1 
knockout mouse line has been created. BIN1 knockout did not alter amphiphysin I 
levels, so the stability of amphiphysin I is not dependent on BIN1. Levels of 
amphiphysin in mouse brain peak at six months of age then decreased with aging 
(Yang et al., 2008). BIN1 knockout also did not cause any structural alterations in 
the brain (Muller et al., 2003). BIN1 knockout mice die shortly after birth, so 
experiments were conducted on mouse embryonic fibroblasts. Surprisingly, BIN1 
knockout fibroblasts showed increased uptake of fluorescently-labelled transferrin 
as compared to wild type cells and there was no alteration in the number of 
clathrin-coated synaptic vesicles (Muller et al., 2003). As previously mentioned, 
BIN1 has a number of different isoforms which are expressed throughout the body, 
so the premature death of these mice may not be due to loss of function of the 
brain-specific isoform of BIN1. 
1.11 Alzheimer’s disease therapeutics 
Over the last decade much effort has been put into developing anti-amyloid 
therapeutics for AD. The attempted strategies can be split into two main groups – 
therapies that aim to decrease the production of Aβ, and therapies that aim to 
increase the degradation of Aβ. There have also been attempts to create drugs that 
prevent the aggregation of Aβ (Kawasaki and Kamijo, 2012; Powell et al., 2012; 
Sharma et al., 2012), though this is not a popular approach as it is mechanistically 
very difficult. Scyllo inositol has been shown to form a complex with Aβ42 
converting it from a structured to unstructured comformation that is not toxic to 
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neurons (McLaurin et al., 2000), however scyllo inositol did not cause a significant 
improvement in clinical trials (Salloway et al., 2009). 
1.11.1 Preventing Aβ generation 
1.11.1.1 Inhibiting β-secretase 
The β-secretase, BACE1, is the rate limiting step for the generation of Aβ and 
so has been a very attractive target for AD therapeutics. Coupled with this, β-
secretase activity is increased in the brains of AD patients, suggesting that 
decreasing the activity of BACE1 could provide an effective treatment for AD. 
However, there are difficulties with targeting BACE1. The active site is large which 
means generation of specific inhibitors is difficult – several of the initial attempts at 
generation of BACE1 inhibitors were not viable as they used peptide-based substrate 
analogues which inhibited other aspartic proteases in the brain (such as BACE2 and 
cathepsin D) (Citron, 2002; Nawrot, 2004). This could lead to unacceptable side 
effects. In 2002 the first crystal structure of an inhibitor in complex with BACE1 
was solved, and this allowed structure-based design of inhibitors. This study 
demonstrated that inhibitors with a low Ki for BACE1 can be generated without 
filling the entire active site (Hong et al., 2002) which is advantageous as it allows 
molecules to be small enough to cross the blood brain barrier. Several BACE1 
inhibitors with high specificity and low Ki have been developed (Ghosh et al., 2008; 
Bjorklund et al., 2010), but none of these have reached the clinic. β-secretase knock 
out mice have been created – initially these appeared to have a normal phenotype 
lending support to the idea that BACE1 inhibition is a viable therapeutic avenue for 
AD treatment (Benjannet et al., 2001; Luo et al., 2001; Yan et al., 2001). However, 
closer examination of BACE1 knockout mice several years later showed they had 
some abnormal cognitive and emotional functions as well as altered insulin 
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metabolism (Kobayashi et al., 2008; Meakin et al., 2012). Although BACE1 
knockout in transgenic mouse models of AD can rescue the AD phenotype (Ohno et 
al., 2004; Nishitomi et al., 2006; Cole and Vassar, 2007; McConlogue et al., 2007; 
Kimura et al., 2010), the recent demonstration that BACE1 knockout mice present 
deleterious phenotypes suggests complete inhibition of BACE1 would have 
detrimental side effects.  
1.11.1.2 Inhibiting γ-secretase 
An alternative to inhibition of β-secretase is inhibition of the other enzyme 
required for generation of Aβ – γ-secretase. Many molecules that inhibit γ-secretase 
and therefore prevent generation of Aβ have been developed (Siemers et al., 2007; 
Fleisher et al., 2008), yet like BACE1 inhibitors none have succeeded in clinical 
trials. In many cases the reason for this has been unacceptable side effects (such as 
altering gastro-intestinal and immune cell function) caused by the drugs: knockout 
of γ-secretase in mice is lethal suggesting that it performs vital functions in the cell 
(Shen et al., 1997; Wong et al., 2004). γ-secretase is involved in the proteolytic 
processing of other molecules apart from APP – for example the Notch protein (De 
Strooper et al., 1999) which is important in development (Daudet et al., 2007; 
Boulton et al., 2008; Nagase et al., 2011) as well as several other proteins (e.g. 
ApoER2 receptor, cadherins, low density lipoprotein receptors, and β-subunits of 
voltage gated sodium channels) so complete inhibition of γ-secretase would prevent 
all of these proteolytic cleavages. Furthermore γ-cleavage of APP generates not only 
Aβ but also AICD which may be important for the functioning of the cell (Chang 
and Suh, 2010). There is also evidence that complete inhibition of γ-secretase may 
cause decreases in memory (Tamayev and D'Adamio, 2012). This has led to the 
development of γ-secretase modulators (Kukar et al., 2008). These modulate the 
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activity of γ-secretase rather than inhibiting it completely, for example decreasing 
the production of Aβ40 and Aβ42, but increasing Aβ37 and Aβ38 (less toxic species of 
Aβ), while not altering AICD generation (Kounnas et al., 2010), or γ-cleavage of 
other substrates (Fraering et al., 2005). 
1.11.1.3 Activating α-secretase 
An alternative to inhibiting the Aβ generating secretases is to activate the α-
secretase, as cleavage of APP by α-secretase prevents the generation of Aβ. α-
secretase can be activated by activating protein kinase C (PKC). PKC activators that 
reduce Aβ generation have been identified in cell culture though it remains unclear 
whether this reduction is due to increased α-cleavage or activation of Aβ degrading 
enzymes (Nelson et al., 2009). There are potential problems with targeting α-
secretase: the α-secretase cleaves numerous other substrates, including Notch. 
Altering Notch cleavage has caused many problems for γ-secretase targeting AD 
therapeutics (Bozkulak and Weinmaster, 2009), suggesting that drugs targeting α-
secretase may have similar side effects. Furthermore there have been several reports 
that altering α-secretase activity does not affect Aβ generation (Blacker et al., 2002; 
Gandhi et al., 2004; Peng et al., 2007), which casts doubt on whether an α-secretase 
activator would be effective in vivo. There are several proteins capable of 
performing the α-cleavage of APP, which can functionally substitute for each other 
(see section 1.6.1) so the protein targeted may be an important factor in whether the 
increased α-cleavage results in a change in Aβ generation.  
1.11.2 Activating Aβ degradation 
1.11.2.1 Activating Aβ degrading enzymes 
Rather than preventing Aβ generation, another therapeutic strategy which has 
been explored is to increase the activity of Aβ degrading enzymes, thus increasing 
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Aβ clearance. The main Aβ degrading enzymes in vivo are neprilysin (NEP) and 
insulin degrading enzyme (IDE), (Kurochkin and Goto, 1994; Qiu et al., 1998; Iwata 
et al., 2000). Over-expression of IDE or NEP in mouse models of AD decreased 
both soluble Aβ and Aβ plaques, reduced markers of pathology in the brains (such 
as gliosis and dystrophic neurites), and reduced the incidence premature death of the 
mice (Leissring et al., 2003; El-Amouri et al., 2008). Potential for an Aβ degrading 
drug has been demonstrated by Jacobsen et al., (2009) who targeted plasminogen, 
another enzyme which can degrade Aβ. Jacobsen et al. identified a small molecule 
inhibitor which increases the generation of plasminogen from its inactive precursor. 
Transgenic mice dosed with this compound had increased Aβ degrading activity and 
reduced Aβ levels in their brain, as well as an improvement in LTP and memory 
(Jacobsen et al., 2008). Activators of IDE have been developed (Song et al., 2003; 
Cabrol et al., 2009) but none have reached the clinic. 
1.11.2.2 Immunotherapy 
One of the most successful potential therapies for AD is immunotherapy. 
Immunotherapy aims to use anti-amyloid antibodies to target Aβ for destruction by 
the immune system. There are two main forms of immunotherapy, passive and 
active. Passive immunotherapy involves treating patients with anti-Aβ antibodies, 
whereas in active immunotherapy patients are vaccinated with Aβ and the anti-Aβ 
antibodies are generated by the patient’s own immune system. This approach was 
very successful in mouse models, however clinical trials had to be halted early as 
some patients developed brain inflammation. Analysis of the data from this halted 
trial showed that even though treatment with the antibody decreased Aβ plaques in 
the brain, there was no change in total Aβ levels and no improvement of cognitive 
function (Kokjohn and Roher, 2009). The anti-Aβ antibody drug bapineuzumab 
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which passed initial clinical trials (Salloway et al., 2009) has recently failed phase 3 
clinical trials on the basis that it did not result in a change in cognition 
(http://www.pfizer.com/news/press_releases/pfizer_press_release.jsp?guid=2012072
2012072en&source=RSS_2011&page=3, Pfizer press release). The latest 
immunotherapy drug in development, CAD106, has passed initial clinical trials and 
did not cause severe adverse side effects, but it remains to be determined whether it 
has any positive effect on the symptoms or Aβ load of AD patients (Winblad et al., 
2012). Other recent work has aimed at developing antibodies specifically to Aβ 
oligomers. The advantages of conformation specific antibodies is that they do not 
recognise Aβ monomers (so do not get mopped up binding just to monomer), do not 
bind to sAPPα or APP (so do not prevent these performing their normal function in 
the brain) and do not bind to Aβ fibrils (binding to fibrils could increase the risk of 
an inflammatory response in the brain). These have been successful in mouse 
models (Hillen et al., 2010). 
Despite much effort being put into the development of therapies targeting Aβ, 
and their success in AD mouse models, none of these have passed clinical trials (e.g. 
(Malamas et al., 2009)). It has been suggested that this is because at the point AD 
symptoms become evident, too much neuronal damage has occurred for any 
treatments to be successful: too many neurons have died, too many synapses have 
been lost and amyloid deposition is too great to reverse. Treatments may need to 
start in the preclinical or mild cognitive impairment stages of the disease to have any 
symptomatic benefit to patients (Golde et al., 2011). 
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1.12 Aims 
The metabolism of APP is an important determinant in the development and 
pathogenesis of AD, yet relatively little is currently known about the regulation of 
APP, and how this is altered in AD. Several drugs targeting APP metabolism 
(inhibiting Aβ production) have failed in clinical trials demonstrating the current 
lack of a full understanding of the role of APP in the pathogenesis of AD. Several 
proteins have been identified that can regulate the processing of APP, and many of 
these are altered in AD or during aging. Since the metabolism and proteolytic 
processing of APP is so tightly regulated by a large number of APP-interacting 
proteins, studies of these proteins represent a window into the normal regulation of 
APP, and the potential to identify new drug targets for AD. The first part of this 
study investigates three novel APP interacting proteins, neurofascin, Thy-1 and 
contactin 5. Due to their proximity to APP and links to Alzheimer’s disease we 
hypothesised that these proteins have a role in the regulation of APP metabolism, 
and, specifically, Aβ generation. 
Recent GWAS into sporadic AD have identified several novel genes 
associated with AD, and these have in turn highlighted the importance of certain 
cellular processes in the development of AD. GWAS have shown us that processes 
at the cell membrane, specifically endocytosis, are involved in the development of 
AD. Endocytosis has been shown to be dysregulated very early in AD pathology, 
and plays an important role in the metabolism of APP and the Aβ peptide. 
Endocytosis (or lack of endocytosis) of APP determines whether the toxic 
aggregation prone Aβ peptide or the non-toxic p3 peptide are generated from APP 
cleavage. Endocytosis is also required for the uptake and arguably for the toxicity of 
Aβ by neurons, as well as for the clearance of the Aβ peptide from the brain. In the 
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second part of this thesis we hypothesised that the endocytic protein BIN1 is 
involved in the generation of Aβ by altering the endocytosis of APP, or in the 
endocytosis of toxic Aβ oligomers by cells.  
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2 Materials and methods 
2.1 Materials 
Unless stated otherwise, chemicals and reagents were from Sigma-Aldrich 
(Pool, Dorset, UK). Absorbance 96 well plate assays were determined using an 
OPSYS MR plate reader from Dynex (Worthing, West Sussex, UK). 
2.1.1 Antibodies 
HRP-conjugated secondary antibodies were from Sigma-Aldrich Ltd (Pool, 
Dorset, UK), AlexaFluor® conjugated secondary antibodies and Texas-red 
conjugated streptavidin were from Invitrogen Life Sciences (Paisley, Scotland, UK). 
Primary antibodies used in western blotting are detailed in table 2.2, and primary 
antibodies used in immuno-fluorescence microscopy and Aβ ELISA are detailed in 
the appropriate methods. 
2.1.2 Molecular biology general materials 
Yeast extract and tryptone were from Melford (Ipswich, Suffolk, UK), agar 
was from Oxoid (Basingstoke, Hampshire, UK). Miniprep and maxiprep plasmid 
purification kits, and gel extraction kits were from Qiagen (Crawley, West Sussex 
UK). NcoI, KpnI, and XbaI were from New England Biolabs (Hitchin, 
Hertfordshire, UK) and Eco0109I was from Fermentas (Glen Burnie, Maryland, 
USA) E.coli XL1 blue competent cells were from Stratagene (Wokingham, 
Berkshire, UK). All polymerase chain reaction reagents were from Invitrogen Life 
Sciences (Paisley, Scotland, UK) except primers which were purchased from Sigma-
Aldrich Ltd (Pool Dorset, UK). One kb DNA ladder was from New England Biolabs 
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(Hitchin, Hertfordshire, UK). Petri dishes were from Sterilin (Fischer Scientific UK 
Ltd, Loughborough, Leicestershire, UK). 
2.1.3 General tissue culture materials 
Unless stated otherwise all tissue culture reagents were from Lonza (Basel, 
Switzerland). Sterile pipettes were from Sterilin (Newport, UK), flasks, plates and 
cryovials were from Nunc A/C (Rosklide, Denmark). Fetal bovine serum was from 
Biosera (East Sussex, UK). OptiMEM reduced sera medium was from Invitrogen 
Life Sciences (Paisley, Scotland, UK). TransIT-LT1 transfection reagent was from 
Mirus (Madison, WI, USA). siRNA and siRNA reagents were from Dharmacon 
(Lafayette, CO, USA). HEK-APP695 cells, SH-SY5Y cells and N2a-APP695 cells 
were from Dr Katherine Kellet (University of Leeds). 
2.2 Cloning methods 
2.2.1 Cloning cDNA into a eukaryotic expression vector 
BIN1 in pcDNA3.1(+) (NM_139343) was obtained from Source Bioscience 
(Nottingham, UK), Neurofascin (IMAGE 40068186), contactin (IMAGE 40146650) 
and Thy-1 (IMAGE 6137513) cDNAs were obtained from Source Bioscience and 
cloned into the eukaryotic expression vector pIRESneo (Clontech, Saint-Germain-
en-Laye, France). APP695 in a pIREShyg vector was provided by previous members 
of the Hooper lab and has been described previously (Belyaev et al., 2010). 
pIRESneo and pIREShyg vectors contain an internal ribosome entry sequence 
(IRES) which allows polycistronic mRNA molecules to be transcribed. The IRES 
sequence in these vectors is between the gene of interest and the antibiotic resistance 
gene, and means the gene of interest and the antibiotic resistance gene are translated 
from a single mRNA transcript. This is advantageous as it means that expression of 
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the antibiotic resistance gene in the absence of the gene of interest does not occur, 
therefore all cells that survive the selection procedure express the gene of interest 
(Rees et al., 1996). 
2.2.2 Culturing E.coli 
2.2.2.1 Luria-Bertani media (LB media) 
 A sterile pipette tip was used to pick a single colony from a LB-agar plate. The 
pipette tip was deposited in 5 ml LB media (10 g tryptone, 5 g yeast extract and 5 g 
NaCl were dissolved in 1 litre of de-ionised water, then autoclaved and allowed to 
cool to 37 oC or below). Either ampicillin or kanomycin was added to the media to a 
final concentration of 100 µg ml-1 and the culture incubated for 8 hours at 37 oC in 
an orbital shaker at 250 rpm. For experiments where a culture volume larger than 5 
ml was required the 5 ml starter culture was used to inoculate a conical flask 
containing 200 ml LB media supplemented with antibiotic. The 200 ml culture was 
incubated at 37 oC at 250 rpm in an orbital shaker overnight. 
2.2.2.2 LB-agar plates 
 Agar was dissolved in LB media (15 g agar per litre of media) then autoclaved 
and allowed to cool to below 50 oC. Ampicillin or kanomycin was added to a final 
concentration of 100 µg ml-1 then the LB-agar was poured into petri dishes and 
allowed to set at room temperature. LB-agar plates were stored for up to one month 
at 4 oC. One hundred microlitres of E.coli growing in LB media were spread across 
the surface of pre-warmed LB-agar plates then incubated over-night at 37 oC. 
Colonies from LB-agar plates or E.coli from a glycerol stock were picked using a 
heat-sterilised metal loop and streaked across the surface of a pre-warmed LB-agar 
plate, then incubated over-night at 37 oC. 
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2.2.3 Glycerol stocks 
 Nine hundred microlitres of E.coli growing in exponential phase in LB media 
were added to 100 µl of 80 % glycerol in a cryovial then stored at -80 oC. 
2.2.4 Plasmid purification 
 Plasmids were extracted from E.coli and purified using a QIAspin miniprep kit 
from QIAGEN according to the manufacturer’s protocol. DNA was eluted with 50 
µl warm ddH2O or the elution buffer provided in the kit. The concentration of DNA 
was determined by absorbance at 260 nm using a nanophotometer from Implen 
(München, Germany), or samples were subjected to agarose gel electrophoresis, 
stained with ethidium bromide, and the intensity of the sample was compared to the 
intensity of a standard (1 kb DNA ladder, New England Biolabs). The ratio of 
absorbance at 260 nm to 280 nm was used to determine the purity of DNA. 
2.2.5 Polymerase chain reactions (PCR) 
 PCR was carried out using a Proteus II thermal cycler (Helena Biosciences, 
Gateshead, Tyne and Wear, UK). The reaction cycle varied according to the cDNA 
being amplified. For specific reaction cycles see table 2.1, for primer sequences see 
table 2.2. Reaction volumes were made to 50 µl with sterile ddH2O. The 
amplification of the correct product was confirmed by agarose gel electrophoresis. 
PCR products were excised from the gel using a scalpel and purified by gel 
extraction using a QIAgen gel extraction kit. 
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Table 2.1: PCR Reactions 
Reaction Reaction Mix Cycle 
Cloning neurofascin 1x amplification buffer, 
0.3 mM each dNTP, 1.35 
mM MgSO4, 0.3 mM 
primer p3, 0.3 mM primer 
p4, 200 ng neurofascin 
cDNA (IMAGE 
40068186), 1 U pfx 
polymerase, 2x enhancer 
solution 
94 ºC for 5 minutes,  
(94 ºC for 30 seconds,  
55 ºC for 30 seconds,  
68 ºC for 4 minutes) x30, 
72 ºC for 10 minutes, 4 ºC 
hold. 
Cloning Contactin 5 2x amplification buffer, 
0.3 mM each dNTP, 1.35 
mM MgSO4, 0.3 mM 
primer p1, 0.3 mM primer 
p2, 200 ng contactin 
cDNA (IMAGE 
40146650), 1 U pfx 
polymerase, 2x enhancer 
solution 
94 ºC for 5 minutes,  
(94 ºC for 30 seconds,  
55 ºC for 30 seconds,  
68 ºC for 4 minutes) x30, 
72 ºC for 10 minutes, 4 ºC 
hold. 
Cloning Thy-1 2x amplification buffer, 
0.3 mM each dNTP, 1.35 
mM MgSO4, 0.3 mM 
primer p5, 0.3 mM primer 
p6, 200 ng Thy-1 cDNA 
(IMAGE 6137513), 1 U 
pfx polymerase, 1x 
enhancer solution 
94 ºC for 5 minutes,  
(94 ºC for 30 seconds,  
55 ºC for 30 seconds,  
68 ºC for 1 minute) x30, 
72 ºC for 10 minutes, 4 ºC 
hold. 
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Table 2.2 Primer sequences. All primers are shown in a 5` to 3` direction. 
Name  Primer Sequence 
p1 Forward primer 
for cloning 
contactin 5 
GATGCTCGTGAGCGGCCGCATGGCTTCCTCTTG
GAAACTAATGCT 
p2 Reverse primer 
for cloning 
contactin 5 
CATAGGAATTCTCACCAGGAAGTTGAAGGAAT
CATCA 
p3 Reverse primer 
for cloning 
neurofascin 186 
GCTAGGAATTCTTAGGCCAGAGAGTAGATAGC
ATTGAC 
p4 Forward primer 
for cloning 
neurofascin 186 
GATGCTCGTGAGCGGCCGCATGGCCAGGCAGC
CACCGCC 
p5 Forward primer 
for cloning Thy-
1 
GATGCTCGTGAGCGGCCGCATGAACCTGGCCA
TCAGCATCGCT 
p6 Reverse primer 
for cloning Thy-
1 
CATAGGAATTCTCACAGGGACATGAAATCCGTG
GCC 
p7 Primer for 
sequencing 
contactin 5 
TCTTGGAAACTAATGCTGTTTCTG 
p8 Primer for 
sequencing 
contactin 5 
GAAATGGAACAGAAATAGATCTGGA 
p9 Primer for 
sequencing 
contactin 5 
GGTGAAAAACACAGTGACGAAT 
p10 Primer for 
sequencing 
contactin 5 
GGGAGCCCTCTCCGAT 
p11 Primer for 
sequencing 
contactin 5 
GGATCCTAAATGCTTCCAAATC 
p12 Primer for 
sequencing 
contactin 5 
CCAGGCCCACCTGG 
p13 Primer for 
sequencing 
contactin 5 
GGGGAAGGCTTCGGCTATAT 
Continued overleaf  
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Table 2.2 Primer sequences (continued) 
Name  Primer Sequence 
p14 Primer for 
sequencing 
contactin 5 
TAACAGGATTAGAAGGAAATACGTTATATC 
p15 Primer for 
sequencing 
neurofascin 186 
CCAGGCAGCCACCGC 
p16 Primer for 
sequencing 
neurofascin 186 
ATGCAGCCTTCCTCCTCTG 
p17 Primer for 
sequencing 
neurofascin 186 
GGTGTCTAAATCTCCTCTGTGGC 
p18 Primer for 
sequencing 
neurofascin 186 
ATCGCCTCC 
p19 Primer for 
sequencing 
neurofascin 186 
GCAGGGCTGTGTACCAGTG 
p20 Primer for 
sequencing 
neurofascin 186 
GGGCACCACGGTGCA 
p21 Primer for 
sequencing 
neurofascin 186 
CAGTTCCAACCTGGGGTCT 
p22 Primer for 
sequencing 
neurofascin 186 
AGGCTGAAAATGACTTCGGG 
p23 Primer for 
sequencing 
neurofascin 186 
TACCGTGGGTGCGACG 
p24 Primer for 
sequencing 
neurofascin 186 
TCCCGGGATGACATACACG 
p25 Primer for 
sequencing Thy-
1 
GCCAT CAGCATCGCT CTC 
p26 Primer for 
sequencing Thy-
1 
CCCCACAGTGCCAAAGAG 
Continued overleaf  
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Table 2.2 Primer sequences (continued) 
Name  Primer Sequence 
p27 Primer for 
sequencing 
contactin 5 
GGCATCTGAGGAATGATAAAGATT 
p28 Primer for 
sequencing 
neurofascin 186 
ACGACAGGGTCTAGGTTTTCCT 
p29 Primer for 
sequencing 
genes inserted to 
pIRESneo 
(binds at the 
promoter) 
TTTTGGCACCAAAATCAACG 
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2.2.6 Agarose gel electrophoresis 
 Agarose powder to make a 0.8 % w/v gel was added to TAE buffer (40 mM 
Tris-HCl, 10 mM sodium acetate, 2 mM EDTA pH 8.0) and heated in short bursts in 
a microwave until the agarose had dissolved. The agarose was then poured into a gel 
cast and allowed to set. Samples and 1 kb DNA ladder were diluted 1/3 with sample 
buffer (50 % glycerol, 0.25 % bromophenol blue) loaded onto the gel and subjected 
to electrophoresis at 100 V for 1 hour. Agarose gels were stained with 10 µl 
ethidium bromide diluted in 20 ml TAE buffer for approximately 30 minutes 
protected from light, and visualised under U.V. light. 
2.2.7 Restriction digests 
2.2.7.1 For cloning 
 Neurofascin, contactin and Thy-1 PCR products amplified from the vectors 
supplied by Source Bioscience, and empty pIRESneo, were digested with restriction 
enzymes. Approximately 2 µg contactin 5, neurofascin, and Thy-1, or 5 µg empty 
pIRESneo, were incubated with 20 U EcoRI, 20 U NotI-HF, 0.2 µg BSA in 1x NEB 
buffer 4 at 37 ºC for 16 hours. The restriction enzymes were then heat-inactivated by 
10 minute incubation at 65 oC. To prevent the linearised pIRESneo plasmid form re-
circularizing digested plasmid was incubated for 30 minutes at 37 ºC with 0.5 U 
Antarctic phosphatase in 1x Antarctic phosphatase buffer (New England Biolabs, 
Hitchin, Hertfordshire, UK). 
2.2.7.2 To confirm insertion of genes into pIRESneo 
 Plasmids were purified from transformed colonies using a Qiagen spin-mini 
prep kit, then 10 µl of each mini-prep were incuated with either 20 U Eco0109I in 
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1x Fermantas buffer tango buffer 4, 20 U KpnI, 0.2 µg BSA in 1x NEB buffer 1 or 
20 U NcoI in 1x NEB buffer 3 for 4 hours at 37 oC. 
2.2.8 Ligation 
 Ligations were performed using a Quick Ligation kit from New England 
Biolabs (Hitchin, Hertfordshire, UK) according to the manufacturer’s instructions. A 
3 molar excess of insert was ligated into 50 ng of pIRESneo using 2000 U Quick T4 
DNA ligase in 1 x Quick Ligation Reaction Buffer (New England Biolabs, Hitchin, 
Hertfordshire, UK). This was incubated for 5 minutes at room temperature then used 
immediately in transformation of XL1 blue E.coli cells.  
2.2.9 Transformation of XL1 blue cells  
 β-mercaptoethanol (1.7 µl) was added to 100 µl XL1 blue competent cells 
which were then incubated for 10 minutes at 4 ºC, with mixing by gentle swirling 
every 2 minutes. The ligation reaction was added to the cell suspension, and 
incubated for a further 30 minutes at 4 ºC. Cells were heat shocked for 45 seconds at 
42 ºC, then incubated for 2 minutes at 4 ºC. Nine hundred microlitres of S.O.C. 
media (2 % tryptone (w/v), 0.5 % yeast extract (w/v), 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2, 10 mM MgSO4, 20 mM glucose) at 42 ºC were added to cells and 
incubated for 1 hour at 37ºC with shaking. Bacteria were spread onto LB-agar plates 
with 100 µg µl-1 ampicillin as a selection marker, and incubated overnight at 37 ºC.  
2.2.10 Ethanol precipitation of DNA 
 One tenth volume of 3 M sodium acetate pH 5.2 and two volumes of absolute 
ethanol at -20 oC were mixed with the DNA then incubated for 1 hour at -20 ºC. 
DNA was pelleted by centrifugation at 11,337 g at 4 ºC for 20 minutes, then washed 
with 300 µl 80 % (v/v) ethanol at -20 oC, and centrifuged again at 11,337 g for 5 
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minutes at 4 ºC. The supernatant was discarded and the pellet was air dried at 37 ºC, 
then re-suspended using sterile ddH2O. 
2.2.11 Sequencing 
 Insertion of genes into pIRESneo was confirmed firstly by restriction 
digestion, and then by sequencing. Sequencing reactions were performed by Dundee 
Sequencing Services using forward primers designed using the OligoPerfectTM 
primer design tool by Invitrogen (see table 2.2 for primer sequences). Sequencing 
results were then aligned with the expected template DNA using the freely available 
web tool MultAlin (http://multalin.toulouse.inra.fr/multalin/multalin.html). 
2.3 Tissue culture methods 
2.3.1 Tissue culture 
 SH-SY5Y (human neuroblastoma), HEK (human embryonic kidney) and N2a 
(mouse neuroblastoma) cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM, 1 ml per 5 cm2 surface area) supplemented with 10 % fetal bovine serum 
(FBS), in a humidified incubator at 37ºC with 5 % CO2. Once cells had reached  
90 % confluency they were rinsed twice with phosphate buffered saline (PBS) 
without Ca2+ or Mg2+ (PBS-M, diluted from 10x stock) then harvested by a 5-10 
minute incubation at 37 ºC in PBS-M (1 ml per 16 cm2 surface area). The resulting 
cell suspension was diluted into DMEM and transferred to a fresh flask. 
2.3.2 Counting cells 
 Cells were rinsed twice with PBS-M, then harvested by a 5-10 minute 
incubation in PBS-M. Cells were pelleted by centrifugation at 1,409 g for 3 minutes 
and resuspended in an appropriate volume of DMEM. Cells were diluted 1/2 in 
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trypan blue, 20 µl cell suspension was pipetted onto a haemocytometer, and cells 
that had not taken up trypan blue stain within the grid areas at each corner of the 
slide were counted. The mean count for each grid was taken.  
2.3.3 Stable transfection 
 SH-SY5Y or HEK cells were stably transfected with expression vectors by 
electroporation. Contactin 5 in pIRESneo vector was linearised before transfection; 
this was performed by digesting plasmid with XbaI (20 U XbaI, 1x NEB buffer 4, 
and 30 µg cDNA, incubated for 2 hours at 37 ºC). Ethanol precipitated DNA was 
used in transfection of SH-SY5Y and HEK cells. Cells were grown to approximately 
80 % confluency in a T80 cm2 flask in DMEM supplemented with 10 % FBS, then 
harvested by washing into PBS-M and pelleted by centrifugation at 1,409 g for 3 
minutes. Cell pellets were re-suspended in 700 µl DMEM (without FBS), then 
mixed with either 30 µg DNA (transfection) or an equivalent volume of ddH2O 
(control) in a 4 mm gap width electroporation cuvette (Geneflow, Staffordshire, 
UK). Cells were electroporated using an Electro Cell Manipulator 630, with a pulse 
at 250 V (Resistance = none, Capacitance=1650 µF). Electroporated cells were 
resuspended in 5 ml warm DMEM (with 10 % FBS), and transferred to a T80 cm2 
flask containing 10 ml DMEM. Cells were grown to approximately 70 % 
confluency, then selected for cells expressing the protein of interest using DMEM 
supplemented with either 1 mg ml-1 G418 (for pIRESneo and pcDNA3.1(+) 
vectors), 0.15 mg ml-1 hygromycin (for pIREShyg vectors). Once control cells had 
been killed off, transfected cells were cultured for a further 7 days in DMEM 
supplemented with either G418 or hygromycin. 
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2.3.4 Cryopreservation of cells 
 Cells were grown to confluence in T80 cm2 flasks, and then harvested by a 5-
10 minute incubation in PBS-M. Cells harvested from one T80 cm2 flask were 
pelleted by centrifugation at 1,409 g for 3 minutes. The cell pellet was resuspended 
in 1 ml of freeze media – DMEM supplemented with 27 % (v/v) FBS and 10 % 
(v/v) dimethylsulphoxide (DMSO), then transferred to a cryovial and cooled to  
-80 °C in a Mr Frosty for 24 hours. Cells were transferred to liquid nitrogen for long 
term storage. 
2.3.5 Transient transfection 
 N2a-APP695 cells were grown to approximately 50 % confluency in a 6-well 
plate then tranfected with contactin 5 cDNA using TransIT-LT1 transfection reagent 
according to the manufacturer’s instructions (volumes of reagents were altered 
slightly to increase transfection efficiency). Briefly, 6 µl room temperature TransIT-
LT1 transfection reagent and 2 µg ethanol precipitated DNA were diluted in 250 µl 
OptiMEM reduced sera media, incubated for 20 minutes at room temperature, then 
added drop-wise to one well of a 6-well plate. Cells were incubated for 24 hours 
with transfection mixture then washed twice with PBS and incubated for 48 hours 
with OptiMEM reduced sera media. 
2.3.6 siRNA transfection 
 Cells were transfected with 50 nM ON-TARGET plus SMARTpool siRNA 
from Dharmacon. siRNA was diluted to 0.5 µM in OptiMEM reduced sera media, 
and Dharmafect 3 was diluted to 40 µl ml-1 in OptiMEM and incubated for 5 
minutes at room temperature. The diluted siRNA was added to the diluted 
Dharmafect and incubated for 20 minutes at room temperature. The 
- 72 - 
siRNA/Dharmafect mixture was diluted with DMEM, so that the final siRNA 
concentration was 50 nM, then this mixture was used to replace the media on cells. 
Cells were incubated for 24 hours with the transfection reagents then washed twice 
with PBS and incubated with OptiMEM reduced sera media. 
2.4 Western blotting methods 
2.4.1 Preparation of cell lysates  
 Cells were washed twice with PBS-M then were harvested by scraping into 
PBS-M, and pelleted by 10 minute centrifugation at either 3,913 g or 15,115 g at 
4ºC. Cells were lysed by re-suspension in RIPA lysis buffer (50 mM Tris, 150 mM 
NaCl, 0.5 %  (w/v) Sodium deoxycholate, 1 % (v/v) NP-40, pH 8.0) with EDTA 
complete protease inhibitor cocktail (Roche Diagnostics, West Sussex, UK), and 
incubated at 4ºC for 30 minutes. Cell lysates were then centrifuged at >13,000 g for 
10 minutes at room temperature. Supernatants were stored at -20 ºC. 
2.4.2 Preparation of concentrated media samples 
 OptiMEM reduced sera medium was removed from cells and centrifuged for 
10 minutes at either 3913 g or 15,115 g at 4 ºC to pellet any cells. Supernatant was 
then concentrated approximately 50 fold using Vivaspin 100,000 Da molecular 
weight cut off polyethersulfone membrane concentrator (Sartoris Stedim Biotech, 
Surrey, UK) by centrifugation at 3913 g at 4 ºC. Concentrated media samples were 
stored at -20 ºC. 
2.4.3 BCA protein assay 
 Protein concentrations of samples were determined by bicinchoninic acid 
(BCA) assay. Lysates were diluted in ddH2O on a 96 well plate (10 µl sample per 
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well) and 200 µl 4 % CuSO4 diluted 1/50 in BCA reagent was added. The plate was 
incubated at 37 oC for 20-30 minutes, enough time to allow sufficient purple colour 
to develop in sample and standard wells, then the absorbance measured at 570 nm. A 
standard curve made up with BSA diluted in ddH2O was used to determine the 
protein concentrations of lysates. 
2.4.4 Sodium dodecyl sulphate gel electrophoresis  
 A BCA assay was performed on samples in order to standardise the 
concentration of protein loaded. Samples were denatured by heating to between 90 
and 100 ºC for 4 minutes in 1x sample buffer (1.6 mM Tris pH 6.8, 2.2 % (w/v) 
SDS, 1.6 % (w/v) DTT, 11 % (v/v) glycerol) followed by centrifugation at  
>13,000 g for 1 minute at room temperature. Samples were electrophoresed on 
polyacrylamide gels (running buffer: 25 mM Tris, 192 mM glycine, 0.1 % (w/v) 
SDS, pH 8.3, from Bio-rad, Hempstead, Hertfordshire, UK), then transferred to a 
PVDF (polyvinylidine difluoride) membrane (transfer buffer: 150 mM glycine,  
20 mM Tris, 20 % (v/v) methanol). Percentage acrylamide of gels, voltage, and 
transfer times were varied according to the molecular weight of protein being 
analysed (see table 2.3).  
2.4.5 Western blotting 
 Membranes were blocked in PBST 5 % (w/v) milk (marvel milk powder made 
up in PBS 0.1% (v/v) Tween: PBST), rinsed three times briefly in PBST then 
incubated with primary antibody diluted in PBST 2 % (w/v) BSA for overnight at  
4 oC (see table 2.3 for dilution). Membranes were rinsed three times briefly with 
PBST, then washed three times for 10 minutes in PBST, with brief rinses in 
between. HRP-conjugated secondary antibodies were diluted 1/4000 in PBST 2 % 
(w/v) BSA (see table 2.3) and incubated for a 1 hour at room temperature with 
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membrane. Membranes were rinsed three times briefly in PBST, then washed for 10 
minutes in PBST followed by two 10 minute washes in PBS without Tween. 
Membranes were developed by 1 minute incubation using 4 ml luminol enhancer 
solution and 4 ml peroxide solution (Thermo Scientific, Waltham, MA, USA). 
Membranes were imaged using a LAS3000 imager (GE healthcare 
Buckinghamshire, UK), exposure times varied. Pre-stained molecular weight 
standards (Fermentas, Glen Burnie, Maryland, USA) were used to estimate 
molecular weight of proteins. Membranes were stripped in 1 mM glycine pH 2.0 for 
30 minutes, then re-probed for actin. As a control for loading, membranes were 
stained with 0.1 % (w/v) amido black, 1 % (v/v) acetic acid for 2 minutes at room 
temperature then destained with H2O to visualise total protein.  
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Table 2.3: Antibodies and conditions used in western and dot blotting 
Antigen Antibody Dilution Secondary Conc. Poly-
acrylamide 
Transfer 
Neurofascin  Ab31457 
(Abcam, 
Cambridg
e, UK) 
1/200  Goat anti-
rabbit 
7% 3 hours 300 
mA 
Contactin 5 AF3030 
(R&D 
systems, 
Abingdon, 
UK) 
1/500  Rabbit anti-
goat 
7% 80 minutes 
120 V or 3 
hours 300 
mA  
Thy-1 MAB2067 
(R&D 
systems, 
Abingdon, 
UK) 
1/2000  Rabbit anti-
mouse 
N.A. N.A. 
APP (full 
length) 
22C11 
(Millipore, 
Billerica, 
MA, 
USA) 
1/2500 Rabbit anti-
mouse 
7% 80 minutes 
120 V or 3 
hours 150 
mA 
sAPPβ  1A9 (a gift 
from 
GlaxoSmit
hKline, 
Harlow, 
UK) 
1/2500 
incubated 
overnight 
at 4˚C 
Rabbit anti-
mouse 
7% or 10% 80 minutes 
120 V or 3 
hours 150 
mA 
sAPPα 6E10 
(Covance, 
New 
Jersey, 
USA) 
1/4000  Rabbit anti-
mouse 
7% or 10% 80 minutes 
120 V or 3 
hours 150 
mA 
Continued overleaf  
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Table 2.3: Antibodies and conditions used in western and dot blotting 
(continued) 
Antigen Antibody Dilution Secondary Conc. Poly-
acrylamide 
Transfer 
APP (C-
terminal) 
A8717 
(Sigma 
Aldrich, 
Poole, 
Dorset, 
UK) 
1/750 Goat anti-
rabbit 
4-17% 50 minutes 
380 mA 
GFP EGFP 
(Clontech, 
Saint-
Germain-
en-Laye, 
France) 
1/5000 Rabbit anti-
mouse 
12% 80 minutes 
120 V 
PICALM HPA0190
53 
(Sigma-
Aldrich) 
1/1000 Goat anti-
rabbit 
10% 80 minutes 
120 V 
BIN1 Ab54764 
(abcam, 
Cambridg
e, UK) 
1/1000 Rabbit anti-
mouse 
10% 80 minutes 
120 V 
Actin Ac15 
(abcam, 
Cambridg
e, UK) 
1/5000 Rabbit anti-
mouse 
N.A. N.A. 
Fibrilar Aβ 
epitope 
OC (gift 
from C. 
Glabe, 
University 
of 
California, 
USA)  
1/5000 Goat anti-
rabbit 
N.A N.A. 
Pre-fibrillar 
Aβ epitope 
A11 (gift 
from C. 
Glabe, 
University 
of 
California, 
USA) 
1/1250 Goat anti-
rabbit 
N.A. N.A. 
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2.5 Dot blotting 
One µg AβOs was spotted onto nitrocellulose membrane (GE Healthcare, 
Buckinghamshire, UK), then air dried for 15 minutes. Membranes were blocked for 
4 hours in 10 % (w/v) milk (marvel milk powder made up in Tris A buffer (0.1 M 
tris, 0.85 % (w/v) NaCl, 0.1 % (v/v) Triton X-100, pH 7.5)), rinsed three times 
briefly in PBST then incubated with primary antibody diluted in Tris A buffer 
containing 3 % (w/v) BSA overnight at 4 oC (see table 2.3 for dilutions). Membranes 
were rinsed 3 times with PBST, then had three 10 minute washes in PBST, with 
brief rinses in between. HRP-conjugated secondary antibodies were diluted 1/4000 
in Tris A buffer containing 2 % (w/v) BSA (see table 2.3) and incubated for 1 hour 
at room temperature with the membrane. Membranes were rinsed 3 times in PBST, 
then washed for 10 minutes in PBST followed by two 10 minute washes in PBS 
without Tween. Membranes were developed by a one minute incubation in 4 ml 
luminol enhancer solution and 4 ml peroxide solution. Membranes were imaged 
using LAS3000 imager (GE healthcare, Buckinghamshire, UK), exposure times 
were varied. 
2.6 Fluorescence microscopy 
2.6.1 Method A, for determining Aβ internalisation: 
2.6.2 Growth of cells 
 Thirteen mm glass coverslips (VWR, West Sussex UK) were coated with fish-
skin (FSG) gelatine by a 30 minute incubation with 200 µl 0.1 % (v/v) FSG in a 24-
well plate at 37ºC. FSG was then removed and SH-SY5Y cells were plated onto the 
coated coverslips in order to be approximately 50-60% confluent the following day.  
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2.6.3 Fixing and staining cells 
 Following treatment with AβOs coverslips were rinsed three times with PBS 
(with Ca2+ and Mg2+, PBS+M)) then fixed by a 10 minute incubation with 4 % 
paraformaldehyde (PFA, diluted in ddH2O from a 16 % stock from Alfa Aesar, 
Ward Hill, MA, USA). The PFA was removed and quenched with 1 ml 50 mM 
NH4Cl. Coverslips were washed three times for 5 minutes with PBS+M, then cells 
were permeabilised by a 4 minute incubation in PBS+M 0.2 % (v/v) Triton X-100. 
Coverslips were rinsed twice with PBS+M then blocked for 18 or more hours at 4ºC 
with 5 % FSG in PBS+M (sterilised using a 0.2 µm filter). Cells were then stained 
with primary antibody: coverslips were transferred to a moist chamber and 
incubated for 1 hour at room temperature with 20 µl anti-BIN1 antibody (ab54764) 
diluted 1/500 in 5 % (v/v) FSG. Coverslips were transferred back to the 24-well 
plate and washed three times for 5 minutes with PBS+M. Coverslips were 
transferred to the moist chamber and stained with secondary antibodies: 20 µl 
AlexaFluor® 488 conjugated donkey anti-mouse (secondary for BIN1) and Texas-
red conjugated streptavidin (secondary for biotinylated Aβ) diluted 1/500 in 5 % 
FSG were incubated with coverslips for 1 hour at room temperature protected from 
light. Coverslips were then transferred back to 24-well plate and washed for 10 
minutes with PBS+M. Nuclei were stained by 10 minute incubation with 2 µg ml-1 
4’,6-diamidino-2-phenylindol dihydrochloride (DAPI, Invitrogen Life Sciences, 
Paisley, Scotland, UK) at room temperature. Coverslips were washed a further two 
times with PBS+M for 10 minutes each. Coverslips were then mounted face down 
onto glass slides using Fluoromount G (SouthernBiotech, Birmingham Alabama, 
USA). Slides were dried overnight at 4 ºC then visualised using a DeltaVision 
Optical Restoration Microscopy System (Applied Precision, Issaquah, Washington, 
USA). 
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2.6.4 Method B, for determining cell surface APP and NMDAR: 
 SH-SY5Y-APP695-BIN1 and SH-SY5Y-APP695-pcDNA3.1(+) cells were 
plated at 50,000 cells per well on 13 mm glass coverslips in a 24-well plate, so that 
they were 80 % confluent the following day. The cells were washed twice with 
PBS+M at 4 oC then incubated for 30 minutes with primary antibody diluted 1/200 
in PBS+M (6E10 for APP, SAB2500699 (Sigma Aldrich, Poole, Dorset, UK) for the 
GluN2B subunit of the NMDA receptor) at 4 oC. Cells were washed twice with 4 oC 
PBS+M, then incubated for 10 minutes with DMEM at either 37 oC or 4 oC. Cells 
were washed twice with PBS+M at 4 oC then fixed, permeabilised and stained with 
secondary antibodies using the same procedure as Method A. Secondary antibodies 
used were Alexa Fluor 488 conjugated donkey anti-mouse for APP or AlexaFluor® 
488 conjugated donkey anti-goat for NMDA receptor. 
2.6.5 Taking and quantifying images 
 Cells were visualised using a DeltaVision Optical Restoration Microscopy 
System (Applied Precision, Issaquah, Washington, USA), and data stacks at 
excitation 360 nm and emission 457 nm (DAPI, (nuclei)), excitation 490 nm and 
emission 526 nm (FITC, for APP, BIN1, or NMDAR), and excitation 555 nm and 
emission 617 nm (Texas-red, for biotin tagged Aβ) were taken for 20 cells per 
treatment condition. Data stacks were deconvolved using SoftWoRx software 
(Applied Precision, Issaquah, Washington, USA). Images were analysed using 
Image J software. For each cell an image from the middle of the Z-stack 
representing a slice through the centre of the cell was selected. For Aβ 
measurements the total fluorescence intensity of Aβ in and around the cell and the 
fluorescence intensity of Aβ close to the edges of the cell were measured. The % of 
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Aβ fluorescence inside the cell (as opposed to bound to the edge of the cell) was 
determined.  
2.6.6 Preparation of Aβ oligomers 
 Synthetic amyloid-beta oligomers (AβOs) were prepared from biotin tagged 
monomeric Aβ42 peptide (biotin-LC-Aβ1-42, from AnaSpec, Freemont, CA, USA) as 
described by (Chromy et al., 2003). Lyophilised Aβ1-42 peptide was re-constituted in 
1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP) then dried under a N2 gas stream to form a 
peptide film, which was stored at -80ºC. The Aβ42 peptide film was resuspended in 
dimethyl sulphoxide (DMSO) then diluted 1/10 using Ham’s F12 medium 
(Invitrogen Life Sciences, Paisley, Scotland, UK) to a 100 µM concentration of Aβ, 
and this was incubated for 16 hours at room temperature to allow the Aβ to 
aggregate and form oligomers. The oligomer preparation was centrifuged for 20 
minutes at 16,000 g to pellet any fibrillar material. As a vehicle control DMSO was 
diluted 1/10 in Ham’s F12 medium, incubated for 16 hours at room temperature and 
centrifuged at 16,000 g for 20 minutes. 
2.7 Flow cytometry 
2.7.1 Method A, for cell surface NMDA receptor levels 
 Cells were plated in a 6-well plate at 500,000 cells per well and incubated for 
48 hours at 37 oC. The following procedure was carried out at 4 oC. Cells were 
washed twice with 500 µl PBS+M, then harvested by scraping into 500 µl PBSM 
and pelleted by centrifugation at 800 g for 5 minutes. The cell pellets were 
resuspended in 200 µl blocking buffer (5 % (v/v) fish skin gelatine in PBS+M) and 
blocked for 20 minutes. Primary antibody was diluted 1/100 into the cell suspension 
(2 µl SAB2500699 was added to each sample), and incubated for 1 hour. Cells were 
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pelleted by centrifugation at 800 g for 5 minutes, then washed by resuspending in 
500 µl PBS+M. Cells were re-pelleted, then resuspended in 200 µl blocking buffer 
and secondary antibody (AlexaFluor® 488 conjugated donkey anti-goat) was diluted 
1/100 into samples and incubated for 1 hour. Cells were pelleted by centrifugation at 
800 g for 5 minutes, then washed by re-suspending in 500 µl PBS+M. Cells were 
then re-pelleted and re-suspended in 500 µl PBSM 2.5 mM EDTA. One microlitre 
of 2 mg ml-1 DAPI was added to each sample less then 1 minute prior to analysis. 
Fluorescence from >10,000 live cells per sample was measured using a BD 
LSRFortessa cell analyser from BD biosciences (San Jose, CA, USA). 
2.7.2 Method B, for endocytosis of APP 
 Cells were plated in a 12-well plate at 200,000 cells per well and incubated for 
48 hours at 37 oC. The entire procedure was carried out at 4 oC unless otherwise 
stated. Cells were washed twice with PBS+M and incubated for 30 minutes with 300 
µl primary antibody (6E10) diluted 1/200 in PBS+M. Cells were washed twice with 
PBS+M, then incubated for 10 minutes with DMEM at either 4 oC or 37 oC. Cells 
were then washed twice with PBS+M at 4 oC, then harvested by scraping into 500 µl 
PBS+M. Cells were pelleted by centrifugation at 800 g for 5 minutes, then re-
suspended in 200 µl blocking buffer and blocked for 20 minutes. The addition of 
secondary antibody (AlexaFluor® 488 conjugated donkey anti-mouse) and analysis 
procedure was the same as for method A. 
2.8 General assays 
2.8.1 Amyloid-Beta Enzyme-linked Immunosorbent Assay (Aβ ELISA) 
 The Aβ ELISA method was developed by (Haugabook et al., 2001), antibodies 
were a kind gift from Drs Chris and Liz Eckman (Mayo Clinic, Jacksonville, FL, 
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USA, current address Atlantic Health System, Morristown, NJ, USA). Maxisorb 
ELISA plates were coated with capture antibody by 24 hour incubation at 4 °C with 
50 µg ml-1 anti-Aβ1-40 (33.1.1) or anti-Aβ1-42 (2.1.3.35.86) antibody diluted in PBS-
M (100 µl per well). Wells were then blocked for 4 hours at room temperature with 
300 µl Block ACE (Serotec, Toronto, Ontario, USA) 0.05 % (w/v) NaN3 in PBS-M. 
Wells were washed two times with 300 µl PBS-M, then samples and standards (Aβ1-
40 and Aβ1-42 from Bachem, Bubendorf, Switzerland) were diluted in EC buffer (5.75 
mM NaH2PO4, 15 mM Na2HPO4, 2 mM EDTA, 0.4 M NaCl, 0.2 % (w/v) BSA, 
0.05 % (w/v) CHAPS, 0.4 % (w/v) Block ACE, 0.05 % (w/v) NaN3, pH 7.0) in the 
plate and incubated at 4 °C for 24 hours. Wells were washed two times with PBS, 
then HRP conjugated detection antibody (anti-Aβ1-40 13.1.1 1/1000, anti-Aβ1-42 4G8 
(from Covance, New Jersey, USA) 1/2000) was diluted in 3.4 mM NaH2PO4, 17 
mM Na2HPO4, 2 mM EDTA 1 % (w/v) BSA pH 7.0 and incubated for 20 hours at  
4 °C. Wells were washed three times with PBS containing 0.05 % (v/v) Tween then 
developed using a 1:1 ratio of TMB 2-component peroxidise substrate kit 
(Kirkegaard and Perry, Gaithersburg, Maryland, USA), the reaction was stopped 
with 1 M H3PO4 and absorbance read at 450 nm. 
2.9 Human brain samples 
2.9.1 Cohorts 1, 2 and 3 
 Brain tissue was obtained from the Medical Research Council London 
Neurodegenerative Diseases Brain Bank (Institute of Psychiatry, King’s College 
London), the study had approval from the Leeds (Central) Research Ethics 
Committee. Brain tissue was homogenised by Dr Isobel Whitehouse as reported in 
(Whitehouse et al., 2010). Briefly, samples were homogenised in 9 volumes of  
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PBS-M, 0.5 % (v/v) NP-40, 0.5 % (w/v) sodium deoxycholate, pH 7.4 with Roche 
complete protease inhibitor cocktail (Roche Diagnostics, West Sussex, UK), using 
an electric homogeniser. Samples were centrifuged at 14,000 g for 10 minutes, 
pellets were discarded. The protein concentration of supernatants was determined by 
BCA assay. 
2.9.2 Cohort 4 
 Brain tissue was obtained from South West Dementia Brain Bank, University 
of Bristol, UK; the study had approval from North Somerset and South Bristol 
Research Ethics Committee and Leeds (Central) Research Ethics Committee. The 
diagnosis of AD in AD cases, and the absence of AD in control cases was made 
according to the criteria of the Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) (Morris et al., 1989). Neuron-specific enolase (Miners et al., 
2009), soluble Aβ and insoluble Aβ (van Helmond et al., 2010a, b) had been 
determined previously. For western blotting, samples were homogenised by Dr 
Isobel Whitehouse as detailed above in cohorts 1, 2, and 3. For Aβ and NSE 
measurements brain samples were homogenised and assays performed by Dr Scott 
Miners from the University of Bristol.  
2.10 Data analysis 
 Data were analysed using GraphPad Prism software. Data were tested for 
normal distribution using Kolmogorov-Smirnov normality test. If the data were 
normal significance was determined using the Paired t-test or Pearson correlation 
accordingly. For non-normally distributed data non-parametric statistical analysis 
were used, either Mann-Whitney, or Spearman’s correlation coefficient.  
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3 The effect of proteins from an in vivo APP interactome on APP 
processing 
3.1 Introduction 
The proteolytic processing of APP has been shown to be modulated by 
interactions with several different cellular proteins. By regulating APP metabolism 
these proteins regulate the production of Aβ. Several large studies have identified 
proteins which interact with APP (Bai et al., 2008; Kohli et al., 2012). This means 
there is a large number of proteins with the potential to regulate APP processing and 
Aβ generation, yet the effects of most of these have not been characterised fully.  
Three proteins were identified from the mouse in vivo APP interactome by Bai 
et al., (2008) for further investigation into their role in the regulation of APP 
metabolism: neurofascin, Thy-1 and contactin 5 (CNTN5). These proteins were 
selected due to their sub-cellular location – they are all cell surface glycoproteins, 
and contactin and Thy-1 are located in lipid rafts (Kemshead et al., 1982; Shimoda 
and Watanabe, 2009) – which means they have a high chance of interacting with 
APP, and of regulating its processing. Furthermore Thy-1 and proteins from the 
contactin family have been previously implicated in AD. Thy-1 expression is 
reduced and its sub-cellular location is altered in the brain during AD (Leifer and 
Kowall, 1992). Proteins from the contactin family have been identified as potential 
CSF biomarkers for AD (Yin et al., 2009). CNTN1, 2, and 4 regulate proteolysis of 
APP (Hu et al., 2003; Hu et al., 2004; Ma et al., 2008; Osterfield et al., 2008), and 
CNTN5 has been associated with AD neuroimaging measures and identified as an 
AD linked gene in GWAS (Biffi et al., 2010). Although CNTN1 was identified by 
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Bai et al., (2008) in the in vivo APP interactome, studies in this chapter focus on 
CNTN5. There are several reasons for this: CNTN5 has been genetically linked to 
AD by GWAS whereas CNTN1 has not. CNTN1 is involved in notch processing 
(Hu et al., 2003; Hu et al., 2004). If CNTN1 was found to regulate APP processing 
the potential to develop it into a drug target in the future may be limited as an AD 
drug targeting CNTN1 is likely to have similar side effects to the γ-secretase 
inhibitors that have failed in clinical trials. CNTN5 knockout mice are viable, and do 
not display a deleterious phenotype (Li et al., 2003) unlike CNTN1 knockout mice 
which died prematurely (Berglund et al., 1999), suggesting an AD drug targeting 
CNTN5 is less likely to have undesirable side effects.  
3.1.1 Aims 
We hypothesied that neurofascin, Thy-1, and contactin 5 would alter APP 
metabolism. To investigate this, APP and each protein was expressed in HEK cells, 
and the effect of over expression on full length APP, sAPPα, sAPPβ and Aβ 
determined by western blotting (for APP, sAPPα, and sAPPβ) and ELISA (for Aβ). 
This showed CNTN5 expression dramatically altered Aβ metabolism, so the 
mechanism of this was further investigated by examining the effect of CNTN5 
expression on APP C-terminal fragments. To determine how our findings in cell 
culture models may relate to the human brain CNTN5 levels in human brain 
samples, during aging, and in sporadic and familial AD were measured by western 
blotting. 
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3.2 Cloning and over-expression of neurofascin 186, Thy-1 and 
contactin 5 
IMAGE human cDNA clones of neurofascin 186 (NF186, IMAGE 40068186), 
Thy-1 (IMAGE 6137513), and contactin 5 (IMAGE 40146650) were obtained from 
Source Bioscience. The cDNA of interest was amplified by PCR from the vector in 
which it was supplied using primers with a 5`NotI and a 3` EcoRI restriction site.  
Forward primers were: 
 NF186: GATGCTCGTGAGCGGCCGCATGGCCAGGCAGCCACCGCC,  
Thy-1: GATGCTCGTGAGCGGCCGCATGAACCTGGCCATCAGCATCGCT, 
CNTN5: 
GATGCTCGTGAGCGGCCGCATGGCTTCCTCTTGGAAACTAATGCT 
 Reverse primers were: 
NF186: GCTAGGAATTCTTAGGCCAGAGAGTAGATAGCATTGAC, 
Thy-1: CATAGGAATTCTCACAGGGACATGAAATCCGTGGCC, 
CNTN5: CATAGGAATTCTCACCAGGAAGTTGAAGGAATCATCA.  
The resulting product was the cDNA of interest flanked by NotI and EcoRI 
restriction sites. The PCR product was gel purified, then PCR product and pIRESneo 
vector were digested with NotI and EcoRI, and the cDNA was ligated into 
pIRESneo. The ligation reaction was used to transform XL1-blue competent E.coli 
cells, which were then plated and incubated overnight. Transformed colonies were 
picked and plasmids were purified. Correct insertion of each gene into pIRESneo 
was assessed by restriction digest reactions. 
- 87 - 
NF186 insertion was confirmed by NcoI digestion. Expected fragments from 
digestion of pIRESneo with NcoI are 3389 bp and 1865 bp, whereas expected 
fragments from digestion of pIRESneo with an NF186 insertion are 4733 bp, 3389 
bp, and 858 bp. Digestion of plasmid purified from colony N2 showed the expected 
fragments (figure 3.1A) so insertion of NF186 into pIRESneo was confirmed by 
sequencing (see appendix). The new plasmid generated was named pIRESneo-
NF186 (figure 3.1B). HEK-APP695 cells were transfected with pIRESneo-NF186 
(empty pIRESneo was transfected in to use as a negative control) then cells were 
selected with the antibiotic G418 to generate a cell line stably expressing NF186 
(figure 3.1C). In NF186 expressing cells the neurofascin antibody detected not only 
a band of 186 kDa (the expected molecular weight of the NF186 isoform) but also 
several bands of lower molecular weight, which were not present in vector only cell 
lysates. When the neurofascin gene was originally cloned in 1992 (Volkmer et al., 
1992) multiple forms were detected in plasma membrane preparations for 
neurofascin protein, some of which were identified as proteolytic cleavage products 
of longer isoforms of neurofascin. This may account for the extra lower molecular 
weight forms seen here. 
Correct insertion of Thy-1 into pIRESneo was assessed by restriction digest 
reactions using Eco0109I. Expected fragments from digestion of pIRESneo with 
Eco0109I are 4844 bp, 356 bp and 54 bp, whereas expected fragments from 
digestion of pIRESneo with a Thy-1 insertion are 4672 bp, 702 bp, 356 bp and 54 
bp. Digestion of plasmid purified from colony T1 showed the expected fragments 
(figure 3.2 A) so insertion of Thy-1 into pIRESneo was confirmed by sequencing 
(see appendix). The new plasmid generated was named pIRESneo-Thy-1 (figure 3.2 
B). HEK-APP695 cells were transfected with pIRESneo-Thy-1 (empty pIRESneo 
was transfected in to use as a negative control) then cells were selected with the 
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antibiotic G418 to generate a cell line stably expressing Thy-1. Expression of Thy-1 
in cells was confirmed by dot blot of cell lysates. Dot blotting, as opposed to 
western blotting, was performed because the Thy-1 antibody MAB2067 recognises 
an epitope that is lost when Thy-1 is denatured (as occurs in western blotting) 
(Figure 3.2 C). 
Correct insertion of CNTN5 into pIRESneo was assessed by restriction digest 
reactions using KpnI. Expected fragments from digestion of pIRESneo with KpnI 
are 4411 bp, and 843 bp, whereas expected fragments from digestion of pIRESneo 
with a CNTN5 insertion are 4411 bp, 3320 bp, and 929 bp. Digestion of plasmid 
purified from colony C6 showed the expected fragments (figure 3.3 A), so insertion 
of CNTN5 into pIRESneo was confirmed by sequencing (see appendix). The new 
plasmid generated was named pIRESneo-CNTN5 (figure 3.3 B). HEK-APP695 cells 
were transfected with pIRESneo-CNTN5 (empty pIRESneo was transfected in to 
use as a negative control) then transfected cells were selected with the antibiotic 
G418 to generate a cell line stably expressing CNTN5. Expression of CNTN5 in 
cells was confirmed by western blot of cell lysates (Figure 3.3 C). 
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Figure 3.1 Expression of NF186 in HEK-APP695. (A) NcoI digests of:  
lane 1, empty pIRESneo; lanes 2-4, plasmid purified from colonies transformed with 
NF186 pIRESneo ligation reaction. Colony N2 contained the expected fragments for 
insertion of NF186 into pIRESneo at the correct sites (4733 bp, 3389 bp, and 858 
bp). (B) Map of the plasmid pIRESneo-NF186. pCMV is the promoter from human 
cytomegalovirus, Intron is a synthetic intron which enhances the stability of the 
mRNA, IRES is the ribosome entry site from encephalomyocarditis virus, neoR is 
the neomycin phosphotransferase gene which confers neomycin resistance, polyA is 
the polyadenylation signal. AmpR is the ampicillin resistance gene. All elements but 
the gene of interest (NF186) come from the pIRESneo plasmid. (C) Western blot for 
neurofascin (with ab31457) of HEK-APP695 cell lysates (60 µg) transfected with 
pIRESneo-NF186 (+) or pIRESneo (-). 
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Figure 3.2 Expression of Thy-1 in HEK-APP695. (A) Eco01095I digests of: 
lanes 1-5, plasmid purified from colonies transformed with Thy-1 pIRESneo ligation 
reaction; lane 6, empty pIRESneo. Colony T1 contained the expected fragments for 
insertion of Thy-1 into pIRESneo at the correct sites (4672 bp, 702 bp, 356 bp and 
54 bp). (B) Map of the plasmid pIRESneo-Thy-1.For details of plasmid components 
see figure 3.1. (C) Dot blot for Thy-1 (with MAB2076) on HEK-APP695 cell lysates 
(40 µg) transfected with pIRESneo-Thy-1 (+) or pIRESneo (-). 
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Figure 3.3 Expression of CNTN5 in HEK-APP695. (A) KpnI digests of:  
lane 1 empty pIRESneo; lanes 2-8, plasmid purified from colonies transformed with 
CNTN5 pIRESneo ligation reaction. Colony C6 contained the expected fragments 
for insertion of CNTN5 into pIRESneo at the correct sites (4411 bp, 3320 bp, and 
929 bp). (B) Map of the plasmid pIRESneo-CNTN5. For details of plasmid 
components see figure 3.1. (C) Western blot for CNTN5 (with AF3030) on HEK-
APP695 cell lysates (30 µg) transfected with pIRESneo-CNTN5 (+) or pIRESneo (-). 
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3.3 Cell line selection and experimental conditions 
HEK cells are a Human Embryonic Kidney cell line. Although they are a 
kidney cell line they expresses many neuronal proteins (Shaw et al., 2002) and so 
were selected for use due to their comparative ease of transfection compared to 
neuronal cell lines. Although HEK cells express endogenous APP, in order to detect 
sAPPβ in conditioned media by western blotting APP695 was over-expressed in the 
cells (HEK-APP695 cells). To determine the effect of each gene on APP processing, 
each protein was over-expressed in HEK-APP695 cells then APP, sAPPα, sAPPβ, 
and Aβ were measured. Before these experiments were undertaken the appropriate 
length of incubation for conditioning media (to measure sAPPα and sAPPβ) was 
determined. HEK-APP695 cells were incubated for either 10, 12, 14, 24, 36 or 48 
hours with OptiMEM reduced sera media. Conditioned medium was harvested and 
cells were harvested and lysed.  
The APP levels in cell lysates and sAPPα and sAPPβ levels in conditioned 
media were measured by western blotting. APP was detected in cell lysates at all 
time points, and APP expression did not change over time (figure 3.4 A). Western 
blots for APP showed 4 bands, these correspond to the different isoforms of mature 
and immature APP. The bands corresponding to the 695 isoform are more intense 
than the 751/770 isoforms as the cells are over-expressing APP695. The resolution of 
the gel is not sufficient to distinguish the 751 and 770 isoforms so these appear 
together as one band. sAPPα was detected at all time points, and more sAPPα 
accumulated in the media the longer the incubation (figure 3.4 B). Two bands 
corresponding to sAPPα were detected at later time points (36 and 48 hours). The 
lower molecular weight band is sAPPα generated from the 695 isoform of APP 
(sAPPα695), and the upper band is sAPPα generated from the 751/770 isoforms of 
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APP (sAPPα751/770). As with APP, there is less sAPPα751/770 than sAPPα695 because 
the cells over-express the 695 isoform of APP. Again, the resolution of the gel is not 
sufficient to distinguish the 751 and 770 isoforms so these appear as a single band. 
sAPPβ was only detected in conditioned media after a 36 hour incubation (figure 3.4 
C). Under normal circumstances the majority of APP is processed via the non-
amyoidogenic α-cleavage pathway, so there is much less sAPPβ than full length 
APP or sAPPα. No band corresponding to sAPPβ751/770 was detected; this is because 
it is not over-expressed so very little is produced. Although sAPPβ was detected 
after a 36 hour incubation significantly more was detected at 48 hours. In order to 
detect sufficient sAPPβ to measure both increases and decreases in sAPPβ levels a 
48 hour incubation was used for subsequent experiments. 
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Figure 3.4 Timecourse of APP, sAPPα and sAPPβ levels over 48 hours in 
HEK-APP695. (A) Western blot for APP (with 22C11) on cell lysates (40 µg). (B) 
western blot for sAPPα (with 6E10) on conditioned media (30 µg). (C) Western blot 
for sAPPβ (with 1A9) on conditioned media (30 µg). The vertical line in blot A 
indicates two separate gels. Although the time points shown in this experiment have 
been run on separate gels, in repeat experiment all samples were run on a single gel. 
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3.4 The effect of neurofascin 186 on APP processing 
HEK-APP695 cells expressing NF186 or empty vector were incubated for 48 
hours, then medium was harvested and cells were harvested and lysed. Cell lysates 
were western blotted for NF186 and APP, and conditioned media was western 
blotted for sAPPα and sAPPβ (figure 3.5 A). Aβ levels in conditioned media were 
determined by ELISA (figure 3.5 E). NF186 over-expression did not alter APP695 
levels in cell lysates, but it did cause a significant 15 % reduction in APP751/770 
(p=0.03) (figure 3.5 B). NF186 over-expression did not significantly alter sAPPα 
(figure 3.5 C), sAPPβ (figure 3.5 D) or Aβ (figure 3.5 E). 
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Figure 3.5 The effect of NF186 over-expression on APP proteolysis. (A) 
Representative western blots on HEK-APP695 cell lysates (40 µg) expressing NF186 
(+) or empty vector (-) for neurofascin, with ab31457 (top panel), APP with 22C11 
(second panel) and conditioned media (30 µg) for sAPPα with 6E10 (third panel) 
and sAPPβ with 1A9 (fourth panel). (B) Quantification of western blots for APP. 
(C) Quantification of western blots for sAPPα. (D) Quantification of western blots 
for sAPPβ. (E) ELISA to determine Aβ in conditioned media. Data are mean ± S.D. 
n=6 (*p<0.05). 
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3.5 The effect of Thy-1 on APP processing 
HEK-APP695 cells expressing Thy-1 or empty vector were incubated for 48 
hours, then media was harvested and cells were harvested and lysed. Cell lysates 
were dot blotted for Thy-1 (figure 3.6 A) and western blotted for APP. Conditioned 
media was western blotted for sAPPα and sAPPβ (figure 3.6 B). Aβ levels in 
conditioned media were determined by ELISA (figure 3.6 F). Thy-1 over-expression 
caused a significant 18 % reduction in APP695 (p=0.02), and a reduction in 
APP751/770 although this was not significant (figure 3.6 C). Thy-1 over-expression 
also caused a significant 22 % decrease in sAPPβ (p=0.004) (figure 3.6 E). Thy-1 
over-expression did not significantly alter sAPPα (figure 3.6 D) or Aβ (figure 3.5 E). 
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Figure 3.6 The effect of Thy-1 over-expression on APP proteolysis (legend 
overleaf)  
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Figure 3.6 The effect of Thy-1 over-expression on APP proteolysis. (A) Dot 
blot on HEK-APP695 cell lysates (40 µg) expressing Thy-1 (+) or empty vector (-) 
for Thy-1 using MAB2076. (B) Representative western blots on cell lysates 
expressing Thy-1 (+) or empty vector (-) (60 µg) for APP with 22C11 (top panel) 
and conditioned media (30 µg) for sAPPα with 6E10 (second panel) and sAPPβ with 
1A9 (third panel). (C) Quantification of western blots for APP. (D) Quantification of 
western blots for sAPPα. (E) Quantification of western blots for sAPPβ. (F) ELISA 
to determine Aβ in conditioned media. Data are mean ± S.D. n=4 (*p<0.05), 
(**p<0.01). 
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3.6 The effect of contactin 5 on APP processing 
HEK-APP695 cells expressing CNTN5 or empty vector were incubated for 48 
hours, then medium was harvested and cells were harvested and lysed. Cell lysates 
were western blotted for CNTN5 and APP, and conditioned media was western 
blotted for sAPPα and sAPPβ (figure 3.7 A). Aβ levels in conditioned media were 
determined by ELISA (figure 3.7 E). CNTN5 over-expression caused a significant 
40 % increase in APP695 (p=0.02), and a significant 22 % increase in APP751/770 
(p=0.02) (figure 3.7 B). CNTN5 over-expression also caused a significant 11 % 
increase in sAPPα695 (p=0.001), but there was no change in sAPPα751/770 (figure 3.7 
C). CNTN5 over-expression did not have a significant effect on sAPPβ (figure 3.7 
D). CNTN5 over-expression caused a 95 % decrease in Aβ40 (p=0.003). Aβ42 was 
decreased to below the limit of detection of the assay (figure 3.7 E). To confirm 
these data in a neuronal cell line CNTN5 was transiently expressed in N2a-APP695 (a 
mouse neuroblastoma cell line), cells were incubated for 48 hours then Aβ in 
conditioned media was determined by ELISA. CNTN5 expression in N2a cells 
caused a significant 79 % decrease in Aβ40 (p=0.0019) and a significant 82 % 
decrease in Aβ42 (p=0.0003). 
NF186, Thy-1 and CNTN5 all regulated the metabolism of APP, but only 
CNTN5 caused a change in Aβ in conditioned media. Therefore the mechanism by 
which CNTN5 decreased Aβ was investigated further. 
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Figure 3.7 The effect of CNTN5 over-expression on APP proteolysis. (A) 
Representative western blots on HEK-APP695 cell lysates (40 µg) expressing 
CNTN5 (+) or empty vector (-) for CNTN5 with AF3030 (top panel), APP with 
22C11 (second panel) and conditioned media (35 µg) for sAPPα with 6E10 (third 
panel) and sAPPβ with 1A9 (fourth panel). (B) Quantification of western blots for 
APP. (C) Quantification of western blots for sAPPα. (D) Quantification of western 
blots for sAPPβ. (E) ELISA to determine Aβ in conditioned media. (F) ELISA to 
determine Aβ in conditioned media from N2a-APP695 cells transiently transfected 
with CNTN5 cDNA or empty vector. Data are mean ± S.D. n=6 (*p<0.05), 
(**p<0.01), (***p<0.001).  
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3.7 The effect of contactin 5 on γ-secretase 
To determine whether CNTN5 was decreasing Aβ in the media by decreasing 
Aβ secretion (so causing a build up of Aβ inside the cells) intracellular Aβ was 
measured in the presence and absence of CNTN5 expression. HEK-APP695 cells 
expressing CNTN5 or empty vector were incubated for 48 hours, and then cells were 
harvested and lysed. Aβ in cell lysates was measured by ELISA. CNTN5 over-
expression did not alter intracellular Aβ (figure 3.8 A), suggesting CNTN5 does not 
inhibit Aβ secretion.  
CNTN5 over-expression decreased Aβ but not sAPPβ, suggesting CNTN5 
inhibits γ-secretase cleavage of APP. To investigate this HEK-APP695 cells 
expressing either CNTN5 or empty vector were incubated for 48 hours, then cells 
were harvested and lysed, and C-terminal fragments of APP (C83, C99 and AICD) 
measured by western blotting (figure 3.8 B). CNTN5 over-expression caused an 
increase in both C83 and C99, confirming the hypothesis that CNTN5 inhibits γ-
secretase cleavage of APP. Due to the instability of AICD it was not robustly 
detected.  
To further investigate the action of CNTN5 on γ-cleavage of APP we sought to 
knock down expression of endogenous CNTN5, and determine the effect on Aβ 
levels in conditioned media. Cell lysates from a number of cell lines were western 
blotted for CNTN5 to identify a cell line in which CNTN5 was endogenously 
expressed. Cell lines examined were Sw13 (a human adrenal cell line), HepG2 (a 
human hepatocellular carcinoma cell line), CHO (a Chinese hamster ovary cell line), 
HuVEC (human umbilical vein endothelial cells,), pHFF (human foreskin fibroblast 
cells), A549 (a human alveolar basal epithelial cell line), A431 (a human epidermoid 
carcinoma cell line), MCF (a human breast adenocarcinoma cell line), HeLa (a 
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human cervical adenocarcinoma cell line), N2a (a mouse neuroblastoma cell line), 
NB7 (a human neuroblastoma cell line), SH-SY5Y (a human neuroblastoma cell 
line), HEK (a human embryonic kidney cell line), H226 (a human lung squamous 
cell carcinoma cell line), T84 (a human colonic carcinoma cell line), HuH7 (a 
human hepatocarcinoma cell line), H1395 (a human lung adenocarcinoma cell line), 
and LS1034 (a human caecal carcinoma cell line). As a positive control for CNTN5 
expression a lysate from SH-SY5Y cells over-expressing CNTN5 was loaded onto 
gels. None of the tested cell lines had detectable levels of CNTN5 (figure 3.9). It is 
worth noting that the anti-CNTN5 antibody is directed against human CNTN5, 
whereas N2a and CHO cells are not of human origin.  
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Figure 3.8 The effect of CNTN5 on γ-secretase cleavage of APP. 
 (A) ELISA on cell lysates to determine intracellular Aβ. (B) Representative western 
blot on cell lysates (50 µg) for C-terminal fragments of APP with A8717. Aβ ELISA 
data are mean ± S.D. n=6. 
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Figure 3.9 Endogenous CNTN5 in cell lines.Western blots on cell lysates 
(30 µg) for endogenous CNTN5 using AF3030. Positive control (+) is SH-SY5Y 
cells over-expressing CNTN5. 
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3.8 Contactin 5 in the human brain 
The level of CNTN5 in the human brain during aging and Alzheimer’s disease, 
and the correlation of CNTN5 with Aβ in the human brain, was investigated by 
western blotting human brain samples for CNTN5. Four different cohorts of brain 
samples were investigated. Aging cohort 1 (table 3.1) are human hippocampal and 
temporal lobe samples from individuals who had died between the ages of 20 and 
88.  
Sporadic AD cohort 2 (table 3.2) are hippocampal and temporal lobe samples 
from patients with sporadic AD, and from age matched controls. There was no 
significant difference in the mean age (79 years) between sporadic AD and age 
matched control hippocampal samples (p=0.97). For temporal lobe samples the 
mean age was 79 for sporadic AD and 78 for age-matched control, the age was not 
significantly different (p=0.90). The post mortem delay was not significantly longer 
for age-matched control samples than for sporadic AD samples (mean 36 hours 
versus 19 hours, p=0.09 for hippocampus, p=0.10 for temporal lobe).  
Familial AD cohort 3 (table 3.3) are hippocampal samples from familial AD 
patients and from age-matched control patients. The mean age for familial AD 
samples was 68, and the mean age for age matched control samples was 63. Ages 
were not significantly different (p=0.86). The post mortem delay was significantly 
longer for age-matched control samples (mean 41 hours versus 13 hours, p=0.01).  
Sporadic AD cohort 4 (table 3.4) are temporal lobe samples from sporadic AD 
patients and from age-matched controls. The mean age for sporadic AD samples was 
83, the mean age for age matched control samples was 76, the ages were not 
significantly different (p=0.20). There was no significant difference in post mortem 
delay between control and sporadic AD samples in cohort 4 (51 hours versus 39 
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hours, p=0.10). Soluble and insoluble Aβ, as well as neuron-specific enolase (NSE) 
measurements have been carried out on these samples previously by Dr Scott Miners 
(Miners et al., 2009; van Helmond et al., 2010a, b). There was no significant 
difference in mean NSE or mean soluble Aβ between sporadic AD and age-matched 
control samples (figure 3.9 A and B respectively). However, there was a significant 
increase in mean insoluble Aβ in sporadic AD samples compared to the age matched 
control samples (a mean value of 139 nM Aβ in sporadic AD compared to 20 nM 
Aβ in age-matched control samples, p<0.0001). 
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Table 3.1 Details of brains from aging cohort 1: Human hippocampal and 
temporal lobe samples from individuals who had died between ages 20 and 88. PM 
= post mortem. 
Gender Age (y) Cause of death PM delay (h) 
    Aging - Hippocampus 
 F 26 Carcinoma of the lung 44 
M 25 Ruptured aortic arch aneurysm 18 
F 20 Sudden accident 38 
F 33 Pulmonary embolus 96 
M 37 Acute necrotic pancreatitis 27 
M 49 Pulmonary oedema 44 
M 49 Coronary artery occlusion 32 
M 58 Myocardial infarction 23 
M 55 Syringomyelia 24 
M 57 Left ventricular failure 45 
F 62 Haemothorax 81 
M 65 Coronary artery occlusion 29 
F 76 Congestive heart failure 28 
M 79 
Septicaemia secondary to faecal 
peritonitis 24 
F 80 
Left ventricular 
failure/bronchopneumonia 31 
F 88 Carcinomatosis 43 
    
    
    Aging - Temporal lobe 
 F 26 Carcinoma of the lung 44 
M 25 Ruptured aortic arch aneurysm 18 
F 20 Sudden accident 38 
M 49 Pulmonary oedema 44 
M 49 Coronary artery occlusion 32 
F 44 Hepatic necrosis 10 
M 58 Myocardial infarction 23 
M 55 Syringomyelia 24 
M 57 Left ventricular failure 45 
F 62 Haemothorax 81 
F 65 Perforated peptic ulcer 30 
M 67 Myocardial infarction 41 
M 76 Bilateral bronchopneumonia 41 
F 79 Chronic obstructive airway disease 38 
M 82 Bronchopneumonia 48 
M 85 Left ventricular failure 48 
F 88 Carcinomatosis 43 
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Table 3.2 Details of brains from Sporadic AD cohort 2: Sporadic AD and 
age matched control human hippocampal and temporal lobe samples. PM = post 
mortem. 
Gender Age (y) Cause of death PM delay (h) 
    Sporadic AD - Hippocampus 
 F 82 Dementia 12 
F 88 Subdural haematoma 19 
F 69 Unknown 16 
F 82 Myocardial infarction 5 
M 65 Unknown 23 
M 87 Unknown 18 
M 80 Unknown 41 
    Control - Hippocampus 
 M 79 Septicaemia secondary to faecal peritonitis 24 
F 79 Chronic obstructive airway disease 38 
M 85 Left ventricular failure 48 
F 87 Carcinoma of the breast 22 
M 80 Carcinoma of prostate 11 
F 62 Haemothorax 81 
F 80 Left ventricular failure/bronchopneumonia 31 
        
    Sporadic AD - Temporal lobe 
 F 82 Dementia 12 
F 88 Subdural haematoma 19 
F 69 Unknown 16 
F 82 Myocardial infarction 5 
M 65 Unknown 23 
M 87 Unknown 18 
M 80 Unknown 41 
    Control - Temporal lobe 
 M 79 Septicaemia secondary to faecal peritonitis 24 
F 79 Chronic obstructive airway disease 38 
M 85 Left ventricular failure 48 
F 87 Carcinoma of the breast 22 
M 80 Carcinoma of prostate 11 
F 62 Haemothorax 81 
F 77 Pulmonary embolus 29 
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Table 3.3 Details of brains from Familial AD cohort 3: Familial AD and 
age matched control hippocampal and temporal lobe samples. PM = post mortem. 
Gender Age (y) Cause of death 
PM 
delay (h) Mutation 
     Familial AD - Hippocampus 
  
M 61 Bronchopneumonia 15 
APP717 (VAL-
GLY) 
F 69 Bronchopneumonia 10 
APP717 (VAL-
ILE) 
F 62 Bronchopneumonia 23 
APP717 (VAL-
ILE) 
M 42 Bronchopneumonia 6 PS1 DELTA4 
F 72 Unknown 4 
APP717 (VAL-
ILE) 
F 65 Pneumonia 22 PS1 (E280G) 
     Control - Hippocampus 
  F 62 Haemothorax 81 - 
M 57 Left ventricular failure 45 - 
F 79 Chronic obstructive airway disease 38 - 
M 37 Acute necrotic pancreatitis 27 - 
M 79 
Septicaemia secondary to faecal 
peritonitis 24 - 
M 65 Coronary artery occlusion 29 - 
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Table 3.4 Details of brains from Sporadic AD cohort 4: Sporadic AD and 
age matched control temporal lobe samples. PM = post mortem. 
Gender Age (y) PM delay (h) 
   Sporadic AD 
 M        69 48 
F        70 25 
M        74 50 
F        74 53 
F        77 43 
F        78 77 
F        78 9 
F        78 35 
M        79 28 
M        80 31 
F        81 42 
F        81 66 
F        83 43 
M        85 58 
M        85 66 
F        87 72 
F        87 67 
F        88 79 
F        89 71 
F        89 82 
F        90 21 
F        91 37 
F        91 70 
F        96 53 
      
Control 
  F        43 12 
F        48 79 
M        53 7 
M        62 4 
M        64 23 
F        72 24 
M        73 36 
M        77 10 
M        78 12 
M        79 24 
M        80 106 
F        80 92 
F        81 103 
M        82 30 
M        82 3 
F        82 37 
M        82 56 
M        84 48 
F        84 17 
F        88 62 
F        88 28 
M        90 45 
M        90 48 
F        93 18 
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Figure 3.10 Aβ and neuron-specific enolase in Sporadic AD cohort 4.  
(A) Neuron-specific enolase (NSE) levels in sporadic AD and age-matched control 
human temporal lobe homogenates determined by ELISA. (B) Soluble Aβ extracted 
from sporadic AD and age-matched control human temporal lobe samples 
determined by ELISA. (C) Insoluble Aβ extracted from sporadic AD and age-
matched control human temporal lobe samples determined by ELISA. n=24, 
(****p<0.0001). Data were obtained by Dr Scott Miners from the University of 
Bristol.  
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Quantification of western blots for CNTN5 on aging cohort 1 hippocampal 
(figure 3.10 A) and temporal lobe (figure 3.10 B) homogenates showed CNTN5 did 
not correlate with age in the hippocampus (figure 3.10 C) or the temporal lobe 
(figure 3.9 D). Quantification of western blots for CNTN5 on Sporadic AD cohort 2 
hippocampal (figure 3.11 A) and temporal lobe (figure 3.11 B) homogenates, and on 
familial AD cohort 3 hippocampal homogenates (figure 3.11 C) showed no 
difference in CNTN5 in sporadic AD brains (figure 3.11 D) or familial AD brains 
(figure 3.11 E) compared to age-matched control brains. Quantification of western 
blots for CNTN5 on sporadic AD cohort 4 temporal lobe homogenates (figure 3.12 
A) showed no difference in CNTN5 in sporadic AD brains compared to age-
matched control (figure 3.12 B). There was no correlation of CNTN5 with either 
soluble (figure 3.12 C) or insoluble Aβ (figure 3.12 D). 
  
- 114 - 
 
Figure 3.11 CNTN5 in the aging brain, aging cohort 1  
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Figure 3.11 CNTN5 in the aging brain, aging cohort 1. (A) Western blot for 
CNTN5 on human hippocampal homogenates (50 µg) from aging cohort 1 using 
AF3030. (B) Western blot for CNTN5 on human temporal lobe homogenates (50 
µg) from aging cohort 1 using AF3030. (C) Quantification of western blots on 
hippocampal homogenates for CNTN5. Samples 20, 25 and 26 were loaded on both 
gels so that CNTN5 levels could be normalised according to these samples allowing 
comparison between gels. The y-axis % CNTN5 refers to CNTN5 as a percentage 
the average of CNTN5 in samples 20, 25 and 26. Pearson correlation showed no 
significant correlation between CNTN5 and age in human hippocampal samples. (D) 
Quantification of western blots on temporal lobe homogenates for CNTN5. Pearson 
correlation showed no significant correlation between CNTN5 and age in human 
temporal lobe samples. 
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Figure 3.12 CNTN5 in the human brain in sporadic AD cohort 2 and 
familial AD cohort 3. (A) Western blot for CNTN5 on sporadic AD cohort 2 SAD 
and age-matched control human hippocampal homogenates (50 µg) using AF3030. 
(B) Western blot for CNTN5 on sporadic AD cohort 2 SAD and age-matched 
control human temporal lobe homogenates (50 µg) using AF3030. (C) Western blot 
for CNTN5 on familial AD cohort 3 FAD and age-matched control hippocampal 
homogenates (50 µg) using AF3030. (D) Quantification of western blots for CNTN5 
on sporadic AD cohort 2 SAD and age matched control human hippocampal and 
temporal lobe homogenates (n=7). (E) Quantification of western blots for CNTN5 
on familial AD cohort 3 FAD and age-matched control human hippocampal 
homogenates (n=6). 
  
- 117 - 
 
Figure 3.13 CNTN5 and Aβ levels in sporadic AD cohort 4 and age-
matched control temporal lobe. (A) Western blot for CNTN5 on sporadic AD 
cohort 4 SAD and age-matched control human temporal lobe homogenates (40 µg, 
cohort 4) using AF3030. (B) Quantification of western blots for CNTN5 on sporadic 
AD cohort 4 SAD and age-matched control human temporal lobe homogenates 
(n=24). (C) Spearman’s correlation analysis showed no correlation between CNTN5 
and soluble Aβ in human temporal lobe samples. (D) Spearman’s correlation 
analysis showed no correlation between CNTN5 and insoluble Aβ in human 
temporal lobe samples. 
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3.9 Discussion 
Expression of neurofascin 186 did not significantly alter β- or α-cleavage of 
APP. There was only a small (approximately 15 %) reduction in APP751/770 levels in 
NF186 expressing cells, with no change in the 695 isoform of APP. As neurofascin 
modulates APP751/770 but not APP695 this suggests if it does interact with APP, it 
binds to the KPI domain which is absent in the 695 isoform. Neurofascin has been 
shown to be required for clustering ion channels and molecules that regulate 
formation of action potentials, as well as synaptic stability and levels of gamma-
aminobutyric acid (GABA) recptor levels at the synapse (Kriebel et al., 2011; Zonta 
et al., 2011). Modulation of GABA receptors has been shown to alter APP 
metabolism increasing sAPPα production (Marcade et al., 2008), though no changes 
in sAPPα were demonstrated here.  
Thy-1 appears to be a promising candidate for involvement in AD, as although 
expression of Thy-1 did not alter sAPPα secretion, it caused a significant 22 % 
decrease in sAPPβ in the media, and a decrease in APP695 in cell lysates. The 
decrease in sAPPβ is likely due to the decreased APP levels, since the decrease in 
sAPPβ is approximately equivalent to the decrease in APP. However, the decreased 
sAPPβ did not extend to a decrease in Aβ production. This is surprising, as β-
secretase cleavage of APP is the rate limiting step in the generation of Aβ (Zhang et 
al., 2011), therefore it would be expected that a decrease in sAPPβ would cause a 
decrease in Aβ. These data suggests that there are further mechanisms in place 
regulating the generation of Aβ.  
Both neurofascin and Thy-1 caused a reduction in full length APP. There have 
been contradicting reports, but it appears that APP mRNA levels are increased in the 
brains of patients with AD (Palmert et al., 1988; Schmechel et al., 1988; Vitek, 
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1989; Matsui et al., 2007), suggesting that dyregulation of neurofascin and Thy-1 
expression (Thy-1 protein levels have been demonstrated to be reduced in AD brains 
(Leifer and Kowall, 1992)) could contribute to the alterations in APP seen in AD. 
Neither neurofascin or Thy-1 over-expression caused a change in the levels of Aβ40 
or Aβ42, so investigations into these proteins were not continued. 
CNTN5 caused multiple changes to APP metabolism: an increase in APP, an 
increase in sAPPα and a decrease in Aβ. Since CNTN5 over-expression caused a 
dramatic decrease in both Aβ40 and Aβ42 secretion this protein became the focus of 
further investigations. CNTN5 expression did not alter intracellular Aβ compared to 
cells expressing the vector alone, therefore is not preventing secretion of Aβ so 
causing it to accumulate within the cell, suggesting it is inhibiting the production of 
extracellular Aβ. It could also be possible that CNTN5 reduces Aβ by increasing Aβ 
degradation for example by activating NEP or IDE or other Aβ degrading proteases. 
This possibility requires further investigation. 
Cleavage of APP by both β- and γ-secretase is required for Aβ generation 
(Evin and Weidemann, 2002). The consistent decrease in Aβ, even in the absence of 
a decrease in sAPPβ levels, suggests that CNTN5 may be modulating Aβ levels via 
γ- rather than β-secretase. In order to confirm that the action of CNTN5 on Aβ 
secretion was via γ-secretase the levels of C-terminal fragments of APP were 
determined. Western blotting showed that CNTN5 expression caused an increase in 
the levels of C83 (CTFα) and C99 (CTFβ). These proteins are substrates for γ-
secretase so a build up of both C-terminal fragments suggests that CNTN5 had 
inhibited γ-secretase. AICD was not consistently detected by western blotting of 
HEK-APP695 cell lysates, so the effect of CNTN5 over-expression on AICD 
generation could not be accurately determined. Furthermore as AICD is not 
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transcriptionally active in non-neuronal cell lines (Belyaev et al., 2010) 
measurement of AICD in HEK cells would not indicate whether AICD is functional. 
In order to further elucidate the role of CNTN5 in APP processing we 
considered knocking down endogenous CNTN5 in a cell line and measuring the 
levels of full length and secreted APP, and Aβ. However, we were unable to identify 
a cell line expressing endogenous CNTN5 either by western blotting for CNTN5 
protein or using RT-PCR to amplify CNTN5 mRNA (data not shown). Work by 
Eckerich et al., (2006) demonstrated that although high levels of CNTN expression 
were found in primary glial cells, no CNTN was detected in cell lines derived from 
these cells (Eckerich et al., 2006). This suggests that CNTN5 expression is not 
required for in vitro growth and that its expression is quickly lost. 
Our data suggested that CNTN5 regulates the production of Aβ, so to 
determine whether CNTN5 might be related to AD we measured the levels of 
CNTN5 in sporadic AD, familial AD and age matched control brains and in a series 
of aging brain samples. This showed that in the hippocampus and the temporal lobe 
there was no difference in CNTN5 levels in either sporadic or familial AD. Also 
there was no change in the levels of CNTN5 in either the hippocampus or the 
temporal lobe during aging. If CNTN5 has a role in the development of AD it 
appears not to be related to CNTN5 expression levels. CNTN5 may, however, 
contribute to the development of AD without any alteration in its expression level.  
The subcellular location of CNTN5 may be altered in AD which may prevent 
its inhibition of γ-secretase. The subcellular location of CNTN1 is regulated by 
CNTNAP1 (contactin associated protein 1). CNTN1 binds CNTNAP1 (Peles et al., 
1997), and when bound to CNTNAP1 glycosylation of CNTN1 is prevented and it is 
targeted to the cell surface at paranodes of the axon. However, when CNTN1 is not 
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bound to CNTNAP1 it is glycosylated and targeted to nodes of Ranvier rather than 
paranodes (Rios et al., 2000; Gollan et al., 2003). Much less is known about the 
interaction between CNTN5 and CNTNAP1 or CNTNAP5 (contactin associated 
protein 5), but it is reasonable to assume that like CNTN1, the subcellular trafficking 
of CNTN5 is regulated by CNTNAP1 or CNTNAP5. Altering the subcellular/cell 
surface location of CNTN5 may alter the proteins with which it can interact. Over-
expression of CNTN5 in our cell culture system may have saturated the binding to 
CNTNAP leaving CNTN5 free to interact with γ-secretase components and inhibit 
Aβ generation. CNTN5 has been shown to interact with APLP1 at the synaptic 
membrane (Shimoda and Watanabe, 2009; Shimoda et al., 2012). APLP1 can 
influence the proteolytic processing of APP, therefore regulating the CNTN5-
APLP1 interaction may indirectly regulate the processing of APP. In one model for 
the endocytosis of APP the adaptor protein Fe65 links APP with LRP1 via 
interactions with the GYENPTY motif and Y682 in the cytoplasmic domain of APP, 
and this complex formation is required for endocytosis of APP (and therefore for β-
secretase cleavage of APP and ultimately Aβ generation). APLP1 can also form a 
complex with Fe65, competitively preventing APP from interacting with LRP1 so 
inhibiting APP endocytosis (Neumann et al., 2006), therefore preventing β-secretase 
cleavage and Aβ generation. The interaction of CNTN5 with APLP1 may act to 
prevent the APLP1-Fe65-LRP1 interaction so allowing more APP-Fe65-LRP1 
complex to form therefore allowing more endocytosis of APP. However, this would 
be expected to increase the generation of Aβ whereas over-expression of CNTN5 
inhibited Aβ production suggesting this model cannot explain the effects of CNTN5 
in our system. Further investigation, particularly into the sub-cellular location of 
CNTN5 in primary neurons is required to fully understand the role of CNTN5 in 
APP processing. 
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4 The effect of BIN1 on amyloid-β metabolism  
4.1 Introduction 
Over the last few years several genome-wide association studies (GWAS) on 
sporadic Alzheimer’s disease (SAD) have been performed, and these have identified 
a number of genes that are related to SAD (Harold et al., 2009; Bertram and Tanzi, 
2010; Seshadri et al., 2010; Carrasquillo et al., 2011; Hollingworth et al., 2011; Hu 
et al., 2011; Wijsman et al., 2011). These genes have implicated several molecular 
and cellular processes in the development of AD, such as immune system functions, 
lipid metabolism and processes at the cell membrane such as endocytosis 
(Hollingworth et al., 2011). Endocytosis is very important in Aβ metabolism, as it is 
involved in the production and uptake (therefore potentially the toxicity) and 
clearance of Aβ by brain cells. One of the genes involved in endocytosis that has 
been implicated in sporadic AD by GWAS is BIN1. Here the role of BIN1 in the 
development of AD was investigated, focusing on whether BIN1 regulates the 
uptake or generation of Aβ. 
4.1.1 Aims 
Due to its role in endocytosis it was hypothesised that BIN1 is involved in 
either the uptake or generation of Aβ by cells and altering the levels of BIN1 would 
alter the amount of Aβ generated (by altering APP endocytosis) or internalised by a 
cell. This was investigated by knockdown and over-expression of BIN1 in SH-
SY5Y cells, a human neuroblastoma cell line. To investigate the role of BIN1 in Aβ 
uptake, a synthetic preparation of AβOs, ADDLs (amyloid-β derived diffusible 
ligands), was used. ADDLs are high molecular weight oligomer with a fibrillar 
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conformation, they correlate with cognitive decline in AD, and have been shown to 
bind to and be toxic to cells (Lambert et al., 1998; Wang et al., 2002; Deshpande et 
al., 2006). Cells were treated with AβOs, then Aβ uptake was assessed by 
fluorescence microscopy. To investigate BIN1 in APP metabolism and Aβ 
generation, BIN1 was either over-expressed or knocked down in SH-SY5Y cells, 
and then full length APP, sAPPα, sAPPβ, and Aβ were measured by western 
blotting (APP, sAPPα and sAPPβ) and ELISA (Aβ). Endocytosis is the key factor 
influencing whether APP is processed in the amyloidogenic or the non-
amyloidogenic pathway (Weidemann et al., 1989). The effect of BIN1 on APP 
endocytosis was determined using flow cytometry to measure cell surface APP 
following an incubation at either 4 oC (to prevent endocytosis) or 37 oC (allowing 
endocytosis). Finally, BIN1 was shown to regulate APP protein levels. APP has 
been shown to influence the levels of cell surface N-methyl-D-aspartate (NMDA) 
receptors, so we hypothesised that BIN1 expression would regulate cell surface 
NMDA receptor levels. NMDA receptors are involved in long term potentiation and 
are required for learning and memory (Morris et al., 1986), over-stimulation of 
NMDA receptors causes neuronal death by excitotoxicity (Manev et al., 1989), and 
NMDA receptor trafficking and cell surface levels has been shown to be disrupted in 
AD (Snyder et al., 2005). The effect of BIN1 on cell surface NMDA receptor levels 
was determined using flow cytometry. Finally, to investigate BIN1 in the human 
brain during aging, and in familial and sporadic AD, the level of BIN1 in human 
brain samples was determined by western blotting.  
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4.2 Optimisation of BIN1 knockdown in SH-SY5Y cells 
To investigate the role of BIN1 in the development of sporadic AD, BIN1 was 
knocked down in the human neuroblastoma cell line SH-SY5Y. SH-SY5Y cells 
were transfected with siRNA directed against BIN1, incubated for 48 hours, then 
cells were harvested and lysed. Cell lysates were western blotted for BIN1 (figure 
4.1 A, C and E). The optimal conditions for BIN1 knockdown were 50 nM siRNA 
(figure 4.1 B) and 6 µl Dharmafect 3 (per well of a 6-well plate) (figure 4.1 D). 
BIN1 knockdown was greater than 75 % after both a 48 and a 72 hour incubation 
(figure 4.1 F) so both of these incubation times were used, depending on the 
experimental set-up.  
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 Figure 4.1 Optimising knockdown of BIN1 in SH-SY5Y cells. (A) Western 
blot for BIN1 on cell lysates (40 µg) transfected with increasing concentrations of 
BIN1 siRNA (8 µl Dharmafect 3, 72 hours post-transfection), using ab54764. (B) 
Quantification of western blot in A. (C) Western blot for BIN1 on cell lysates (40 
µg) transfected with increasing volumes of Dharmafect 3 (50 nM BIN1 siRNA or 
RNAse free water (control), 72 hours post-transfection), using ab54764. (D) 
Quantification of western blot for BIN1 in C. (E) Western blot for BIN on cell 
lysates (40 µg) either 48 or 72 hours post-transfection (50 nM BIN1 siRNA or 
RNAse free water (control), 6 µl Dharmafect 3), using ab54764. (F) Quantification 
of western blot in E.  
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4.3 The effect of BIN1 on Aβ uptake 
AβOs (the toxic species in AD) are taken up into neurons by endocytosis, and 
this may be an important event for their toxicity (Cizas et al., 2011; Song et al., 
2011). To investigate the role of BIN1 in AβO endocytosis, a synthetic preparation 
of soluble AβOs was used. An SDS-polyacrylamine gel and western blot for Aβ 
confirmed the presence of high molecular weight oligomers in the AβO preparation 
(figure 4.2 A). The fibrillar epitope of the AβOs was confirmed by dot blot with the 
fibrillar conformation specific OC antibody (figure 4.2 B). Absence of a pre-fibrillar 
epitope was confirmed by dot blot with the conformation specific pre-fibrillar A11 
antibody (figure 4.2 B). SH-SY5Y cells were transfected with 50 nM BIN1 or non-
targeting control siRNA and incubated for 48 hours. Cells were then incubated for 
30 minutes at 37 oC with 400 nM (total peptide) AβOs then fixed, permeabilised and 
stained for Aβ and BIN1. Aβ was detected inside cells transfected with BIN1 and 
with non-targeting control siRNA. There was very little co-localisation of BIN1 with 
Aβ (figure 4.2 C). There was no significant difference in the proportion of Aβ inside 
cells transfected with BIN1 compared to cells transfected with non-targeting control 
siRNA (figure 4.2 D).  
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Figure 4.2 The effect of BIN1 knockdown on Aβ uptake by SH-SY5Y cells 
(legend overleaf)  
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Figure 4.2 The effect of BIN1 knockdown on Aβ uptake by SH-SY5Y cells. 
(A) Western blot of Aβ oligomers (AβOs, 4 µg) and Aβ monomers (AβM, 4µg), 
blotted for Aβ using 6E10. (B) Dot blots of AβOs (1 µg) for total Aβ using 6E10 
(first panel), for fibrillar Aβ using OC (middle panel) and non fibrillar Aβ using A11 
(last panel). (C) SH-SY5Y incubated with 400 nM (total peptide) biotin-tagged 
AβOs fixed, permeabilised and stained for AβOs using Texas-red conjugated 
streptavidin (red), and BIN1 using ab54764 (green); nuclei were stained with  
2 µg ml-1 DAPI (blue). (D) Quantification of Aβ staining inside cells in fluorescence 
images expressed as a percentage of total Aβ staining (total Aβ = Aβ inside +Aβ on 
the edge of cells). Aβ staining was measured using Image software. Aβ inside cells 
was mearured by drawing round the cell and determining the fluorescence intensity 
inside that area. Aβ on the edge of cells was measured by drawing a line around the 
cell and measuring the fluorescence intensity on the line. 19 cells from two separate 
experiments were measured for quantification. Data are mean ± S.D. 
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4.4 The effect of BIN1 on APP processing 
To determine the effect of BIN1 on APP processing, BIN1 was knocked down 
in SH-SY5Y cells over-expressing APP695 (SH-SY5Y-APP695). SH-SY5Y-APP695 
cells were transfected with either siRNA targeted against BIN1, or a non-targeting 
control sequence, and incubated for 24 hours. Cells were washed and incubated for 
48 hours with serum free medium, then medium was harvested and cells were 
harvested and lysed. Cell lysates were western blotted for BIN1 and APP, 
conditioned media was western blotted for sAPPα and sAPPβ (figure 4.3. A). Aβ 
levels in conditioned media were determined by ELISA (figure 4.3 E). BIN1 was 
knocked down by 65 % (p<0.001) in cells transfected with BIN siRNA (figure 4.3 
B). BIN1 knockdown caused a significant 7 % increase in APP695 (p=0.04) but did 
not alter APP751/770 in cell lysates (figure 4.3 C). BIN1 knockdown did not 
significantly alter sAPPα (figure 4.3 D), sAPPβ (figure 4.3 E) or Aβ (figure 4.3 F). 
To confirm the results of the knockdown of BIN1 on APP processing the 
converse experiment was performed and BIN1 was over-expressed in SH-SY5Y-
APP695 cells. The neuronal isoform of BIN1 in the vector pcDNA3.1(+) was 
obtained from Source Bioscience. SH-SY5Y-APP695 cells were transfected with 
BIN1 in pcDNA3.1(+) (empty vector was transfected in as a control), then 
transfected cells were selected with the antibiotic G418 to generate a cell line stably 
expressing BIN1: SH-SY5Y-APP695-BIN1. SH-SY5Y-APP695-BIN1 and SH-SY5Y-
APP695-vector cells were incubated for 48 hours, then medium was harvested and 
cells were harvested and lysed. Cell lysates were western blotted for BIN1 and APP, 
conditioned medium was western blotted for sAPPα and sAPPβ (figure 4.4 A). Aβ 
levels in conditioned media were determined by ELISA (figure 4.4 E). The neuronal 
isoform of BIN1 appeared as a doublet band on western blots. There is no evidence 
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in the literature for post-translational modification of BIN1 (e.g. by glycosylation or 
phosphorylation), so the lower molecular weight band may result from cleavage of 
the full length BIN1 by an un-identified protease. BIN1 over-expression caused a 
significant 19 % decrease in APP695 in cell lysates (p=0.03) but did not significantly 
alter APP751/770 (figure 4.4 B). BIN1 over-expression did not significantly alter 
sAPPα (figure 4.4 C), or sAPPβ (figure 3.5 D). BIN1 over-expression caused a 
significant 10 % decrease in Aβ40 (p=0.005) but no change in Aβ42 (figure 4.4 E). 
Together these data show that BIN1 expression regulates APP and Aβ levels. 
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Figure 4.3 The effect of BIN1 knockdown on APP proteolysis. (A) 
Representative western blots on cell lysates (30 µg) transfected with siRNA for 
BIN1 (+) or non-targeting control (-) for: BIN1 with ab54764 (top panel), APP with 
22C11 (second panel) and conditioned media (40 µg) for sAPPα with 6E10 (third 
panel) and sAPPβ with 1A9 (fourth panel). (B) Quantification of western blots for 
BIN1. (C) Quantification of western blots for APP. (D) Quantification of western 
blots for sAPPα. (E) Quantification of western blots for sAPPβ. (F) ELISA to 
determine Aβ in conditioned media. Data are mean ± S.D. n=3 (*p<0.05). 
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Figure 4.4 The effect of BIN1 over-expression on APP proteolysis.  
(A) Representative western blots on SH-SY5Y-APP695 cell lysates (30 µg) 
transfected with BIN1 cDNA (+) or empty vector (-) for: BIN1 with ab54764 (top 
panel), APP with 22C11 (second panel) and conditioned media (30 µg) for sAPPα 
with 6E10 (third panel) and sAPPβ with 1A9 (fourth panel). (B) Quantification of 
western blots for APP. (C) Quantification of western blots for sAPPα. (D) 
Quantification of western blots for sAPPβ. (E) ELISA to determine Aβ in 
conditioned media. Data are mean ± S.D. n=3 (*p<0.05)(**p<0.01).  
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4.5 The effect of BIN1 on APP endocytosis 
Altering the expression of BIN1 alters the levels of APP in the cells, and Aβ 
secreted, suggesting that it affects the amount of APP processed in the 
amyloidogenic pathway. Processing in the amyloidogenic pathway requires 
endocytosis of APP, therefore BIN1 may play a role in regulating the endocytosis of 
APP. Cell surface APP in SH-SY5Y-APP695 cells expressing BIN1 or empty vector 
was labelled, cells were incubated for 10 minutes at either 4 oC or 37 oC, then cells 
were either fixed, permeabilised, and stained for APP (figure 4.5 A), or cell surface 
APP was determined by flow cytometry (figure 4.5 B). Cells that had been 
incubated at 4 oC showed APP fluorescence at the cell surface with very little 
staining inside the cells. Cells that had been incubated at 37 oC showed APP 
fluorescence in intracellular vesicles with considerably less APP at the cell surface 
(figure 4.5 A). Flow cytometry showed a significant 60 % decrease in cell surface 
APP in vector transfected cells (p=0.04), and a significant 70 % decrease in cell 
surface APP in BIN1 over-expressing cells (p<0.0001) at 37 oC compared to 4 oC 
(figure 4.5 C). However, over-expression of BIN1 did not significantly alter the 
amount of APP endocytosed (figure 4.5 C, compare vector and BIN1 at 37 oC). 
BIN1 over-expression did not alter cell surface APP levels (figure 4.5 D). These 
data suggest that BIN1 does not regulate APP endocytosis. 
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Figure 4.5 The effect of BIN1 over-expression on APP endocytosis.  
(A) SH-SY5Y-APP695 cells transfected with either BIN1 cDNA or empty vector 
stained with anti-APP antibody 6E10 were incubated for 10 minutes at either 4 oC or 
37 oC fixed, permeabilised and stained for APP (green), nuclei were stained with 2 
µgml-1 DAPI (blue). (B) Representative histograms showing cell surface APP (FITC 
fluorescence) after a 10 minute incubation at either 4 oC (top) or 37 oC (bottom). (C) 
Geometric mean of cell surface APP expressed as a percentage cell surface APP at  
4 oC. (D) Geometric mean of cell surface APP in samples incubated at 4 oC, 
expressed as a percentage cell surface APP on cells expressing the empty vector. 
Data are mean ± S.D., n=3. (*p<0.05)(****p<0.0001). 
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4.6 The effect of BIN1 on cell surface N-methyl–D-aspartate 
receptors 
Cell surface NMDA receptors have been shown to be regulated by APP 
expression (Cousins et al., 2009; Innocent et al., 2012). The data presented here 
demonstrate that BIN1 regulates APP levels and therefore may regulate cell surface 
NMDA receptors via APP. Cell surface NMDA receptors in SH-SY5Y-APP695 cells 
expressing BIN1 or empty vector were labelled using an anti-GluN2B antibody, then 
cells were either fixed, permeabilised and stained for NMDA receptors (figure 4.6 
A) or cell surface NMDAR was determined by flow cytometry (figure 4.6 B). The 
GluN2B subunit of NMDAR is not trafficked to the cell surface unless it has formed 
the whole NMDAR complex, therefore GluN2B at the cell surface accurately 
reflects cell surface levels of NMDAR containing the GluN2B subunit. (McIlhinney 
et al., 1998). BIN1 over-expression did not cause a significant change in cell surface 
NMDAR (figure 4.6 C). 
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Figure 4.6 The effect of BIN1 over-expression on cell surface NMDA 
receptors. (A) SH-SY5Y-APP695 cells were fixed, permeabilised and NMDA 
receptors stained with SAB2500699 (green), nuclei were stained with 2 µg ml-1 
DAPI (blue). (B) Representative histograms showing cell surface NMDA receptors 
(FITC fluorescence) on SH-SY5Y-APP695 transfected with BIN1 cDNA or empty 
vector. (C) Geometric mean of cell surface NMDA receptors on SH-SY5Y-APP695 
transfected with either BIN1 cDNA or empty vector. Data are mean ± S.D. n=3. 
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4.7 BIN1 in the human brain 
BIN1 in the human brain during aging and Alzheimer’s disease, and the 
correlation of BIN1 with Aβ in the human brain was investigated. Four different 
cohorts of brain samples were investigated: aging cohort 1 (table 3.1), sporadic AD 
cohort 2 (table 3.2), familial AD cohort 3 (table 3.3) and sporadic AD cohort 4 (table 
3.4). For details on the brain samples in each cohort see chapter 3. 
A preliminary western blot for BIN1 on a selection of temporal lobe 
homogenates from sporadic AD cohort 4 showed prominent bands at approximately 
90 kDa and 60 kDa (figure 4.7 A). The predicted molecular weight of the neuronal 
isoform (and the longest isoform) of BIN1 is approximately 70 kDa, however BIN1 
migrates at an aberrantly high molecular weight on SDS-PAGE (Ramjaun et al., 
1997). The neuronal isoform of BIN1 expressed in SH-SY5Y cells migrates as a 
doublet at approximately 90 kDa (figure 4.7 B) suggesting the 90 kDa band in 
human brain homogenates is the neuronal isoform of BIN1. The lower molecular 
weight 60 kDa band is also detected in SH-SY5Y cell lysates, and its intensity is 
decreased by BIN1 siRNA (figure 4.4 A), demonstrating that this band is another 
isoform of BIN1. Both the 90 and 60 kDa isoforms of BIN1 were quantified. 
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Figure 4.7 BIN1 detected in human brain homogenates and SH-SY5Y cell 
lysates. (A) Western blot of a selection of human temporal lobe homogenates (40 
µg) from cohort 4 for BIN1 using ab54764. (B) Western blot SH-SY5Y-APP695 cell 
lysates (30 µg) expressing the neuronal isoform of BIN1 for BIN1 using ab54764. 
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Quantification of western blots for BIN1 on aging cohort 1 hippocampal 
(figure 4.8 A) and temporal lobe (figure 4.8 B) homogenates showed a significant 
negative correlation between both 60 kDa BIN1 (figure 4.8 C, p=0.03) and 90 kDa 
BIN1 (figure 4.8 E, p=0.01) and age in the hippocampus, suggesting BIN1 decreases 
in the hippocampus with age. There was no significant correlation between 60 kDa 
BIN1 (figure 4.8 D) or 90 kDa BIN1 (figure 4.8 F) and age in the temporal lobe. 
Quantification of western blots for BIN1 on Sporadic AD cohort 2 
hippocampal (figure 4.9 A) and temporal lobe (figure 4.9 B) homogenates, and on 
familial AD cohort 3 hippocampal homogenates (figure 4.9 C) showed no 
significant difference in 60 kDa BIN1 in sporadic AD brains compared to age-
matched control samples (figure 4.9 D). The 90 kDa neuronal isoform of BIN1 was 
not detected in sporadic AD cohort 2 brains. There was no significant difference in 
either 60 kDa (figure 4.9 E) or 90 kDa BIN1 (figure 4.9 F) in familial AD brains 
compared to age-matched controls. 
Quantification of western blots for BIN1 on sporadic AD cohort 4 temporal 
lobe homogenates (figure 4.10 A) showed a significant decrease of both 60 kDa 
BIN1 (figure 4.10 B, p=0.03) and 90 kDa BIN1 (figure 4.10 C, p=0.01) in sporadic 
AD brains compared to age-matched controls. There was no correlation of either  
60 kDa (figure 4.10 D) or 90 kDa BIN1 (figure 4.10 F) with soluble Aβ. There was 
no correlation of 60 kDa BIN1 with insoluble Aβ (figure 4.10 E), but there was a 
significant negative correlation of 90 kDa BIN1 with insoluble Aβ (figure 4.10 G, 
p=0.046). These results support the data from cell culture models showing that 
increased BIN1 results in decreased Aβ levels.  
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Figure 4.8 BIN1 in the aging brain, aging cohort 1 (legend overleaf) 
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Figure 4.8 BIN1 in the aging brain, aging cohort 1. (A) Western blot for 
BIN1 on human hippocampal homogenates (50 µg) from aging cohort 1 using 
ab54764. (B) Western blot for BIN1 on human temporal lobe homogenates (50 µg) 
from aging cohort 1 using ab54764. (C) Quantification of 60 kDa BIN1 from 
western blots on hippocampal homogenates for BIN1 (both bands indicated by 
arrows were quantified together). Spearman’s correlation showed a significant 
(p<0.05) correlation between 60 kDa BIN1 and age in human hippocampal samples. 
(D) Quantification of 60 kDa BIN1 from western blots on temporal lobe 
homogenates for BIN1. Spearman’s correlation showed no significant correlation 
between 60 kDa BIN1 and age in human temporal lobe samples. (E) Quantification 
of 90 kDa BIN1 from western blots on hippocampal homogenates for BIN1. 
Spearman’s correlation showed a significant (p<0.05) correlation between 90 kDa 
BIN1 and age in human hippocampal samples. (F) Quantification of 90 kDa BIN1 
from western blots on temporal lobe homogenates for BIN1. Spearman’s correlation 
showed no significant correlation between 90 kDa BIN1 and age in human temporal 
lobe samples. 
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Figure 4.9 BIN1 in the human brain in sporadic AD cohort 2 and familial AD 
cohort 3 (legend overleaf)  
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Figure 4.9 BIN1 in the human brain in Sporadic AD cohort 2 and Familial 
AD cohort 3. (A) Western blot for BIN1 on Sporadic AD cohort 2 SAD and age-
matched control human hippocampal homogenates (50 µg) using ab54764. (B) 
Western blot for BIN1 on Sporadic AD cohort 2 SAD and age-matched control 
human temporal lobe homogenates (50 µg) using ab54764. (C) Western blot for 
BIN1 on Familial AD cohort 3 FAD and age-matched control hippocampal 
homogenates (50 µg) using ab54764. (D) Quantification of 60 kDa BIN1 from 
western blots for BIN1 on sporadic AD cohort 2 SAD and age matched control 
human hippocampal and temporal lobe homogenates (n=7). (E) Quantification of  
60 kDa BIN1 from western blots for BIN1 on Familial AD cohort 3 FAD and age-
matched control human hippocampal homogenates (n=6). (F) Quantification of  
90 kDa BIN1 from western blots for BIN1 on Familial AD cohort 3 FAD and age-
matched control human hippocampal homogenates (n=6). 
  
- 144 - 
 
Figure 4.10 BIN1 and Aβ levels in sporadic AD cohort 4 and age-matched 
control temporal lobe (legend overleaf)  
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Figure 4.10 BIN1 and Aβ levels in Sporadic AD cohort 4 and age-matched 
control temporal lobe. (A) Western blot for BIN1 on Sporadic AD cohort 4 SAD 
and age-matched control human temporal lobe homogenates (40 µg) using ab54764. 
(B) Quantification of 60 kDa BIN1 from western blots for BIN1 on Sporadic AD 
cohort 4 SAD and age-matched control human temporal lobe homogenates (n=24). 
(C) Quantification of 90 kDa BIN1 from western blots for BIN1 on Sporadic AD 
cohort 4 SAD and age-matched control human temporal lobe homogenates (n=24). 
(D) Spearman’s correlation analysis showed no correlation between 60 kDa BIN1 
and soluble Aβ in human temporal lobe samples. (E) Spearman’s correlation 
analysis showed no correlation between 60 kDa BIN1 and insoluble Aβ in human 
temporal lobe samples. (F) Spearman’s correlation analysis showed no correlation 
between 90 kDa BIN1 and soluble Aβ in human temporal lobe samples. (G) 
Spearman’s correlation analysis showed a significant correlation (p<0.05) between 
90 kDa BIN1 and insoluble Aβ in human temporal lobe samples. 
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4.8 Discussion 
 Endocytosis is critical in the generation and the uptake of Aβ. BIN1 is 
involved in endocytosis in neurons (Ramjaun et al., 1997; Wigge et al., 1997) so the 
role of BIN1 in both of these processes was investigated. 
 BIN1 knockdown in SH-SY5Y cells did not affect the uptake of Aβ and BIN1 
did not co-localise with Aβ, which suggests that BIN1 does not regulate the uptake 
of Aβ by neurons. Aβ is generated within cells, and then secreted to the extracellular 
space, where it can then be re-internalised by neurons. Several groups have shown 
that Aβ is taken up by endocytosis, and the uptake of Aβ may be required for Aβ 
toxicity (Cizas et al., 2011; Song et al., 2011). Studies have shown that AβO binds to 
specific receptors on neurons (for example the cellular prion protein and RAGE, 
receptor for advanced glycation end products) (Sturchler et al., 2008; Lauren et al., 
2009; Kudo et al., 2012), so it is possible that the SH-SY5Y cells used do not 
express the required Aβ-receptor proteins (SH-SY5Y cells for example do not 
express the prion protein). Other groups have shown that Aβ is internalised in an 
endocytosis-independent manor (Kandimalla et al., 2009), in which case expression 
of BIN1 would not be expected to alter Aβ uptake. It is also not clear whether Aβ 
needs to be internalised in order to mediate toxic effects on the cell, or whether Aβ 
can initiate intracellular signalling cascades upon binding to cell surface receptors 
which result in cell death. It is possible that BIN1 may be involved in the regulation 
of these signalling cascades or the cell surface expression of these receptors. It is 
also important to note that during endocytosis BIN1 forms a heterodimer with 
amphiphysin 1, a BIN1 homologue. Amphiphysin 1 is capable of forming 
homodimers in the absence of BIN1 (Wigge et al., 1997), so BIN1 knockdown may 
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not have a significant effect on endocytosis in the absence of also reducing 
amphiphysin I. 
 BIN1 did not regulate Aβ uptake, so the effect of BIN1 on Aβ generation and 
APP proteolytic processing was determined. BIN1 knockdown significantly 
increased APP levels, and caused a trend towards increased sAPPβ. BIN1 over-
expression caused a significant decrease in both APP and Aβ, as well as a trend 
towards decreased sAPPβ. BIN1 did not affect sAPPα levels. These data suggest 
that BIN1 regulates Aβ generation, and leads to the hypothesis that high levels of 
BIN1 decrease Aβ generation so are protective against development of AD.  
 Increasing BIN1 expression decreased APP levels, and decreased Aβ but did 
not alter sAPPα, which suggests that BIN1 regulates APP that is processed in the 
amyloidogenic rather than the non-amyloidogenic pathway. Endocytosis of APP 
from the cell surface is the key event influencing whether APP is processed by α-or 
β-secretase, and so dictating through which pathway APP is processed. To 
determine whether BIN1 can regulate the endocytosis or the cell surface levels of 
APP, cell surface APP was measured by flow cytometry after a 10 minute 
incubation at either 4 or 37 oC. At 4 oC, which reflects steady state cell surface APP 
levels, there was less APP at the cell surface in cells expressing BIN1, however, this 
difference was not significant. Both in cells expressing BIN1 or empty vector there 
was a significant decrease in cell surface APP after a 10 minute incubation at 37 oC 
indicating that endocytosis of APP occurred in both cases. This suggests that BIN1 
is not regulating the total amount of APP endocytosed; therefore it is not regulating 
β-cleavage of APP by regulating the gross endocytosis of APP. Since the decrease in 
Aβ is accompanied by a decrease in full length APP this suggests that rather than 
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simply retaining APP intracellularly BIN1 is re-directing APP that is normally 
processed in the amyloidogenic pathway to be degraded in another pathway.  
 Altering the expression of BIN1 regulates APP levels; this may have several 
implications for the functioning of neuronal cells and AD. APP has been shown to 
regulate both cell surface NMDAR levels (Cousins et al., 2009; Innocent et al., 
2012) and cell surface choline transporter levels (Wang et al., 2007).  
 Innocent et al., (2012) have shown that increasing APP expression increases 
cell surface NMDAR levels (Innocent et al., 2012). Activation of NMDAR has been 
shown to be important for synaptic plasticity and long term potentiation, which is 
involved in learning and memory (Bliss and Collingridge, 1993; Collingridge and 
Bliss, 1995). Several different proteins have been implicated in the trafficking and 
metabolism of NMDAR, and Lau and Zukin have proposed that dysregulation of 
this trafficking may have a role in the development of AD (Lau and Zukin, 2007). 
Furthermore the drug Memantine, an NMDAR antagonist, has had some success in 
treating severe AD (Winblad and Poritis, 1999; Forstl et al., 2011). To determine the 
functional consequences of altering BIN1 expression levels on cell surface NMDAR 
levels, BIN1 was over-expressed in SH-SY5Y-APP695 cells, and cell surface 
NMDAR levels were measured by flow cytometry. The functional NMDAR is a 
tetramer composed of four subunits, normally subtypes of GluN1 and GluN2 
subunits (Paoletti and Neyton, 2007). GluN1 or GluN2 subunits are not transported 
to the cell surface unless in a full NMDAR complex (McIlhinney et al., 1998), so 
using an anti-GluN2B antibody directed against a part of the NMDA receptor that is 
extracellular allows measurement of full/functional NMDAR at the cell surface. 
This showed that increasing BIN1 expression (so decreasing APP expression) 
caused a trend towards increased (rather than decreased as was reported previously) 
cell surface NMDAR containing GluN2B, suggesting that if BIN1 regulates cell 
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surface NMDAR it is by a different mechanism than altering APP expression. 
NMDAR function has been shown to decrease with age (Gonzales et al., 1991; 
Wenk et al., 1991; Magnusson et al., 2002), and it has been hypothesised that 
chronic decreases in NMDAR function can lead to neurodegenerative changes in the 
brain, by causing excessive release of acetylcholine and glutamate (Giovannini et 
al., 1994; Moghaddam et al., 1997) which causes hyperstimulation and 
excitotoxicity to the post synaptic neuron (Newcomer and Krystal, 2001). High 
levels of BIN1 may be neuroprotective by keeping NMDAR levels high so 
counteracting the age related decrease in NMDAR. 
To investigate BIN1 in the human brain during AD and aging BIN1 in four 
different cohorts of brain samples was determined by western blotting. Two 
isoforms of BIN1, one at 60 kDa and one at 90 kDa were detected in human brain 
samples. It is clear that both these bands are BIN1: the 60 kDa band is detected in 
SH-SY5Y cells lysates, and is reduced by treatment with BIN1 siRNA, and the  
90 kDa band corresponds to the neuronal isoform of BIN1 over-expressed in SH-
SY5Y. Both isoforms of BIN1 decreased with age in human hippocampal samples, 
but not temporal lobe samples. There was no significant difference in the amount of 
BIN1 in sporadic AD or familial AD brain samples compared to age matched 
control samples in cohorts 2 and 3, but there was significantly less BIN1 in sporadic 
AD temporal lobe samples compared to age matched control samples in cohort 4. 
These data show that BIN1 is reduced in the brain in aging and in AD, and therefore 
agree with the hypothesis that high levels of BIN1 expression are protective against 
development of AD. Reduced levels of the 90 kDa isoform of BIN1 were associated 
with increased levels of insoluble Aβ in cohort 4. There was no significant 
association between the 60 kDa isoform of BIN1 and Aβ suggesting that only the 
neuronal isoform has a role in regulating Aβ metabolism. The non-neuronal 
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isoforms of BIN1 are located in the nucleus and do not have a role in endocytosis, so 
it is unlikely that they would influence Aβ generation (Butler et al., 1997; Elliott et 
al., 2000). The 90 kDa isoform of BIN1 did not correlate with soluble Aβ levels in 
the temporal lobe. However, there was no difference in the levels of soluble Aβ in 
sporadic AD temporal lobe samples compared to age-matched controls, suggesting 
that the form of soluble Aβ detected by the ELISA is not related to sporadic AD.  
It is possible that BIN1 may have a non-endocytic related role in the 
development of AD. The nuclear isoform of BIN1 (the isoform expressed by most 
somatic cells rather than just neuronal cells) has no effect on endocytosis, but is 
involved in caspase-independent programmed cell death (Elliott et al., 2000). 
Programmed cell death contributes to neuronal death in AD, and cells undergoing 
caspase-independent programmed cell death have been reported in the AD brain (Yu 
et al., 2010b). However, a number of endocytosis-related proteins have been 
implicated in the development of AD by GWAS (e.g. PICALM, BIN1, CD2AP 
(Tebar et al., 1999; Meyerholz et al., 2005; Harel et al., 2008)) and there is a lot of 
evidence that endocytosis is important for AD pathogenesis. Furthermore the 
neuronal isoform of BIN1, but not the non-neuronal isoforms of BIN1, has a role in 
endocytosis (Elliott et al., 2000). Together with the data presented here showing that 
BIN1 alters the processing of APP, this makes it highly likely that BIN1 is involved 
in the development of AD due to its endocytic rather than its cell death promoting 
functions. 
Together these data suggest that increased levels of BIN1 reduce the 
development of sporadic AD by decreasing the amount of APP, and decreasing the 
amount of Aβ produced by neurons. Furthermore, BIN1 levels decrease in the brain 
with age, which may contribute to the increased risk of developing AD with 
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increasing age. BIN1 has been related to SAD by two single nucleotide 
polymorphisms (SNPs), rs744373 and rs7561528 both of which lie approximately 
30 kb upstream of the start of the BIN1 gene. The consequence of this is that the 
primary or the three-dimensional structure of BIN1 is not altered by either of these 
SNPs; however, they may cause alterations in the expression of BIN1 such as 
altering timing of expression, altering expression levels or altering the isoform 
expressed. In light of the evidence shown here it would be interesting to determine 
whether either of these SNPs are in regions of the DNA involved in regulation of 
BIN1 expression. 
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5 Discussion 
5.1 Contactin 5 
The Proteins studied in chapter 3, neurofascin, Thy-1 and CNTN5, were all 
identified from an in vivo APP interactome study (Bai et al., 2008). All three of 
these proteins had some effect on the regulation of APP metabolism, altering either 
levels of full length APP, sAPPα, sAPPβ or Aβ. Table 1.1 (section 1.8) shows 
several proteins, all with roles in the regulation of APP. This demonstrates the 
complexity of the regulation of APP metabolism, and in turn the complexity of 
Alzheimer’s disease: dysregulation of one or more of these regulatory proteins may 
contribute to the development of AD. Although all the proteins investigated in 
chapter 3 appeared to be involved in the regulation of APP metabolism, the most 
dramatic results were obtained with CNTN5.  
5.1.1 Contactin proteins and γ-secretase 
Over-expression of CNTN5 in HEK-APP695 cells caused a decrease in Aβ 
secretion, and an increase in the C-terminal fragments C83 and C99 in the cells. This 
decrease in the γ-secretase cleavage product (Aβ) and increase in the γ-secretase 
substrates (the C-terminal fragments) suggests that CNTN5 inhibits γ-secretase. 
Other members of the contactin family have been shown to be regulators of γ-
secretase: CNTN1 is capable of inducing γ-secretase dependent release of the Notch 
intracellular domain (NICD) (Hu et al., 2003), and CNTN2 has been shown to cause 
γ-secretase dependent release of the AICD (Ma et al., 2008). γ-secretase is required 
for generation of Aβ, and for this reason inhibition of γ-secretase is being 
investigated as an AD therapeutic strategy. Treating mice with a potent γ-secretase 
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inhibitor caused weight loss, a decrease in the number of B and T cells, altered 
morphology in the gastrointestinal tract, and 40 % of the mice on a higher dose of 
the inhibitor had died by day 15 of the trial (Wong et al., 2004). Furthermore PS1 
knockout mice die within minutes of birth (Shen et al., 1997). Regardless of the 
adverse effects observed in mice, γ-secretase inhibitors have been developed as 
potential AD therapeutics, but none of them have passed clinical trials. The most 
recent example is Semagacestat (LY450139), a γ-secretase inhibitor developed by 
Eli Lilly. This drug showed promise in early trials, it did not cause adverse side 
effects and it decreased plasma Aβ levels (Siemers et al., 2007; Fleisher et al., 
2008). However, in phase three trials this drug performed worse than the placebo, 
and increased the risk of skin cancer, so trials were discontinued 
(http://newsroom.lilly.com/releasedetail.cfm?releaseid=499794, Eli Lilly press 
release). This suggests that complete inhibition of γ-secretase may not be a suitable 
therapeutic strategy for treatment of AD. 
5.1.2 Contactin 5 as a γ-secretase modulator 
More recently, due to the problems with γ-secretase inhibitors, research has 
moved towards the development of γ-secretase modulators. γ-secretase modulators 
can differentially affect the activity of γ-secretase towards Aβ and AICD generation, 
without affecting γ-secretase cleavage of other substrates (such as Notch). Some 
examples of γ-secretase modulators are γ-secretase activating protein (GSAP) and 
the drug Gleevec (Eisele et al., 2007; He et al., 2010). These modulators have the 
potential to inhibit the generation of Aβ without the unpleasant side effects caused 
by complete inhibition of γ-secretase. The drug Gleevec (Imatinib) decreases Aβ 
secretion and increases AICD generation in cell culture, by modulating γ-secretase 
activity via GSAP. The model proposed for this is that GSAP binds the γ-secretase-
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APP ternary complex, altering the structure of the complex and so promoting 
cleavage of APP at the γ-site and thus increasing the generation of Aβ (figure 5.1). 
Gleevec prevents GSAP from binding to the γ-secretase-APP ternary complex, so γ-
secretase cleaves predominantly at the ε-site of APP reducing Aβ and increasing 
AICD generation. Increased generation of AICD could then further decrease Aβ 
levels by causing an AICD induced increase in neprilysin (NEP) expression, leading 
to increased Aβ degradation (Eisele et al., 2007; He et al., 2010). If CNTN5 is a γ-
secretase modulator, rather than an outright γ-secretase inhibitor, it could have 
potential as a target for AD therapeutics, so further work should focus on this. To 
determine whether CNTN5 could be a γ-secretase modulator the effect of CNTN5 
on generation of AICD from APP, as well as the effect of CNTN5 on the cleavage 
of other γ-secretase substrates, needs to be determined. Measurement of AICD by 
western blotting in HEK-APP695 cells expressing CNTN5 was attempted but not 
achieved. An alternative way to measure AICD generation is to measure expression 
of genes whose expression is regulated by AICD, such as NEP. Increased generation 
of AICD results in increased expression of NEP, and this can be measured by 
quantitative reverse transcription PCR for NEP mRNA (Pardossi-Piquard et al., 
2005). 
It has previously been demonstrated that transcriptionally active AICD is only 
generated in neuronal cell lines, rather than in non-neuronal cell lines such as HEK 
cells (Belyaev et al., 2010). The effect of CNTN5 on γ-secretase has been 
demonstrated in both HEK cells and the neuronal cell line N2a cells, so NEP and 
AICD levels could be determined in N2a cells over-expressing CNTN5. Both HEK 
and N2a cells are immortalised cell lines so further studies into the effect of CNTN5 
on Aβ generation could be carried out in primary neurons. Determining the effect of 
knockdown of CNTN5 expression on APP metabolism was not carried out as no cell 
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lines endogenously expressing CNTN5 were identified. Primary glial cells express 
CNTN, but this expression is quickly lost when the cells are grown in vitro 
(Eckerich et al., 2006), suggesting that CNTN5 may be expressed in primary 
neuronal cells. If that is the case CNTN5 expression can be knocked down in 
primary neuronal cells, then the effect of this on Aβ and NEP can be determined by 
ELISA and quantitative reverse transcription PCR, respectively. 
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Figure 5.1 GSAP and Gleevec as γ-secretase modulators. On the left γ-
secretase activating protein (GSAP) binds the γ-secretase-APP ternary complex and 
causes γ-secretase to cleave APP at the γ-site generating Aβ. On the right in the 
presence of Gleevec, GSAP does not bind the γ-secretase-APP ternary complex. In 
the absence of GSAP γ-secretase cleaves APP predominantly at the ε-site generating 
AICD. The AICD upregulates expression of neprilysin, which increases Aβ 
degradation, further reducing Aβ levels. 
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5.1.3 Contactin 5 and Notch processing 
The second important factor that could determine whether CNTN5 is a viable 
therapeutic target for AD is whether CNTN5 regulates the cleavage of Notch by γ-
secretase. The involvement of γ-secretase in Notch proteolysis and generation of the 
NICD has previously been a problem for γ-secretase inhibiting AD therapeutics. 
Notch has also been shown to have a role in cancer and both oncogenic and tumour 
suppressive roles have been demonstrated (Klinakis et al., 2011). Mutations that 
inactivate Notch have been found in patients with leukaemia, and inducing these 
mutations in mouse haematopoietic stem cells caused a leukaemia-like disease 
(Klinakis et al., 2011), demonstrating further potential complications for 
therapeutics that alter the activity of γ-secretase. This demonstrates the importance 
of Notch cleavage in cells, so it is vital that γ-secretase targeting drugs do not 
interfere with Notch cleavage and NICD generation. The effect of CNTN5 on NICD 
generation can be determined by expression of CNTN5 and Notch∆E in cell lines, 
then examining the effect of CNTN5 expression on levels of NICD. Notch∆E is a 
truncated form of Notch. Cleavage of Notch by γ-secretase occurs after an initial 
cleavage event, which is activated by receptor binding, generating Notch∆E. 
Therefore Notch∆E, rather than the full-length Notch protein is the substrate for γ-
secretase (Fortini, 2002).  
5.2 BIN1 
5.2.1 BIN1 expression and Aβ 
 BIN1 has been genetically linked to sporadic AD by GWAS (Harold et al., 
2009; Bertram and Tanzi, 2010; Seshadri et al., 2010; Carrasquillo et al., 2011; 
Hollingworth et al., 2011; Hu et al., 2011; Wijsman et al., 2011) so investigations 
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into the effect of BIN1 on APP metabolism can not only identify potential 
therapeutic targets for AD, but also shed some light onto the mechanisms involved 
in the of development of sporadic AD, as BIN1 levels were found to be decreased 
both during aging and in sporadic AD brain samples. Examination of BIN1 levels in 
human brain samples suggest that high levels of BIN1 protein in the brain are 
protective against the development of sporadic AD. Data from over-expression and 
knockdown studies of BIN1 in SH-SY5Y cells provide a potential mechanism for 
the protection afforded by BIN1. Higher levels of BIN1 expression reduced total 
APP levels, leading to reduced processing of APP in the amyloidogenic pathway, 
ultimately resulting in reduced Aβ generation. This is the first time a potential role 
for BIN1 in the development of sporadic AD has been identified. 
 The data in chapter 4 suggests that modulating expression of BIN1 could be a 
potential therapeutic intervention for AD. Variation at two SNPs 30 kb upstream of 
the start codon of BIN1 appears to influence the development of sporadic AD 
(Harold et al., 2009; Seshadri et al., 2010). In light of the data presented here it 
would be interesting to determine whether either of the AD-causing SNPs cause a 
decrease in expression of the neuronal isoform of BIN1 in the brain. If these SNPs 
result in reduced BIN1 expression, an increase in Aβ generation would be expected, 
which may lead to an increased chance of developing AD. A recent study by 
Jonsson et al., (2012) shows that a mutation in APP which decreases Aβ generation 
decreases the risk of developing AD. This shows that Aβ levels throughout life 
affect the development of AD. It also suggests that if treatment with an Aβ lowering 
drug begins early in the disease process then lowering Aβ could be an effective 
therapeutic approach for treating AD. Identification of carriers of the AD-related 
BIN1 SNPs could identify individuals at risk of developing AD, and early 
- 159 - 
intervention with Aβ lowering therapies has the potential to prevent AD 
development. 
5.2.2 BIN1 expression and APP 
 Another avenue for further investigation is the effects of the BIN1 induced 
changes in APP levels. Increasing BIN1 expression decreased APP levels, whereas 
decreasing BIN1 expression increased APP levels. APP expression has been shown 
to alter synaptic strength and the number of functional synpases (Priller et al., 2006). 
Wang et al., (2007) showed that an increase in APP expression increases 
endocytosis of the high affinity choline transporter from pre-synaptic terminals, so 
decreasing the uptake of choline from the synaptic cleft. Re-uptake of choline is 
important for the re-synthesis of the neurotransmitter acetylcholine. Acetylcholine 
has important functions in learning and memory, and many of the current treatments 
for AD focus on increasing levels of acetylcholine in the synapse. This means 
increases in APP expression may contribute to symptoms such as reduced memory 
and reduced synaptic activity by reducing the amount of acetylcholine synthesis 
(Wang et al., 2007). Acetylcholine synthesis and choline uptake are decreased in 
AD, causing decreases in cholinergic function (Francis et al., 1999; Sharp et al., 
2009) which correlates with cognitive decline (Garcia-Alloza et al., 2005). 
 The decreased levels of acetylcholine in AD has been therapeutically targeted 
using acetylcholine esterase inhibitors, such as Donepezil and Galantamine, to 
inhibit the breakdown and so increase levels of acetylcholine. These drugs have 
been shown to be neuroprotective in cells in culture, and can causes a temporary 
stabilisation or less than predicted decline in cognitive function in AD patients 
(Wilkinson et al., 2004; Francis et al., 2005) showing that increasing acetylcholine 
can have a therapeutic benefit. APP expression has also been shown to modulate 
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LTP – in mouse models both increases and decreases in expression of APP decrease 
LTP (Matsuyama et al., 2007). This means that the increase in APP caused by a loss 
of BIN1 could cause a decrease in LTP so decrease learning and memory formation. 
Innocent et al., (2012) showed that APP expression regulates cell surface NMDAR 
expression and so potentially can regulate the strength and activity of synapses 
(Innocent et al., 2012).  
 Data in chapter four showed that BIN1 expression in SH-SY5Y cells, however, 
did not cause sufficient APP alterations to affect cell surface levels NDMA receptor 
containing the GluN2B sunbunit. NMDA receptors are composed of a GluN1 
subunit, and one of more GluN2 subunits. There are four different GluN2 subunit, 
GluN2(A-D) (Hynd et al., 2004). The work in chapter four only investigated NMDA 
receptors containing the GluN2B subunit, therefore further work could investugate 
whether the BIN1 induced alterations in APP can affect cell surface levels of 
NMDA receptors containing the GluN2A, C or D sunbunits. It remains to be 
determined whether the BIN1 induced increases in APP expression can modulate 
any other processes, but if so then therapeutics targeting this increase in APP have 
potential to prevent AD symptoms caused by decreased acetylcholine, decreased 
LTP and alterations in cell surface NMDA receptors. 
5.3 Concluding remarks 
 Alzheimer’s disease is a complex disease: many proteins regulate the 
processing of APP and the generation of Aβ, many proteins regulate the binding and 
toxicity of Aβ to neurons and many proteins and cell types are involved in the 
clearance of Aβ from the brain. Dysregulation of these proteins has been shown to 
have the potential to influence the development of AD, yet it is not clear which of 
these contribute to the development of AD in vivo. It is likely that dysregulation of 
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several pathways is involved in the development of the disease. Over the last decade 
numerous large studies have been carried out, such as GWAS and APP interactome 
studies, which have identified proteins with an involvement in AD. However there 
has been a severe lacking of research into how these newly identified genes and 
proteins influence the development of AD. For example the AlzGene database 
(www.alzgene.org) currently contains details of 1395 studies and 695 genes that 
have been shown to be related to AD, yet with the exception of APOE no 
mechanism for the involvement of any of these genes in the development of AD has 
been published. In order for this newly generated information to advance the field of 
AD detailed studies into these proteins need to be carried out. Recent work by Bali 
et al., (2012) has begun this, by knocking down expression of 25 SAD related genes, 
and determining the effect this has on sAPPβ and Aβ40, and Aβ42. This research 
showed that knockdown of 17 out of 24 SAD related genes caused an increase in Aβ 
production (Bali et al., 2012). The results generated by Bali et al., support the data 
presented here showing that BIN1 knockdown causes an increase in amyloidogenic 
cleavage of APP. The work presented in this thesis furthers the investigations by 
Bali and co-workers, showing that BIN1 over-expression has the opposite effect to 
BIN1 knockdown on APP processing as well as showing that BIN1 is not involved 
in the up-take of AβOs.  
 The work presented here is a detailed analysis of the involment of two novel 
proteins, BIN1 and CNTN5,  in the regulation of APP processing and Aβ generation. 
CNTN5 and BIN1 regulate APP processing at different points – BIN1 regulates the 
levels of APP and the amount of APP directed down the amyloidogenic pathway, 
whereas CNTN5 regulates the γ-secretase cleavage of APP (figure 5.2). Both of 
these reduce Aβ generation, and represent potential targets for future AD 
therapeutics.  
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 Figure 5.2 The role of BIN1 and CNTN5 in the regulation of APP 
processing. BIN1 and CNTN5 regulate the processing of APP after it has been 
synthesized, transported to the cell surface and endocytosed. BIN1 is involved in the 
trafficking of APP re-directing it from processing on the amyloidogenic pathway to 
compartments of the cell where it is degraded, so reducing the amount of APP that is 
cleaved on the amyloidogenic pathway. CNTN5 inhibits γ-secretase cleavage of 
APP reducing Aβ generation. 
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7 Appendix 
7.1 DNA sequences of constructs used in over-expression studies 
7.1.1 Empty pcDNA3.1(+) sequence  
   1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGCACTCT CAGTACAATC 
  51 TGCTCTGATG CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT 
 101 GGAGGTCGCT GAGTAGTGCG CGAGCAAAAT TTAAGCTACA ACAAGGCAAG 
 151 GCTTGACCGA CAATTGCATG AAGAATCTGC TTAGGGTTAG GCGTTTTGCG 
 201 CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT GATTATTGAC 
 251 TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 
 301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG 
 351 CCCAACGACC CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT 
 401 AACGCCAATA GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT 
 451 AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC 
 501 CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA 
 551 CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA 
 601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA 
 651 TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA 
 701 TGGGAGTTTG TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA 
 751 ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG 
 801 GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG 
 851 GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTGGCTAGC 
 901 GTTTAAACTT AAGCTTGGTA CCGAGCTCGG ATCCACTAGT CCAGTGTGGT 
 951 GGAATTCTGC AGATATCCAG CACAGTGGCG GCCGCTCGAG TCTAGAGGGC 
1001 CCGTTTAAAC CCGCTGATCA GCCTCGACTG TGCCTTCTAG TTGCCAGCCA 
1051 TCTGTTGTTT GCCCCTCCCC CGTGCCTTCC TTGACCCTGG AAGGTGCCAC 
1101 TCCCACTGTC CTTTCCTAAT AAAATGAGGA AATTGCATCG CATTGTCTGA 
1151 GTAGGTGTCA TTCTATTCTG GGGGGTGGGG TGGGGCAGGA CAGCAAGGGG 
1201 GAGGATTGGG AAGACAATAG CAGGCATGCT GGGGATGCGG TGGGCTCTAT 
1251 GGCTTCTGAG GCGGAAAGAA CCAGCTGGGG CTCTAGGGGG TATCCCCACG 
1301 CGCCCTGTAG CGGCGCATTA AGCGCGGCGG GTGTGGTGGT TACGCGCAGC 
1351 GTGACCGCTA CACTTGCCAG CGCCCTAGCG CCCGCTCCTT TCGCTTTCTT 
1401 CCCTTCCTTT CTCGCCACGT TCGCCGGCTT TCCCCGTCAA GCTCTAAATC 
1451 GGGGGCTCCC TTTAGGGTTC CGATTTAGTG CTTTACGGCA CCTCGACCCC 
1501 AAAAAACTTG ATTAGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA 
1551 GACGGTTTTT CGCCCTTTGA CGTTGGAGTC CACGTTCTTT AATAGTGGAC 
1601 TCTTGTTCCA AACTGGAACA ACACTCAACC CTATCTCGGT CTATTCTTTT 
1651 GATTTATAAG GGATTTTGCC GATTTCGGCC TATTGGTTAA AAAATGAGCT 
1701 GATTTAACAA AAATTTAACG CGAATTAATT CTGTGGAATG TGTGTCAGTT 
1751 AGGGTGTGGA AAGTCCCCAG GCTCCCCAGC AGGCAGAAGT ATGCAAAGCA 
1801 TGCATCTCAA TTAGTCAGCA ACCAGGTGTG GAAAGTCCCC AGGCTCCCCA 
1851 GCAGGCAGAA GTATGCAAAG CATGCATCTC AATTAGTCAG CAACCATAGT 
1901 CCCGCCCCTA ACTCCGCCCA TCCCGCCCCT AACTCCGCCC AGTTCCGCCC 
1951 ATTCTCCGCC CCATGGCTGA CTAATTTTTT TTATTTATGC AGAGGCCGAG 
2001 GCCGCCTCTG CCTCTGAGCT ATTCCAGAAG TAGTGAGGAG GCTTTTTTGG 
2051 AGGCCTAGGC TTTTGCAAAA AGCTCCCGGG AGCTTGTATA TCCATTTTCG 
2101 GATCTGATCA AGAGACAGGA TGAGGATCGT TTCGCATGAT TGAACAAGAT 
2151 GGATTGCACG CAGGTTCTCC GGCCGCTTGG GTGGAGAGGC TATTCGGCTA 
2201 TGACTGGGCA CAACAGACAA TCGGCTGCTC TGATGCCGCC GTGTTCCGGC 
2251 TGTCAGCGCA GGGGCGCCCG GTTCTTTTTG TCAAGACCGA CCTGTCCGGT 
2301 GCCCTGAATG AACTGCAGGA CGAGGCAGCG CGGCTATCGT GGCTGGCCAC 
2351 GACGGGCGTT CCTTGCGCAG CTGTGCTCGA CGTTGTCACT GAAGCGGGAA 
2401 GGGACTGGCT GCTATTGGGC GAAGTGCCGG GGCAGGATCT CCTGTCATCT 
2451 CACCTTGCTC CTGCCGAGAA AGTATCCATC ATGGCTGATG CAATGCGGCG 
2501 GCTGCATACG CTTGATCCGG CTACCTGCCC ATTCGACCAC CAAGCGAAAC 
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2551 ATCGCATCGA GCGAGCACGT ACTCGGATGG AAGCCGGTCT TGTCGATCAG 
2601 GATGATCTGG ACGAAGAGCA TCAGGGGCTC GCGCCAGCCG AACTGTTCGC 
2651 CAGGCTCAAG GCGCGCATGC CCGACGGCGA GGATCTCGTC GTGACCCATG 
2701 GCGATGCCTG CTTGCCGAAT ATCATGGTGG AAAATGGCCG CTTTTCTGGA 
2751 TTCATCGACT GTGGCCGGCT GGGTGTGGCG GACCGCTATC AGGACATAGC 
2801 GTTGGCTACC CGTGATATTG CTGAAGAGCT TGGCGGCGAA TGGGCTGACC 
2851 GCTTCCTCGT GCTTTACGGT ATCGCCGCTC CCGATTCGCA GCGCATCGCC 
2901 TTCTATCGCC TTCTTGACGA GTTCTTCTGA GCGGGACTCT GGGGTTCGAA 
2951 ATGACCGACC AAGCGACGCC CAACCTGCCA TCACGAGATT TCGATTCCAC 
3001 CGCCGCCTTC TATGAAAGGT TGGGCTTCGG AATCGTTTTC CGGGACGCCG 
3051 GCTGGATGAT CCTCCAGCGC GGGGATCTCA TGCTGGAGTT CTTCGCCCAC 
3101 CCCAACTTGT TTATTGCAGC TTATAATGGT TACAAATAAA GCAATAGCAT 
3151 CACAAATTTC ACAAATAAAG CATTTTTTTC ACTGCATTCT AGTTGTGGTT 
3201 TGTCCAAACT CATCAATGTA TCTTATCATG TCTGTATACC GTCGACCTCT 
3251 AGCTAGAGCT TGGCGTAATC ATGGTCATAG CTGTTTCCTG TGTGAAATTG 
3301 TTATCCGCTC ACAATTCCAC ACAACATACG AGCCGGAAGC ATAAAGTGTA 
3351 AAGCCTGGGG TGCCTAATGA GTGAGCTAAC TCACATTAAT TGCGTTGCGC 
3401 TCACTGCCCG CTTTCCAGTC GGGAAACCTG TCGTGCCAGC TGCATTAATG 
3451 AATCGGCCAA CGCGCGGGGA GAGGCGGTTT GCGTATTGGG CGCTCTTCCG 
3501 CTTCCTCGCT CACTGACTCG CTGCGCTCGG TCGTTCGGCT GCGGCGAGCG 
3551 GTATCAGCTC ACTCAAAGGC GGTAATACGG TTATCCACAG AATCAGGGGA 
3601 TAACGCAGGA AAGAACATGT GAGCAAAAGG CCAGCAAAAG GCCAGGAACC 
3651 GTAAAAAGGC CGCGTTGCTG GCGTTTTTCC ATAGGCTCCG CCCCCCTGAC 
3701 GAGCATCACA AAAATCGACG CTCAAGTCAG AGGTGGCGAA ACCCGACAGG 
3751 ACTATAAAGA TACCAGGCGT TTCCCCCTGG AAGCTCCCTC GTGCGCTCTC 
3801 CTGTTCCGAC CCTGCCGCTT ACCGGATACC TGTCCGCCTT TCTCCCTTCG 
3851 GGAAGCGTGG CGCTTTCTCA TAGCTCACGC TGTAGGTATC TCAGTTCGGT 
3901 GTAGGTCGTT CGCTCCAAGC TGGGCTGTGT GCACGAACCC CCCGTTCAGC 
3951 CCGACCGCTG CGCCTTATCC GGTAACTATC GTCTTGAGTC CAACCCGGTA 
4001 AGACACGACT TATCGCCACT GGCAGCAGCC ACTGGTAACA GGATTAGCAG 
4051 AGCGAGGTAT GTAGGCGGTG CTACAGAGTT CTTGAAGTGG TGGCCTAACT 
4101 ACGGCTACAC TAGAAGAACA GTATTTGGTA TCTGCGCTCT GCTGAAGCCA 
4151 GTTACCTTCG GAAAAAGAGT TGGTAGCTCT TGATCCGGCA AACAAACCAC 
4201 CGCTGGTAGC GGTTTTTTTG TTTGCAAGCA GCAGATTACG CGCAGAAAAA 
4251 AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC TGACGCTCAG 
4301 TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG 
4351 GATCTTCACC TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT 
4401 AAAGTATATA TGAGTAAACT TGGTCTGACA GTTACCAATG CTTAATCAGT 
4451 GAGGCACCTA TCTCAGCGAT CTGTCTATTT CGTTCATCCA TAGTTGCCTG 
4501 ACTCCCCGTC GTGTAGATAA CTACGATACG GGAGGGCTTA CCATCTGGCC 
4551 CCAGTGCTGC AATGATACCG CGAGACCCAC GCTCACCGGC TCCAGATTTA 
4601 TCAGCAATAA ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA GTGGTCCTGC 
4651 AACTTTATCC GCCTCCATCC AGTCTATTAA TTGTTGCCGG GAAGCTAGAG 
4701 TAAGTAGTTC GCCAGTTAAT AGTTTGCGCA ACGTTGTTGC CATTGCTACA 
4751 GGCATCGTGG TGTCACGCTC GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG 
4801 TTCCCAACGA TCAAGGCGAG TTACATGATC CCCCATGTTG TGCAAAAAAG 
4851 CGGTTAGCTC CTTCGGTCCT CCGATCGTTG TCAGAAGTAA GTTGGCCGCA 
4901 GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC TTACTGTCAT 
4951 GCCATCCGTA AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT 
5001 TCTGAGAATA GTGTATGCGG CGACCGAGTT GCTCTTGCCC GGCGTCAATA 
5051 CGGGATAATA CCGCGCCACA TAGCAGAACT TTAAAAGTGC TCATCATTGG 
5101 AAAACGTTCT TCGGGGCGAA AACTCTCAAG GATCTTACCG CTGTTGAGAT 
5151 CCAGTTCGAT GTAACCCACT CGTGCACCCA ACTGATCTTC AGCATCTTTT 
5201 ACTTTCACCA GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC AAAATGCCGC 
5251 AAAAAAGGGA ATAAGGGCGA CACGGAAATG TTGAATACTC ATACTCTTCC 
5301 TTTTTCAATA TTATTGAAGC ATTTATCAGG GTTATTGTCT CATGAGCGGA 
5351 TACATATTTG AATGTATTTA GAAAAATAAA CAAATAGGGG TTCCGCGCAC 
5401 ATTTCCCCGA AAAGTGCCAC CTGACGTC 
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7.1.2 BIN1 insert sequence 
   1 GAGACCCAAG CTGGCTAGCG TTTAAACTTA AGCTTGCCAC CATGGCCGAG 
  51 ATGGGCAGCA AGGGCGTGAC CGCCGGCAAG ATCGCCAGCA ACGTGCAGAA 
 101 GAAGCTGACC AGAGCCCAAG AAAAGGTGCT GCAGAAGCTG GGCAAGGCCG 
 151 ACGAGACAAA GGACGAGCAG TTCGAGCAGT GCGTGCAGAA CTTCAACAAG 
 201 CAGCTGACCG AGGGCACCCG GCTGCAGAAG GACCTGAGAA CCTACCTGGC 
 251 CAGCGTGAAG GCCATGCACG AGGCCAGCAA GAAACTGAAC GAGTGCCTGC 
 301 AAGAAGTGTA CGAGCCCGAC TGGCCCGGCA GGGATGAGGC CAACAAGATC 
 351 GCCGAGAACA ACGACCTGCT GTGGATGGAC TACCACCAGA AACTGGTGGA 
 401 CCAGGCCCTG CTGACCATGG ACACATACCT GGGCCAGTTC CCCGACATCA 
 451 AGAGCCGGAT CGCCAAGCGG GGACGGAAGC TGGTGGACTA CGACAGCGCC 
 501 AGACACCACT ACGAGAGCCT GCAGACCGCC AAGAAGAAGG ACGAGGCCAA 
 551 GATTGCCAAG CCCGTGTCCC TGCTGGAAAA GGCCGCTCCC CAGTGGTGCC 
 601 AGGGCAAGCT GCAGGCCCAT CTGGTGGCCC AGACCAACCT GCTGCGGAAC 
 651 CAGGCCGAGG AAGAACTGAT CAAGGCCCAG AAAGTGTTCG AAGAGATGAA 
 701 CGTGGACCTG CAAGAAGAAC TGCCCAGCCT TTGGAACAGC AGAGTGGGCT 
 751 TCTACGTGAA CACCTTCCAG TCTATCGCCG GCCTGGAAGA GAACTTCCAC 
 801 AAAGAGATGA GCAAGCTGAA CCAGAACCTG AACGACGTGC TGGTCGGACT 
 851 GGAAAAGCAG CACGGCAGCA ACACCTTTAC CGTGAAGGCC CAGCCCAGCG 
 901 ACAACGCCCC TGCCAAGGGC AACAAGAGCC CCAGCCCTCC TGATGGCAGC 
 951 CCTGCCGCCA CCCCCGAGAT CAGAGTGAAC CACGAGCCTG AGCCAGCCGG 
1001 CGGAGCCACA CCTGGCGCCA CACTGCCTAA GAGCCCCTCC CAGCTGAGAA 
1051 AGGGCCCTCC CGTGCCCCCT CCACCCAAGC ACACCCCTAG CAAAGAAGTG 
1101 AAGCAAGAAC AGATCCTGAG CCTGTTCGAG GACACCTTCG TGCCCGAGAT 
1151 CTCCGTGACC ACCCCCAGCC AGTTTGAGGC CCCTGGCCCT TTCAGCGAGC 
1201 AGGCCTCCCT GCTGGACCTG GACTTCGACC CCCTGCCCCC TGTGACCAGC 
1251 CCTGTGAAGG CCCCTACCCC CAGCGGCCAG AGCATCCCCT GGGATCTGTG 
1301 GGAGCCTACC GAGAGCCCAG CCGGCTCTCT GCCTTCTGGC GAGCCTAGTG 
1351 CCGCCGAGGG CACATTCGCC GTGTCCTGGC CTAGCCAGAC AGCCGAGCCT 
1401 GGACCTGCTC AGCCTGCCGA GGCTTCTGAA GTGGCTGGCG GCACACAGCC 
1451 TGCCGCTGGC GCTCAAGAAC CTGGCGAGAC AGCCGCCTCT GAGGCCGCCT 
1501 CTTCTAGCCT GCCTGCCGTG GTGGTGGAAA CCTTCCCCGC CACCGTGAAC 
1551 GGCACCGTGG AAGGCGGATC TGGCGCCGGA AGGCTGGATC TGCCTCCCGG 
1601 CTTCATGTTT AAGGTGCAGG CCCAGCACGA CTACACCGCC ACCGACACCG 
1651 ACGAGCTGCA GCTGAAAGCC GGCGACGTGG TGCTGGTGAT CCCATTCCAG 
1701 AACCCCGAGG AACAGGACGA GGGCTGGCTG ATGGGCGTGA AAGAGAGCGA 
1751 CTGGAACCAG CACAAAGAAC TGGAAAAGTG CAGAGGCGTG TTCCCCGAGA 
1801 ACTTCACCGA GCGGGTGCCC TAATCTAGAG GGCCCGTTTA AACCCGCTGA 
1851 TCAGCCTC 
7.1.3 pcDNA3.1(+)-BIN1 (pcDNA3.1(+) with a BIN1 insert) 
   1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGCACTCT CAGTACAATC 
  51 TGCTCTGATG CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT 
 101 GGAGGTCGCT GAGTAGTGCG CGAGCAAAAT TTAAGCTACA ACAAGGCAAG  
 151 GCTTGACCGA CAATTGCATG AAGAATCTGC TTAGGGTTAG GCGTTTTGCG  
 201 CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT GATTATTGAC  
 251 TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA  
 301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG  
 351 CCCAACGACC CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT  
 401 AACGCCAATA GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT  
 451 AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC  
 501 CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA  
 551 CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA  
 601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA  
 651 TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA  
 701 TGGGAGTTTG TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA  
 751 ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG  
 801 GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG  
 851 GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTGGCTAGC  
 901 GTTTAAACTT AAGCTTGCCA CCATGGCCGA GATGGGCAGC AAGGGCGTGA  
 951 CCGCCGGCAA GATCGCCAGC AACGTGCAGA AGAAGCTGAC CAGAGCCCAA  
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1001 GAAAAGGTGC TGCAGAAGCT GGGCAAGGCC GACGAGACAA AGGACGAGCA  
1051 GTTCGAGCAG TGCGTGCAGA ACTTCAACAA GCAGCTGACC GAGGGCACCC  
1101 GGCTGCAGAA GGACCTGAGA ACCTACCTGG CCAGCGTGAA GGCCATGCAC  
1151 GAGGCCAGCA AGAAACTGAA CGAGTGCCTG CAAGAAGTGT ACGAGCCCGA  
1201 CTGGCCCGGC AGGGATGAGG CCAACAAGAT CGCCGAGAAC AACGACCTGC  
1251 TGTGGATGGA CTACCACCAG AAACTGGTGG ACCAGGCCCT GCTGACCATG  
1301 GACACATACC TGGGCCAGTT CCCCGACATC AAGAGCCGGA TCGCCAAGCG  
1351 GGGACGGAAG CTGGTGGACT ACGACAGCGC CAGACACCAC TACGAGAGCC  
1401 TGCAGACCGC CAAGAAGAAG GACGAGGCCA AGATTGCCAA GCCCGTGTCC  
1451 CTGCTGGAAA AGGCCGCTCC CCAGTGGTGC CAGGGCAAGC TGCAGGCCCA  
1501 TCTGGTGGCC CAGACCAACC TGCTGCGGAA CCAGGCCGAG GAAGAACTGA  
1551 TCAAGGCCCA GAAAGTGTTC GAAGAGATGA ACGTGGACCT GCAAGAAGAA  
1601 CTGCCCAGCC TTTGGAACAG CAGAGTGGGC TTCTACGTGA ACACCTTCCA  
1651 GTCTATCGCC GGCCTGGAAG AGAACTTCCA CAAAGAGATG AGCAAGCTGA  
1701 ACCAGAACCT GAACGACGTG CTGGTCGGAC TGGAAAAGCA GCACGGCAGC  
1751 AACACCTTTA CCGTGAAGGC CCAGCCCAGC GACAACGCCC CTGCCAAGGG  
1801 CAACAAGAGC CCCAGCCCTC CTGATGGCAG CCCTGCCGCC ACCCCCGAGA  
1851 TCAGAGTGAA CCACGAGCCT GAGCCAGCCG GCGGAGCCAC ACCTGGCGCC  
1901 ACACTGCCTA AGAGCCCCTC CCAGCTGAGA AAGGGCCCTC CCGTGCCCCC  
1951 TCCACCCAAG CACACCCCTA GCAAAGAAGT GAAGCAAGAA CAGATCCTGA  
2001 GCCTGTTCGA GGACACCTTC GTGCCCGAGA TCTCCGTGAC CACCCCCAGC  
2051 CAGTTTGAGG CCCCTGGCCC TTTCAGCGAG CAGGCCTCCC TGCTGGACCT  
2101 GGACTTCGAC CCCCTGCCCC CTGTGACCAG CCCTGTGAAG GCCCCTACCC  
2151 CCAGCGGCCA GAGCATCCCC TGGGATCTGT GGGAGCCTAC CGAGAGCCCA  
2201 GCCGGCTCTC TGCCTTCTGG CGAGCCTAGT GCCGCCGAGG GCACATTCGC  
2251 CGTGTCCTGG CCTAGCCAGA CAGCCGAGCC TGGACCTGCT CAGCCTGCCG  
2301 AGGCTTCTGA AGTGGCTGGC GGCACACAGC CTGCCGCTGG CGCTCAAGAA  
2351 CCTGGCGAGA CAGCCGCCTC TGAGGCCGCC TCTTCTAGCC TGCCTGCCGT  
2401 GGTGGTGGAA ACCTTCCCCG CCACCGTGAA CGGCACCGTG GAAGGCGGAT  
2451 CTGGCGCCGG AAGGCTGGAT CTGCCTCCCG GCTTCATGTT TAAGGTGCAG  
2501 GCCCAGCACG ACTACACCGC CACCGACACC GACGAGCTGC AGCTGAAAGC  
2551 CGGCGACGTG GTGCTGGTGA TCCCATTCCA GAACCCCGAG GAACAGGACG  
2601 AGGGCTGGCT GATGGGCGTG AAAGAGAGCG ACTGGAACCA GCACAAAGAA  
2651 CTGGAAAAGT GCAGAGGCGT GTTCCCCGAG AACTTCACCG AGCGGGTGCC  
2701 CTAATCTAGA GGGCCCGTTT AAACCCGCTG ATCAGCCTCG ACTGTGCCTT  
2801 CTGGAAGGTG CCACTCCCAC TGTCCTTTCC TAATAAAATG AGGAAATTGC  
2851 ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT GGGGTGGGGC  
2901 AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT  
2951 GCGGTGGGCT CTATGGCTTC TGAGGCGGAA AGAACCAGCT GGGGCTCTAG  
3001 GGGGTATCCC CACGCGCCCT GTAGCGGCGC ATTAAGCGCG GCGGGTGTGG  
3051 TGGTTACGCG CAGCGTGACC GCTACACTTG CCAGCGCCCT AGCGCCCGCT  
3101 CCTTTCGCTT TCTTCCCTTC CTTTCTCGCC ACGTTCGCCG GCTTTCCCCG  
3151 TCAAGCTCTA AATCGGGGGC TCCCTTTAGG GTTCCGATTT AGTGCTTTAC  
3201 GGCACCTCGA CCCCAAAAAA CTTGATTAGG GTGATGGTTC ACGTAGTGGG  
3251 CCATCGCCCT GATAGACGGT TTTTCGCCCT TTGACGTTGG AGTCCACGTT  
3301 CTTTAATAGT GGACTCTTGT TCCAAACTGG AACAACACTC AACCCTATCT  
3351 CGGTCTATTC TTTTGATTTA TAAGGGATTT TGCCGATTTC GGCCTATTGG  
3401 TTAAAAAATG AGCTGATTTA ACAAAAATTT AACGCGAATT AATTCTGTGG  
3451 AATGTGTGTC AGTTAGGGTG TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG  
3501 AAGTATGCAA AGCATGCATC TCAATTAGTC AGCAACCAGG TGTGGAAAGT  
3551 CCCCAGGCTC CCCAGCAGGC AGAAGTATGC AAAGCATGCA TCTCAATTAG  
3601 TCAGCAACCA TAGTCCCGCC CCTAACTCCG CCCATCCCGC CCCTAACTCC  
3651 GCCCAGTTCC GCCCATTCTC CGCCCCATGG CTGACTAATT TTTTTTATTT  
3701 ATGCAGAGGC CGAGGCCGCC TCTGCCTCTG AGCTATTCCA GAAGTAGTGA  
3751 GGAGGCTTTT TTGGAGGCCT AGGCTTTTGC AAAAAGCTCC CGGGAGCTTG  
3801 TATATCCATT TTCGGATCTG ATCAAGAGAC AGGATGAGGA TCGTTTCGCA  
3851 TGATTGAACA AGATGGATTG CACGCAGGTT CTCCGGCCGC TTGGGTGGAG  
3901 AGGCTATTCG GCTATGACTG GGCACAACAG ACAATCGGCT GCTCTGATGC  
3951 CGCCGTGTTC CGGCTGTCAG CGCAGGGGCG CCCGGTTCTT TTTGTCAAGA  
4001 CCGACCTGTC CGGTGCCCTG AATGAACTGC AGGACGAGGC AGCGCGGCTA  
4051 TCGTGGCTGG CCACGACGGG CGTTCCTTGC GCAGCTGTGC TCGACGTTGT  
4101 CACTGAAGCG GGAAGGGACT GGCTGCTATT GGGCGAAGTG CCGGGGCAGG  
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4151 ATCTCCTGTC ATCTCACCTT GCTCCTGCCG AGAAAGTATC CATCATGGCT  
4201 GATGCAATGC GGCGGCTGCA TACGCTTGAT CCGGCTACCT GCCCATTCGA  
4251 CCACCAAGCG AAACATCGCA TCGAGCGAGC ACGTACTCGG ATGGAAGCCG  
4301 GTCTTGTCGA TCAGGATGAT CTGGACGAAG AGCATCAGGG GCTCGCGCCA  
4351 GCCGAACTGT TCGCCAGGCT CAAGGCGCGC ATGCCCGACG GCGAGGATCT  
4401 CGTCGTGACC CATGGCGATG CCTGCTTGCC GAATATCATG GTGGAAAATG  
4451 GCCGCTTTTC TGGATTCATC GACTGTGGCC GGCTGGGTGT GGCGGACCGC  
4501 TATCAGGACA TAGCGTTGGC TACCCGTGAT ATTGCTGAAG AGCTTGGCGG  
4551 CGAATGGGCT GACCGCTTCC TCGTGCTTTA CGGTATCGCC GCTCCCGATT  
4601 CGCAGCGCAT CGCCTTCTAT CGCCTTCTTG ACGAGTTCTT CTGAGCGGGA  
4651 CTCTGGGGTT CGAAATGACC GACCAAGCGA CGCCCAACCT GCCATCACGA  
4701 GATTTCGATT CCACCGCCGC CTTCTATGAA AGGTTGGGCT TCGGAATCGT  
4751 TTTCCGGGAC GCCGGCTGGA TGATCCTCCA GCGCGGGGAT CTCATGCTGG  
4801 AGTTCTTCGC CCACCCCAAC TTGTTTATTG CAGCTTATAA TGGTTACAAA  
4851 TAAAGCAATA GCATCACAAA TTTCACAAAT AAAGCATTTT TTTCACTGCA  
4901 TTCTAGTTGT GGTTTGTCCA AACTCATCAA TGTATCTTAT CATGTCTGTA  
4951 TACCGTCGAC CTCTAGCTAG AGCTTGGCGT AATCATGGTC ATAGCTGTTT  
5001 CCTGTGTGAA ATTGTTATCC GCTCACAATT CCACACAACA TACGAGCCGG  
5051 AAGCATAAAG TGTAAAGCCT GGGGTGCCTA ATGAGTGAGC TAACTCACAT  
5101 TAATTGCGTT GCGCTCACTG CCCGCTTTCC AGTCGGGAAA CCTGTCGTGC  
5151 CAGCTGCATT AATGAATCGG CCAACGCGCG GGGAGAGGCG GTTTGCGTAT  
5201 TGGGCGCTCT TCCGCTTCCT CGCTCACTGA CTCGCTGCGC TCGGTCGTTC  
5251 GGCTGCGGCG AGCGGTATCA GCTCACTCAA AGGCGGTAAT ACGGTTATCC  
5301 ACAGAATCAG GGGATAACGC AGGAAAGAAC ATGTGAGCAA AAGGCCAGCA  
5351 AAAGGCCAGG AACCGTAAAA AGGCCGCGTT GCTGGCGTTT TTCCATAGGC  
5401 TCCGCCCCCC TGACGAGCAT CACAAAAATC GACGCTCAAG TCAGAGGTGG  
5451 CGAAACCCGA CAGGACTATA AAGATACCAG GCGTTTCCCC CTGGAAGCTC  
5501 CCTCGTGCGC TCTCCTGTTC CGACCCTGCC GCTTACCGGA TACCTGTCCG  
5551 CCTTTCTCCC TTCGGGAAGC GTGGCGCTTT CTCATAGCTC ACGCTGTAGG  
5601 TATCTCAGTT CGGTGTAGGT CGTTCGCTCC AAGCTGGGCT GTGTGCACGA  
5651 ACCCCCCGTT CAGCCCGACC GCTGCGCCTT ATCCGGTAAC TATCGTCTTG  
5701 AGTCCAACCC GGTAAGACAC GACTTATCGC CACTGGCAGC AGCCACTGGT  
5751 AACAGGATTA GCAGAGCGAG GTATGTAGGC GGTGCTACAG AGTTCTTGAA  
5801 GTGGTGGCCT AACTACGGCT ACACTAGAAG AACAGTATTT GGTATCTGCG  
5851 CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG CTCTTGATCC  
5901 GGCAAACAAA CCACCGCTGG TAGCGGTTTT TTTGTTTGCA AGCAGCAGAT  
5951 TACGCGCAGA AAAAAAGGAT CTCAAGAAGA TCCTTTGATC TTTTCTACGG  
6001 GGTCTGACGC TCAGTGGAAC GAAAACTCAC GTTAAGGGAT TTTGGTCATG  
6051 AGATTATCAA AAAGGATCTT CACCTAGATC CTTTTAAATT AAAAATGAAG  
6101 TTTTAAATCA ATCTAAAGTA TATATGAGTA AACTTGGTCT GACAGTTACC  
6151 AATGCTTAAT CAGTGAGGCA CCTATCTCAG CGATCTGTCT ATTTCGTTCA  
6201 TCCATAGTTG CCTGACTCCC CGTCGTGTAG ATAACTACGA TACGGGAGGG  
6251 CTTACCATCT GGCCCCAGTG CTGCAATGAT ACCGCGAGAC CCACGCTCAC  
6301 CGGCTCCAGA TTTATCAGCA ATAAACCAGC CAGCCGGAAG GGCCGAGCGC  
6351 AGAAGTGGTC CTGCAACTTT ATCCGCCTCC ATCCAGTCTA TTAATTGTTG  
6401 CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT TAATAGTTTG CGCAACGTTG  
6451 TTGCCATTGC TACAGGCATC GTGGTGTCAC GCTCGTCGTT TGGTATGGCT  
6501 TCATTCAGCT CCGGTTCCCA ACGATCAAGG CGAGTTACAT GATCCCCCAT  
6551 GTTGTGCAAA AAAGCGGTTA GCTCCTTCGG TCCTCCGATC GTTGTCAGAA  
6601 GTAAGTTGGC CGCAGTGTTA TCACTCATGG TTATGGCAGC ACTGCATAAT  
6651 TCTCTTACTG TCATGCCATC CGTAAGATGC TTTTCTGTGA CTGGTGAGTA  
6701 CTCAACCAAG TCATTCTGAG AATAGTGTAT GCGGCGACCG AGTTGCTCTT  
6751 GCCCGGCGTC AATACGGGAT AATACCGCGC CACATAGCAG AACTTTAAAA  
6801 GTGCTCATCA TTGGAAAACG TTCTTCGGGG CGAAAACTCT CAAGGATCTT  
6851 ACCGCTGTTG AGATCCAGTT CGATGTAACC CACTCGTGCA CCCAACTGAT  
6901 CTTCAGCATC TTTTACTTTC ACCAGCGTTT CTGGGTGAGC AAAAACAGGA  
6951 AGGCAAAATG CCGCAAAAAA GGGAATAAGG GCGACACGGA AATGTTGAAT  
7001 ACTCATACTC TTCCTTTTTC AATATTATTG AAGCATTTAT CAGGGTTATT  
7051 GTCTCATGAG CGGATACATA TTTGAATGTA TTTAGAAAAA TAAACAAATA  
7101 GGGGTTCCGC GCACATTTCC CCGAAAAGTG CCACCTGACG TC 
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7.1.4 Empty pIRESneo sequence 
   1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC  
  51 TGCTCTGATG CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT  
 101 GGAGGTCGCT GAGTAGTGCG CGAGCAAAAT TTAAGCTACA ACAAGGCAAG  
 151 GCTTGACCGA CAATTGCATG AAGAATCTGC TTAGGGTTAG GCGTTTTGCG  
 201 CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT GATTATTGAC  
 251 TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA  
 301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG  
 351 CCCAACGACC CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT  
 401 AACGCCAATA GGGACTTTCC ATTGACGTCA ATGGGTGGAC TATTTACGGT  
 451 AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC  
 501 CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA  
 551 CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA  
 601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA  
 651 TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA  
 701 TGGGAGTTTG TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA  
 751 ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG  
 801 GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG  
 851 GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTTGGTACC  
 901 GAGCTCGGAT CGATATCTGC GGCCGCGTCG ACGGAATTCA GTGGATCCAC  
 951 TAGTAACGGC CGCCAGTGTG CTGGAATTAA TTCGCTGTCT GCGAGGGCCA  
1001 GCTGTTGGGG TGAGTACTCC CTCTCAAAAG CGGGCATGAC TTCTGCGCTA  
1051 AGATTGTCAG TTTCCAAAAA CGAGGAGGAT TTGATATTCA CCTGGCCCGC  
1101 GGTGATGCCT TTGAGGGTGG CCGCGTCCAT CTGGTCAGAA AAGACAATCT  
1151 TTTTGTTGTC AAGCTTGAGG TGTGGCAGGC TTGAGATCTG GCCATACACT  
1201 TGAGTGACAA TGACATCCAC TTTGCCTTTC TCTCCACAGG TGTCCACTCC  
1251 CAGGTCCAAC TGCAGGTCGA GCATGCATCT AGGGCGGCCA ATTCCGCCCC  
1301 TCTCCCTCCC CCCCCCCTAA CGTTACTGGC CGAAGCCGCT TGGAATAAGG  
1351 CCGGTGTGCG TTTGTCTATA TGTGATTTTC CACCATATTG CCGTCTTTTG  
1401 GCAATGTGAG GGCCCGGAAA CCTGGCCCTG TCTTCTTGAC GAGCATTCCT  
1451 AGGGGTCTTT CCCCTCTCGC CAAAGGAATG CAAGGTCTGT TGAATGTCGT  
1501 GAAGGAAGCA GTTCCTCTGG AAGCTTCTTG AAGACAAACA ACGTCTGTAG  
1551 CGACCCTTTG CAGGCAGCGG AACCCCCCAC CTGGCGACAG GTGCCTCTGC  
1601 GGCCAAAAGC CACGTGTATA AGATACACCT GCAAAGGCGG CACAACCCCA  
1651 GTGCCACGTT GTGAGTTGGA TAGTTGTGGA AAGAGTCAAA TGGCTCTCCT  
1701 CAAGCGTATT CAACAAGGGG CTGAAGGATG CCCAGAAGGT ACCCCATTGT  
1751 ATGGGATCTG ATCTGGGGCC TCGGTGCACA TGCTTTACAT GTGTTTAGTC  
1801 GAGGTTAAAA AAACGTCTAG GCCCCCCGAA CCACGGGGAC GTGGTTTTCC  
1851 TTTGAAAAAC ACGATGATAA GCTTGCCACA ACCCGGGATA ATTCCTGCAG  
1901 CCAATATGGG ATCGGCCATT GAACAAGATG GATTGCACGC AGGTTCTCCG  
1951 GCCGCTTGGG TGGAGAGGCT ATTCGGCTAT GACTGGGCAC AACAGACAAT  
2001 CGGCTGCTCT GATGCCGCCG TGTTCCGGCT GTCAGCGCAG GGGCGCCCGG  
2051 TTCTTTTTGT CAAGACCGAC CTGTCCGGTG CCCTGAATGA ACTGCAGGAC  
2101 GAGGCAGCGC GGCTATCGTG GCTGGCCACG ACGGGCGTTC CTTGCGCAGC  
2151 GTGCTCGACC GTTGTCACTG AAGCGGGAAG GGACTGGCTG CTATTGGGCG  
2201 AAGTGCCGGG GCAGGATCTC CTGTCATCTC ACCTTGCTCC TGCCGAGAAA  
2251 GTATCCATCA TGGCTGATGC AATGCGGCGG CTGCATACGC TTGATCCGGC  
2301 TACCTGCCCA TTCGACCACC AAGCGAAACA TCGCATCGAG CGAGCACGTA  
2351 CTCGGATGGA AGCCGGTCTT GTCGATCAGG ATGATCTGGA CGAAGAGCAT  
2401 CAGGGGCTCG CGCCAGCCGA ACTGTTCGCC AGGCTCAAGG CGCGCATGCC  
2451 CGACGGCGAT GATCTCGTCG TGACCCATGG CGATGCCTGC TTGCCGAATA  
2501 TCATGGTGGA AAATGGCCGC TTTTCTGGAT TCATCGACTG TGGCCGGCTG  
2551 GGTGTGGCGG ACCGCTATCA GGACATAGCG TTGGCTACCC GTGATATTGC  
2601 TGAAGAGCTT GGCGGCGAAT GGGCTGACCG CTTCCTCGTG CTTTACGGTA  
2651 TCGCCGCTCC CGATTCGCAG CGCATCGCCT TCTATCGCCT TCTTGACGAG  
2701 TTCTTCTGAG GGGATCAATT CTCTAGAGCT CGCTGATCAG CCTCGACTGT  
2751 GCCTTCTAGT TGCCAGCCAT CTGTTGTTTG CCCCTCCCCC GTGCCTTCCT  
2801 TGACCCTGGA AGGTGCCACT CCCACTGTCC TTTCCTAATA AAATGAGGAA  
2851 ATTGCATCGC ATTGTCTGAG TAGGTGTCAT TCTATTCTGG GGGGTGGGGT  
2901 GGGGCAGGAC AGCAAGGGGG AGGATTGGGA AGACAATAGC AGGCATGCTG  
2951 GGGATGCGGT GGGCTCTATG GCTTCTGAGG CGGAAAGAAC CAGCTGGGGC  
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3001 TCGAGTGCAT TCTAGTTGTG GTTTGTCCAA ACTCATCAAT GTATCTTATC  
3051 ATGTCTGTAT ACCGTCGACC TCTAGCTAGA GCTTGGCGTA ATCATGGTCA  
3101 TAGCTGTTTC CTGTGTGAAA TTGTTATCCG CTCACAATTC CACACAACAT  
3151 ACGAGCCGGA AGCATAAAGT GTAAAGCCTG GGGTGCCTAA TGAGTGAGCT  
3201 AACTCACATT AATTGCGTTG CGCTCACTGC CCGCTTTCCA GTCGGGAAAC  
3251 CTGTCGTGCC AGCTGCATTA ATGAATCGGC CAACGCGCGG GGAGAGGCGG  
3301 TTTGCGTATT GGGCGCTCTT CCGCTTCCTC GCTCACTGAC TCGCTGCGCT  
3351 CGGTCGTTCG GCTGCGGCGA GCGGTATCAG CTCACTCAAA GGCGGTAATA  
3401 CGGTTATCCA CAGAATCAGG GGATAACGCA GGAAAGAACA TGTGAGCAAA  
3451 AGGCCAGCAA AAGGCCAGGA ACCGTAAAAA GGCCGCGTTG CTGGCGTTTT  
3501 TCCATAGGCT CCGCCCCCCT GACGAGCATC ACAAAAATCG ACGCTCAAGT  
3551 CAGAGGTGGC GAAACCCGAC AGGACTATAA AGATACCAGG CGTTTCCCCC  
3401 TGGAAGCTCC CTCGTGCGCT CTCCTGTTCC GACCCTGCCG CTTACCGGAT  
3451 ACCTGTCCGC CTTTCTCCCT TCGGGAAGCG TGGCGCTTTC TCAATGCTCA  
3501 CGCTGTAGGT ATCTCAGTTC GGTGTAGGTC GTTCGCTCCA AGCTGGGCTG  
3551 TGTGCACGAA CCCCCCGTTC AGCCCGACCG CTGCGCCTTA TCCGGTAACT  
3601 ATCGTCTTGA GTCCAACCCG GTAAGACACG ACTTATCGCC ACTGGCAGCA  
3651 GCCACTGGTA ACAGGATTAG CAGAGCGAGG TATGTAGGCG GTGCTACAGA  
3701 GTTCTTGAAG TGGTGGCCTA ACTACGGCTA CACTAGAAGG ACAGTATTTG  
3751 GTATCTGCGC TCTGCTGAAG CCAGTTACCT TCGGAAAAAG AGTTGGTAGC  
3801 TCTTGATCCG GCAAACAAAC CACCGCTGGT AGCGGTGGTT TTTTTGTTTG  
3851 CAAGCAGCAG ATTACGCGCA GAAAAAAAGG ATCTCAAGAA GATCCTTTGA  
3901 TCTTTTCTAC GGGGTCTGAC GCTCAGTGGA ACGAAAACTC ACGTTAAGGG  
3951 ATTTTGGTCA TGAGATTATC AAAAAGGATC TTCACCTAGA TCCTTTTAAA  
4001 TTAAAAATGA AGTTTTAAAT CAATCTAAAG TATATATGAG TAAACTTGGT  
4051 CTGACAGTTA CCAATGCTTA ATCAGTGAGG CACCTATCTC AGCGATCTGT  
4101 CTATTTCGTT CATCCATAGT TGCCTGACTC CCCGTCGTGT AGATAACTAC  
4151 GATACGGGAG GGCTTACCAT CTGGCCCCAG TGCTGCAATG ATACCGCGAG  
4201 ACCCACGCTC ACCGGCTCCA GATTTATCAG CAATAAACCA GCCAGCCGGA  
4251 AGGGCCGAGC GCAGAAGTGG TCCTGCAACT TTATCCGCCT CCATCCAGTC  
4301 TATTAATTGT TGCCGGGAAG CTAGAGTAAG TAGTTCGCCA GTTAATAGTT  
4351 TGCGCAACGT TGTTGCCATT GCTACAGGCA TCGTGGTGTC ACGCTCGTCG  
4401 TTTGGTATGG CTTCATTCAG CTCCGGTTCC CAACGATCAA GGCGAGTTAC  
4451 ATGATCCCCC ATGTTGTGCA AAAAAGCGGT TAGCTCCTTC GGTCCTCCGA  
4501 TCGTTGTCAG AAGTAAGTTG GCCGCAGTGT TATCACTCAT GGTTATGGCA  
4551 GCACTGCATA ATTCTCTTAC TGTCATGCCA TCCGTAAGAT GCTTTTCTGT  
4601 GACTGGTGAG TACTCAACCA AGTCATTCTG AGAATAGTGT ATGCGGCGAC  
4651 CGAGTTGCTC TTGCCCGGCG TCAATACGGG ATAATACCGC GCCACATAGC  
4701 AGAACTTTAA AAGTGCTCAT CATTGGAAAA CGTTCTTCGG GGCGAAAACT  
4751 CTCAAGGATC TTACCGCTGT TGAGATCCAG TTCGATGTAA CCCACTCGTG  
4801 CACCCAACTG ATCTTCAGCA TCTTTTACTT TCACCAGCGT TTCTGGGTGA  
4851 GCAAAAACAG GAAGGCAAAA TGCCGCAAAA AAGGGAATAA GGGCGACACG  
4901 GAAATGTTGA ATACTCATAC TCTTCCTTTT TCAATATTAT TGAAGCATTT  
4951 ATCAGGGTTA TTGTCTCATG AGCGGATACA TATTTGAATG TATTTAGAAA  
5001 AATAAACAAA TAGGGGTTCC GCGCACATTT CCCCGAAAAG TGCCACCTGA  
5051 CGTC 
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7.1.5 Contactin 5 insert sequence 
   1 ATGGCTTCC TCTTGGAAAC TAATGCTGTT TCTGTCAGTC ACCATGTGTC  
  51 TTTCAGAGTA TTCAAAATCT CTTCCTGGTC TCTCCACTTC ATATGCTGCT  
 101 TTGTTAAGAA TTAAGAAGAG TTCATCTTCA TCTCTCTTTG GTTCCAAAAC  
 151 CAGACCACGA TACAGCAGCC CTTCATTAGG AACACTGAGT GCTTCTTCAC  
 201 CCAGCTGGCT AGGGGCAGCT CAGAATTATT ATTCCCCCAT CAATCTTTAT  
 251 CATTCCTCAG ATGCCTTCAA ACAAGATGAA AGTGTGGACT ATGGGCCAGT  
 301 TTTTGTGCAA GAACCAGATG ATATTATTTT TCCAACTGAT TCTGATGAAA  
 351 AGAAGGTAGC ATTGAATTGT GAAGTTCGTG GCAATCCAGT TCCCAGTTAC  
 401 AGATGGCTTC GAAATGGAAC AGAAATAGAT CTGGAAAGTG ATTATCGCTA  
 451 CAGTTTGATA GATGGCACCT TCATTATAAG CAATCCAAGT GAAGCAAAGG  
 501 ATTCTGGTCA TTATCAGTGT TTAGCAACCA ACACTGTGGG GAGTATTCTT  
 551 AGTAGAGAAG CTACACTGCA GTTTGCCTAT CTGGGAAATT TTAGTGGCCG  
 601 GACAAGAAGT GCAGTCTCTG TGAGGGAAGG CCAGGGTGTC GTTCTGATGT  
 651 GCTCTCCTCC GCCACATTCA CCAGAGATCA TCTATAGCTG GGTATTTAAT  
 701 GAGTTCCCTT CCTTTGTGGC GGAAGACAGC CGGCGGTTCA TCTCCCAGGA  
 751 GACAGGCAAC CTTTATATTT CTAAAGTCCA AACATCAGAT GTTGGCAGCT  
 801 ATATTTGTCT GGTGAAAAAC ACAGTGACGA ATGCTAGAGT CCTTAGTCCT  
 851 CCAACGCCAC TCACTCTGCG TAATGATGGT GTGATGGGAG AATATGAGCC  
 901 GAAAATTGAG GTCCATTTTC CTTTCACGGT TACAGCTGCT AAAGGAACAA  
 951 CTGTTAAGAT GGAATGCTTT GCACTTGGCA ACCCCGTTCC AACAATCACA  
1001 TGGATGAAGG TTAATGGTTA TATTCCTAGT AAGGCACGTC TGCGGAAATC  
1051 TCAGGCGGTG CTGGAAATAC CGAATGTACA GCTGGATGAT GCAGGCATTT  
1101 ATGAGTGCAG AGCTGAAAAC TCACGTGGAA AAAATTCCTT TCGTGGACAA  
1151 TTACAAGTAT ACACCTACCC ACACTGGGTA GAAAAACTGA ATGATACTCA  
1201 GTTAGACAGT GGGAGCCCTC TCCGATGGGA ATGTAAGGCT ACTGGAAAAC  
1251 CCAGACCCAC GTATCGTTGG CTGAAGAATG GAGTACCCCT CTCACCTCAG  
1301 AGTAGGGTTG AGATGGTTAA TGGAGTATTG ATGATCCACA ATGTGAATCA  
1351 ATCAGATGCT GGAATGTATC AGTGTTTGGC TGAAAATAAG TATGGAGCCA  
1401 TTTACGCTAG TGCTGAGCTG AAGATTCTAG CTTCAGCTCC CACTTTTGCA  
1451 CTGAATCAAC TGAAGAAAAC AATAATTGTT ACCAAAGACC AAGAAGTTGT  
1501 CATAGAGTGC AAACCCCAAG GCTCTCCAAA ACCAACCATC TCTTGGAAGA  
1551 AAGGAGACAG AGCAGTTAGA GAAAACAAAA GAATAGCTAT TCTTCCAGAC  
1601 GGGAGTCTAC GGATCCTAAA TGCTTCCAAA TCAGACGAGG GAAAGTACGT  
1651 TTGCCGAGGG GAAAACGTCT TTGGTTCTGC TGAAATTATA GCTTCGCTAT  
1701 CTGTAAAAGA ACCTACAAGG ATAGAACTTA CTCCTAAAAG AACAGAATTG  
1751 ACAGTGGGAG AAAGCATTGT CCTTAATTGC AAAGCAATTC ACGATGCTAG  
1801 TTTGGATGTC ACTTTCTACT GGACTCTGAA AGGACAGCCT ATTGATTTCG  
1851 AGGAAGAGGG TGGACATTTT GAAAGCATCA GGGCCCAAGC ATCCTCTGCA  
1901 GATTTAATGA TCAGGAACAT CCTTCTGATG CATGCTGGGA GATATGGCTG  
1951 CAGGGTACAG ACCACAGCAG ACAGTGTGTC AGATGAGGCA GAACTTCTTG  
2001 TTAGGGGACC CCCAGGCCCA CCTGGGATAG TAATTGTTGA GGAAATAACC  
2051 GAAAGTACGG CCACACTGTC CTGGAGCCCA GCAGCTGACA ACCACAGCCC  
2101 AATCTCCTCC TACAACCTTC AAGCTCGCAG CCCATTTTCC CTGGGCTGGC  
2151 AAACAGTAAA GACAGTCCCA GAAATCATAA CAGGGGACAT GGAGTCAGCC  
2201 ATGGCTGTGG ACCTAAATCC CTGGGTGGAA TATGAATTTC GAGTGGTAGC  
2251 CACCAACCCT ATTGGGACAG GAGATCCAAG CACCCCATCT CGAATGATCC  
2301 GCACAAATGA AGCAGTTCCG AAGACAGCAC CCACCAATGT AAGCGGAAGA  
2351 AGTGGAAGAA GGCATGAGTT AGTCATTGCC TGGGAGCCAG TATCTGAAGA  
2401 GTTTCAGAAT GGGGAAGGCT TCGGCTATAT TGTGGCTTTC AGACCCAATG  
2451 GAACACGTGG CTGGAAGGAA AAAATGGTGA CATCCTCTGA AGCTTCCAAA  
2501 TTCATTTATC GAGATGAAAG TGTCCCTCCT CTTACTCCCT TTGAAGTGAA  
2551 AGTTGGCGTT TATAACAATA AAGGAGATGG GCCTTTTAGT CAAATTGTGG  
2601 TCATCTGTTC AGCTGAAGGA GAACCCAGTG CTGCTCCCAC AGATGTCAAG  
2651 GCGACAAGTG TGTCTGTGTC AGAGATTCTT GTTGCATGGA AACACATTAA  
2701 AGAGAGTCTA GGAAGACCAC AGGGATTTGA GGTTGGTTAC TGGAAAGACA  
2751 TGGAACAGGA AGATACAGCA GAAACAGTCA AAACTAGAGG GAATGAGTCT  
2801 TTCGTCATCC TAACAGGATT AGAAGGAAAT ACGTTATATC ACTTCACAGT  
2851 GAGGGCTTAC AATGGAGCTG GATATGGGCC ACCTAGCAGT GAAGTGAGTG  
2901 CAACCACCAA GAAATCCCCT CCTAGTCAAG CACCTAGCAA CCTCAGGTGG  
2951 GAGCAGCAAG GCTCTCAGGT TTCTCTGGGC TGGGAACCCG TCATACCATT  
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3001 AGCCAACGAA TCTGAAGTTG TGGGTTACAA GGTTTTTTAT AGGCAAGAGG  
3051 GTCACAGCAA CAGCCAAGTT ATTGAAACAC AGAAACTTCA AGCAGTAGTA  
3101 CCACTCCCAG ATGCTGGAGT CTATATTATT GAAGTTCGAG CATATAGTGA  
3151 AGGAGGAGAT GGAACAGCTA GTTCTCAAAT TAGGGTACCA TCATATTCAG  
3201 GTGGAAAAAT CACAAGTGCA CAGTCGACCC TTCACACTCT CTCCACATCT  
3251 TCGTCATCAG TCACCTTGCT CTTGGCATTG ATGATTCCTT CAACTTCCTG  
3301 GTGA 
 
7.1.6 pIRESneo-CNTN5 (pIRESneo with a CNTN5 insert) 
   1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC  
  51 TGCTCTGATG CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT  
 101 GGAGGTCGCT GAGTAGTGCG CGAGCAAAAT TTAAGCTACA ACAAGGCAAG  
 151 GCTTGACCGA CAATTGCATG AAGAATCTGC TTAGGGTTAG GCGTTTTGCG  
 201 CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT GATTATTGAC  
 251 TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA  
 301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG  
 351 CCCAACGACC CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT  
 401 AACGCCAATA GGGACTTTCC ATTGACGTCA ATGGGTGGAC TATTTACGGT  
 451 AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC  
 501 CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA  
 551 CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA  
 601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA  
 651 TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA  
 701 TGGGAGTTTG TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA  
 751 ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG  
 801 GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG  
 851 GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTTGGTACC  
 901 GAGCTCGGAT CGATATCTGC GGCCGCATGG CTTCCTCTTG GAAACTAATG  
 951 CTGTTTCTGT CAGTCACCAT GTGTCTTTCA GAGTATTCAA AATCTCTTCC  
1001 TGGTCTCTCC ACTTCATATG CTGCTTTGTT AAGAATTAAG AAGAGTTCAT  
1051 CTTCATCTCT CTTTGGTTCC AAAACCAGAC CACGATACAG CAGCCCTTCA  
1101 TTAGGAACAC TGAGTGCTTC TTCACCCAGC TGGCTAGGGG CAGCTCAGAA  
1151 TTATTATTCC CCCATCAATC TTTATCATTC CTCAGATGCC TTCAAACAAG  
1201 ATGAAAGTGT GGACTATGGG CCAGTTTTTG TGCAAGAACC AGATGATATT  
1251 ATTTTTCCAA CTGATTCTGA TGAAAAGAAG GTAGCATTGA ATTGTGAAGT  
1301 TCGTGGCAAT CCAGTTCCCA GTTACAGATG GCTTCGAAAT GGAACAGAAA  
1351 TAGATCTGGA AAGTGATTAT CGCTACAGTT TGATAGATGG CACCTTCATT  
1401 ATAAGCAATC CAAGTGAAGC AAAGGATTCT GGTCATTATC AGTGTTTAGC  
1451 AACCAACACT GTGGGGAGTA TTCTTAGTAG AGAAGCTACA CTGCAGTTTG  
1501 CCTATCTGGG AAATTTTAGT GGCCGGACAA GAAGTGCAGT CTCTGTGAGG  
1551 GAAGGCCAGG GTGTCGTTCT GATGTGCTCT CCTCCGCCAC ATTCACCAGA  
1601 GATCATCTAT AGCTGGGTAT TTAATGAGTT CCCTTCCTTT GTGGCGGAAG  
1651 ACAGCCGGCG GTTCATCTCC CAGGAGACAG GCAACCTTTA TATTTCTAAA  
1701 GTCCAAACAT CAGATGTTGG CAGCTATATT TGTCTGGTGA AAAACACAGT  
1751 GACGAATGCT AGAGTCCTTA GTCCTCCAAC GCCACTCACT CTGCGTAATG  
1801 ATGGTGTGAT GGGAGAATAT GAGCCGAAAA TTGAGGTCCA TTTTCCTTTC  
1851 ACGGTTACAG CTGCTAAAGG AACAACTGTT AAGATGGAAT GCTTTGCACT  
1901 TGGCAACCCC GTTCCAACAA TCACATGGAT GAAGGTTAAT GGTTATATTC  
1951 CTAGTAAGGC ACGTCTGCGG AAATCTCAGG CGGTGCTGGA AATACCGAAT  
2001 GTACAGCTGG ATGATGCAGG CATTTATGAG TGCAGAGCTG AAAACTCACG  
2051 TGGAAAAAAT TCCTTTCGTG GACAATTACA AGTATACACC TACCCACACT  
2101 GGGTAGAAAA ACTGAATGAT ACTCAGTTAG ACAGTGGGAG CCCTCTCCGA  
2151 TGGGAATGTA AGGCTACTGG AAAACCCAGA CCCACGTATC GTTGGCTGAA  
2201 GAATGGAGTA CCCCTCTCAC CTCAGAGTAG GGTTGAGATG GTTAATGGAG  
2251 TATTGATGAT CCACAATGTG AATCAATCAG ATGCTGGAAT GTATCAGTGT  
2301 TTGGCTGAAA ATAAGTATGG AGCCATTTAC GCTAGTGCTG AGCTGAAGAT  
2351 TCTAGCTTCA GCTCCCACTT TTGCACTGAA TCAACTGAAG AAAACAATAA  
2401 TTGTTACCAA AGACCAAGAA GTTGTCATAG AGTGCAAACC CCAAGGCTCT  
2451 CCAAAACCAA CCATCTCTTG GAAGAAAGGA GACAGAGCAG TTAGAGAAAA  
2501 CAAAAGAATA GCTATTCTTC CAGACGGGAG TCTACGGATC CTAAATGCTT  
2551 CCAAATCAGA CGAGGGAAAG TACGTTTGCC GAGGGGAAAA CGTCTTTGGT  
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2601 TCTGCTGAAA TTATAGCTTC GCTATCTGTA AAAGAACCTA CAAGGATAGA  
2651 ACTTACTCCT AAAAGAACAG AATTGACAGT GGGAGAAAGC ATTGTCCTTA  
2701 ATTGCAAAGC AATTCACGAT GCTAGTTTGG ATGTCACTTT CTACTGGACT  
2751 CTGAAAGGAC AGCCTATTGA TTTCGAGGAA GAGGGTGGAC ATTTTGAAAG  
2801 CATCAGGGCC CAAGCATCCT CTGCAGATTT AATGATCAGG AACATCCTTC  
2851 TGATGCATGC TGGGAGATAT GGCTGCAGGG TACAGACCAC AGCAGACAGT  
2901 GTGTCAGATG AGGCAGAACT TCTTGTTAGG GGACCCCCAG GCCCACCTGG  
2951 GATAGTAATT GTTGAGGAAA TAACCGAAAG TACGGCCACA CTGTCCTGGA  
3001 GCCCAGCAGC TGACAACCAC AGCCCAATCT CCTCCTACAA CCTTCAAGCT  
3051 CGCAGCCCAT TTTCCCTGGG CTGGCAAACA GTAAAGACAG TCCCAGAAAT  
3101 CATAACAGGG GACATGGAGT CAGCCATGGC TGTGGACCTA AATCCCTGGG  
3151 TGGAATATGA ATTTCGAGTG GTAGCCACCA ACCCTATTGG GACAGGAGAT  
3201 CCAAGCACCC CATCTCGAAT GATCCGCACA AATGAAGCAG TTCCGAAGAC  
3251 AGCACCCACC AATGTAAGCG GAAGAAGTGG AAGAAGGCAT GAGTTAGTCA  
3301 TTGCCTGGGA GCCAGTATCT GAAGAGTTTC AGAATGGGGA AGGCTTCGGC  
3351 TATATTGTGG CTTTCAGACC CAATGGAACA CGTGGCTGGA AGGAAAAAAT  
3401 GGTGACATCC TCTGAAGCTT CCAAATTCAT TTATCGAGAT GAAAGTGTCC  
3451 CTCCTCTTAC TCCCTTTGAA GTGAAAGTTG GCGTTTATAA CAATAAAGGA  
3501 GATGGGCCTT TTAGTCAAAT TGTGGTCATC TGTTCAGCTG AAGGAGAACC  
3551 CAGTGCTGCT CCCACAGATG TCAAGGCGAC AAGTGTGTCT GTGTCAGAGA  
3601 TTCTTGTTGC ATGGAAACAC ATTAAAGAGA GTCTAGGAAG ACCACAGGGA  
3651 TTTGAGGTTG GTTACTGGAA AGACATGGAA CAGGAAGATA CAGCAGAAAC  
3701 AGTCAAAACT AGAGGGAATG AGTCTTTCGT CATCCTAACA GGATTAGAAG  
3751 GAAATACGTT ATATCACTTC ACAGTGAGGG CTTACAATGG AGCTGGATAT  
3801 GGGCCACCTA GCAGTGAAGT GAGTGCAACC ACCAAGAAAT CCCCTCCTAG  
3851 TCAAGCACCT AGCAACCTCA GGTGGGAGCA GCAAGGCTCT CAGGTTTCTC  
3901 TGGGCTGGGA ACCCGTCATA CCATTAGCCA ACGAATCTGA AGTTGTGGGT  
3951 TACAAGGTTT TTTATAGGCA AGAGGGTCAC AGCAACAGCC AAGTTATTGA  
4001 AACACAGAAA CTTCAAGCAG TAGTACCACT CCCAGATGCT GGAGTCTATA  
4051 TTATTGAAGT TCGAGCATAT AGTGAAGGAG GAGATGGAAC AGCTAGTTCT  
4101 CAAATTAGGG TACCATCATA TTCAGGTGGA AAAATCACAA GTGCACAGTC  
4151 GACCCTTCAC ACTCTCTCCA CATCTTCGTC ATCAGTCACC TTGCTCTTGG  
4201 CATTGATGAT TCCTTCAACT TCCTGGTGAA ATTCAGTGGA TCCACTAGTA  
4251 ACGGCCGCCA GTGTGCTGGA ATTAATTCGC TGTCTGCGAG GGCCAGCTGT  
4301 TGGGGTGAGT ACTCCCTCTC AAAAGCGGGC ATGACTTCTG CGCTAAGATT  
4351 GTCAGTTTCC AAAAACGAGG AGGATTTGAT ATTCACCTGG CCCGCGGTGA  
4401 TGCCTTTGAG GGTGGCCGCG TCCATCTGGT CAGAAAAGAC AATCTTTTTG  
4451 TTGTCAAGCT TGAGGTGTGG CAGGCTTGAG ATCTGGCCAT ACACTTGAGT  
4501 GACAATGACA TCCACTTTGC CTTTCTCTCC ACAGGTGTCC ACTCCCAGGT  
4551 CCAACTGCAG GTCGAGCATG CATCTAGGGC GGCCAATTCC GCCCCTCTCC  
4601 CTCCCCCCCC CCTAACGTTA CTGGCCGAAG CCGCTTGGAA TAAGGCCGGT  
4651 GTGCGTTTGT CTATATGTGA TTTTCCACCA TATTGCCGTC TTTTGGCAAT  
4701 GTGAGGGCCC GGAAACCTGG CCCTGTCTTC TTGACGAGCA TTCCTAGGGG  
4751 TCTTTCCCCT CTCGCCAAAG GAATGCAAGG TCTGTTGAAT GTCGTGAAGG  
4801 AAGCAGTTCC TCTGGAAGCT TCTTGAAGAC AAACAACGTC TGTAGCGACC  
4851 CTTTGCAGGC AGCGGAACCC CCCACCTGGC GACAGGTGCC TCTGCGGCCA  
4901 AAAGCCACGT GTATAAGATA CACCTGCAAA GGCGGCACAA CCCCAGTGCC  
4951 ACGTTGTGAG TTGGATAGTT GTGGAAAGAG TCAAATGGCT CTCCTCAAGC  
5001 GTATTCAACA AGGGGCTGAA GGATGCCCAG AAGGTACCCC ATTGTATGGG  
5051 ATCTGATCTG GGGCCTCGGT GCACATGCTT TACATGTGTT TAGTCGAGGT  
5101 TAAAAAAACG TCTAGGCCCC CCGAACCACG GGGACGTGGT TTTCCTTTGA  
5151 AAAACACGAT GATAAGCTTG CCACAACCCG GGATAATTCC TGCAGCCAAT  
5201 ATGGGATCGG CCATTGAACA AGATGGATTG CACGCAGGTT CTCCGGCCGC  
5251 TTGGGTGGAG AGGCTATTCG GCTATGACTG GGCACAACAG ACAATCGGCT  
5301 GCTCTGATGC CGCCGTGTTC CGGCTGTCAG CGCAGGGGCG CCCGGTTCTT  
5351 TTTGTCAAGA CCGACCTGTC CGGTGCCCTG AATGAACTGC AGGACGAGGC  
5401 AGCGCGGCTA TCGTGGCTGG CCACGACGGG CGTTCCTTGC GCAGCTGTGC  
5451 TCGACGTTGT CACTGAAGCG GGAAGGGACT GGCTGCTATT GGGCGAAGTG  
5501 CCGGGGCAGG ATCTCCTGTC ATCTCACCTT GCTCCTGCCG AGAAAGTATC  
5551 CATCATGGCT GATGCAATGC GGCGGCTGCA TACGCTTGAT CCGGCTACCT  
5601 GCCCATTCGA CCACCAAGCG AAACATCGCA TCGAGCGAGC ACGTACTCGG  
5651 ATGGAAGCCG GTCTTGTCGA TCAGGATGAT CTGGACGAAG AGCATCAGGG  
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5701 GCTCGCGCCA GCCGAACTGT TCGCCAGGCT CAAGGCGCGC ATGCCCGACG  
5751 GCGATGATCT CGTCGTGACC CATGGCGATG CCTGCTTGCC GAATATCATG  
5801 GTGGAAAATG GCCGCTTTTC TGGATTCATC GACTGTGGCC GGCTGGGTGT  
5851 GGCGGACCGC TATCAGGACA TAGCGTTGGC TACCCGTGAT ATTGCTGAAG  
5901 AGCTTGGCGG CGAATGGGCT GACCGCTTCC TCGTGCTTTA CGGTATCGCC  
5951 GCTCCCGATT CGCAGCGCAT CGCCTTCTAT CGCCTTCTTG ACGAGTTCTT  
6001 CTGAGGGGAT CAATTCTCTA GAGCTCGCTG ATCAGCCTCG ACTGTGCCTT  
6051 CTAGTTGCCA GCCATCTGTT GTTTGCCCCT CCCCCGTGCC TTCCTTGACC  
6101 CTGGAAGGTG CCACTCCCAC TGTCCTTTCC TAATAAAATG AGGAAATTGC  
6151 ATCGCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT GGGGTGGGGC  
6201 AGGACAGCAA GGGGGAGGAT TGGGAAGACA ATAGCAGGCA TGCTGGGGAT  
6251 GCGGTGGGCT CTATGGCTTC TGAGGCGGAA AGAACCAGCT GGGGCTCGAG  
6301 TGCATTCTAG TTGTGGTTTG TCCAAACTCA TCAATGTATC TTATCATGTC  
6351 TGTATACCGT CGACCTCTAG CTAGAGCTTG GCGTAATCAT GGTCATAGCT  
6401 GTTTCCTGTG TGAAATTGTT ATCCGCTCAC AATTCCACAC AACATACGAG  
6451 CCGGAAGCAT AAAGTGTAAA GCCTGGGGTG CCTAATGAGT GAGCTAACTC  
6501 ACATTAATTG CGTTGCGCTC ACTGCCCGCT TTCCAGTCGG GAAACCTGTC  
6551 GTGCCAGCTG CATTAATGAA TCGGCCAACG CGCGGGGAGA GGCGGTTTGC  
6601 GTATTGGGCG CTCTTCCGCT TCCTCGCTCA CTGACTCGCT GCGCTCGGTC  
6651 GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC TCAAAGGCGG TAATACGGTT  
6701 ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA GCAAAAGGCC  
6751 AGCAAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT  
6801 AGGCTCCGCC CCCCTGACGA GCATCACAAA AATCGACGCT CAAGTCAGAG  
6851 GTGGCGAAAC CCGACAGGAC TATAAAGATA CCAGGCGTTT CCCCCTGGAA  
6901 GCTCCCTCGT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC CGGATACCTG  
6951 TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG CTTTCTCAAT GCTCACGCTG  
7001 TAGGTATCTC AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG GGCTGTGTGC  
7051 ACGAACCCCC CGTTCAGCCC GACCGCTGCG CCTTATCCGG TAACTATCGT  
7101 CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC  
7151 TGGTAACAGG ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT  
7201 TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGGACAGT ATTTGGTATC  
7251 TGCGCTCTGC TGAAGCCAGT TACCTTCGGA AAAAGAGTTG GTAGCTCTTG  
7301 ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC  
7351 AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT  
7401 TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT  
7451 GGTCATGAGA TTATCAAAAA GGATCTTCAC CTAGATCCTT TTAAATTAAA  
7501 AATGAAGTTT TAAATCAATC TAAAGTATAT ATGAGTAAAC TTGGTCTGAC  
7551 AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA TCTGTCTATT  
7601 TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA ACTACGATAC  
7651 GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA  
7701 CGCTCACCGG CTCCAGATTT ATCAGCAATA AACCAGCCAG CCGGAAGGGC  
7751 CGAGCGCAGA AGTGGTCCTG CAACTTTATC CGCCTCCATC CAGTCTATTA  
7801 ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC  
7851 AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT CGTCGTTTGG  
7901 TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT  
7951 CCCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT  
8001 GTCAGAAGTA AGTTGGCCGC AGTGTTATCA CTCATGGTTA TGGCAGCACT  
8051 GCATAATTCT CTTACTGTCA TGCCATCCGT AAGATGCTTT TCTGTGACTG  
8101 GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG GCGACCGAGT  
8151 TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC ATAGCAGAAC  
8201 TTTAAAAGTG CTCATCATTG GAAAACGTTC TTCGGGGCGA AAACTCTCAA  
8251 GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC  
8301 AACTGATCTT CAGCATCTTT TACTTTCACC AGCGTTTCTG GGTGAGCAAA  
8351 AACAGGAAGG CAAAATGCCG CAAAAAAGGG AATAAGGGCG ACACGGAAAT  
8401 GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG CATTTATCAG  
8451 GGTTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA  
8501 ACAAATAGGG GTTCCGCGCA CATTTCCCCG AAAAGTGCCA CCTGACGTC  
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7.1.7 Neurofascin insert sequence 
   1 ATGGCCAGGC AGCCACCGCC GCCCTGGGTC CATGCAGCCT TCCTCCTCTG  
  51 CCTCCTCAGT CTTGGCGGAG CCATCGAAAT TCCTATGGAT CCAAGCATTC  
 101 AGAATGAGCT GACGCAGCCG CCAACCATCA CCAAGCAGTC AGCGAAGGAT  
 151 CACATCGTGG ACCCCCGTGA TAACATCCTG ATTGAGTGTG AAGCAAAAGG  
 201 GAACCCTGCC CCCAGCTTCC ACTGGACACG AAACAGCAGA TTCTTCAACA  
 251 TCGCCAAGGA CCCCCGGGTG TCCATGAGGA GGAGGTCTGG GACCCTGGTG  
 301 ATTGACTTCC GCAGTGGCGG GCGGCCGGAG GAATATGAGG GGGAATATCA  
 351 GTGCTTCGCC CGCAACAAAT TTGGCACGGC CCTGTCCAAT AGGATCCGCC  
 401 TGCAGGTGTC TAAATCTCCT CTGTGGCCCA AGGAAAACCT AGACCCTGTC  
 451 GTGGTCCAAG AGGGCGCTCC TTTGACGCTC CAGTGCAACC CCCCGCCTGG  
 501 ACTTCCATCC CCGGTCATCT TCTGGATGAG CAGCTCCATG GAGCCCATCA  
 551 CCCAAGACAA ACGTGTCTCT CAGGGCCATA ACGGAGACCT ATACTTCTCC  
 601 AACGTGATGC TGCAGGACAT GCAGACCGAC TACAGTTGTA ACGCCCGCTT  
 651 CCACTTCACC CACACCATCC AGCAGAAGAA CCCTTTCACC CTCAAGGTCC  
 701 TCACCACCCG AGGAGTTGCA GAAAGAACAC CAAGCTTCAT GTATCCCCAG  
 751 GGCACCGCGA GCAGCCAGAT GGTGCTTCGT GGCATGGACC TCCTGCTGGA  
 801 ATGCATCGCC TCCGGGGTCC CAACACCAGA CATCGCATGG TACAAGAAAG  
 851 GTGGGGACCT CCCATCTGAT AAGGCCAAGT TTGAGAACTT TAATAAGGCC  
 901 CTGCGTATCA CAAATGTCTC TGAGGAAGAC TCCGGGGAGT ATTTCTGCCT  
 951 GGCCTCCAAC AAGATGGGCA GCATCCGGCA CACGATCTCG GTGAGAGTAA  
1001 AGGCTGCTCC CTACTGGCTG GACGAACCCA AGAACCTTAT TCTGGCTCCT  
1051 GGCGAGGATG GGAGACTGGT GTGTCGAGCC AATGGAAACC CCAAACCCAC  
1101 TGTCCAGTGG ATGGTGAATG GGGAACCTTT GCAATCGGCA CCACCTAACC  
1151 CAAACCGTGA GGTGGCCGGA GACACCATCA TCTTCCGGGA CACCCAGATC  
1201 AGCAGCAGGG CTGTGTACCA GTGCAACACC TCCAACGAGC ATGGCTACCT  
1251 GCTGGCCAAC GCCTTTGTCA GTGTGCTGGA TGTGCCGCCT CGGATGCTGT  
1301 CGCCCCGGAA CCAGCTCATT CGAGTGATTC TTTACAACCG GACGCGGCTG  
1351 GACTGCCCTT TCTTTGGGTC TCCCATCCCC ACACTGCGAT GGTTTAAGAA  
1401 TGGGCAAGGA AGCAACCTGG ATGGTGGCAA CTACCATGTT TATGAGAACG  
1451 GCAGTCTGGA AATTAAGATG ATCCGCAAAG AGGACCAGGG CATCTACACC  
1501 TGTGTCGCCA CCAACATCCT GGGCAAAGCT GAAAACCAAG TCCGCCTGGA  
1551 GGTCAAAGAC CCCACCAGGA TCTACCGGAT GCCCGAGGAC CAGGTGGCCA  
1601 GAAGGGGCAC CACGGTGCAG CTGGAGTGTC GGGTGAAGCA CGACCCCTCC  
1651 CTGAAACTCA CCGTCTCCTG GCTGAAGGAT GACGAGCCGC TCTATATTGG  
1701 AAACAGGATG AAGAAGGAAG ACGACTCCCT GACCATCTTT GGGGTGGCAG  
1751 AGCGGGACCA GGGCAGTTAC ACGTGTGTCG CCAGCACCGA GCTAGACCAA  
1801 GACCTGGCCA AGGCCTACCT CACCGTGCTA GCTGATCAGG CCACTCCAAC  
1851 TAACCGTTTG GCTGCCCTGC CCAAAGGACG GCCAGACCGG CCCCGGGACC  
1901 TGGAGCTGAC CGACCTGGCC GAGAGGAGCG TGCGGCTGAC CTGGATCCCC  
1951 GGGGATGCTA ACAACAGCCC CATCACAGAC TACGTCGTCC AGTTTGAAGA  
2001 AGACCAGTTC CAACCTGGGG TCTGGCATGA CCATTCCAAG TACCCCGGCA  
2051 GCGTTAACTC AGCCGTCCTC CGGCTGTCCC CGTATGTCAA CTACCAGTTC  
2101 CGTGTCATTG CCATCAACGA GGTTGGGAGC AGCCACCCCA GCCTCCCATC  
2151 CGAGCGCTAC CGAACCAGTG GAGCACCCCC CGAGTCCAAT CCTGGTGACG  
2201 TGAAGGGAGA GGGGACCAGA AAGAACAACA TGGAGATCAC GTGGACGCCC  
2251 ATGAATGCCA CCTCGGCCTT TGGCCCCAAC CTGCGCTACA TTGTCAAGTG  
2301 GAGGCGGAGA GAGACTCGAG AGGCCTGGAA CAACGTCACA GTGTGGGGCT  
2351 CTCGCTACGT GGTGGGGCAG ACCCCAGTCT ACGTGCCCTA TGAGATCCGA  
2401 GTCCAGGCTG AAAATGACTT CGGGAAGGGC CCTGAGCCAG AGTCCGTCAT  
2451 CGGTTACTCC GGAGAAGATT TACCCAGTGC CCCTAGGCGT TTCCGAGTCC  
2501 GGCAGCCCAA CCTGGAGACA ATCAACCTGG AATGGGATCA TCCTGAGCAT  
2551 CCAAATGGGA TCATGATTGG ATACACTCTC AAATATGTGG CCTTTAACGG  
2601 GACCAAAGTA GGAAAGCAGA TAGTGGAAAA CTTCTCTCCC AATCAGACCA  
2651 AGTTCACGGT GCAAAGAACG GACCCCGTGT CACGCTACCG CTTTACCCTC  
2701 AGCGCCAGGA CGCAGGTGGG CTCTGGGGAA GCCGTCACAG AGGAGTCACC  
2751 AGCACCCCCG AATGAAGCTA CTCCAACCGC AGCTCCTCCC ACATTGCCCC  
2801 CGACTACCGT GGGTGCGACG GGCGCTGTGA GCAGTACCGA TGCTACTGCC  
2851 ATTGCTGCCA CCACCGAAGC CACAACAGTC CCCATCATCC CAACTGTCGC  
2901 ACCTACCACC ATCGCCACCA CCACCACCGT CGCCACAACT ACTACAACCA  
2951 CTGCTGCCGC CACCACCACC ACGGAGAGTC CTCCCACCAC CACCTCCGGG  
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3001 ACTAAGATAC ACGAATCCGC CCCTGATGAG CAGTCCATAT GGAACGTCAC  
3051 GGTGCTCCCC AACAGTAAAT GGGCCAACAT CACCTGGAAG CACAATTTCG  
3101 GGCCCGGAAC TGACTTTGTG GTTGAGTACA TCGACAGCAA CCATACGAAA  
3151 AAAACTGTCC CAGTTAAGGC CCAGGCTCAG CCTATACAGC TGACAGACCT  
3201 CTATCCCGGG ATGACATACA CGTTGCGGGT TTATTCCCGG GACAACGAGG  
3251 GCATCAGCAG TACCGTCATC ACCTTTATGA CCAGTACAGC TTACACCAAC  
3301 AACCAAGCAG ACATCGCCAC CCAGGGCTGG TTCATTGGGC TTATGTGCGC  
3351 CATCGCCCTC CTGGTGCTGA TCCTGCTCAT CGTCTGTTTC ATCAAGAGGA  
3401 GTCGCGGCGG CAAGTACCCA GTACGAGAAA AGAAGGATGT TCCCCTTGGC  
3451 CCTGAAGACC CCAAGGAAGA GGATGGCTCA TTTGACTATA GTGATGAGGA  
3501 CAACAAGCCC CTGCAGGGCA GTCAGACATC TCTGGACGGC ACCATCAAGC  
3551 AGCAGGAGAG TGACGACAGC CTGGTGGACT ATGGCGAGGG TGGCGAGGGT  
3601 CAGTTCAATG AAGACGGCTC CTTCATCGGC CAGTACACGG TCAAAAAGGA  
3651 CAAGGAGGAA ACAGAGGGCA ACGAAAGCTC AGAGGCCACG TCACCTGTCA  
3701 ATGCTATCTA CTCTCTGGCC TAA 
 
7.1.8 pIRESneo-NF186 (pIRESneo with a neurofascin 186 insert) 
   1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC  
  51 TGCTCTGATG CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT  
 101 GGAGGTCGCT GAGTAGTGCG CGAGCAAAAT TTAAGCTACA ACAAGGCAAG  
 151 GCTTGACCGA CAATTGCATG AAGAATCTGC TTAGGGTTAG GCGTTTTGCG  
 201 CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT GATTATTGAC  
 251 TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA  
 301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG  
 351 CCCAACGACC CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT  
 401 AACGCCAATA GGGACTTTCC ATTGACGTCA ATGGGTGGAC TATTTACGGT  
 451 AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC  
 501 CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA  
 551 CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA  
 601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA  
 651 TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA  
 701 TGGGAGTTTG TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA  
 751 ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG  
 801 GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG  
 851 GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTTGGTACC  
 901 GAGCTCGGAT CGATATCTGC GGCCGCATGG CCAGGCAGCC ACCGCCGCCC  
 951 TGGGTCCATG CAGCCTTCCC CTCTGCCTCC TCAGTCTTGG CGGAGCCATC  
1001 GAAATTCCTA TGGATCCAAG CATTCAGAAT GAGCTGACGC AGCCGCCAAC  
1051 CATCACCAAG CAGTCAGCGA AGGATCACAT CGTGGACCCC CGTGATAACA  
1101 TCCTGATTGA GTGTGAAGCA AAAGGGAACC CTGCCCCCAG CTTCCACTGG  
1151 ACACGAAACA GCAGATTCTT CAACATCGCC AAGGACCCCC GGGTGTCCAT  
1201 GAGGAGGAGG TCTGGGACCC TGGTGATTGA CTTCCGCAGT GGCGGGCGGC  
1251 CGGAGGAATA TGAGGGGGAA TATCAGTGCT TCGCCCGCAA CAAATTTGGC  
1301 ACGGCCCTGT CCAATAGGAT CCGCCTGCAG GTGTCTAAAT CTCCTCTGTG  
1351 GCCCAAGGAA AACCTAGACC CTGTCGTGGT CCAAGAGGGC GCTCCTTTGA  
1401 CGCTCCAGTG CAACCCCCCG CCTGGACTTC CATCCCCGGT CATCTTCTGG  
1451 ATGAGCAGCT CCATGGAGCC CATCACCCAA GACAAACGTG TCTCTCAGGG  
1501 CCATAACGGA GACCTATACT TCTCCAACGT GATGCTGCAG GACATGCAGA  
1551 CCGACTACAG TTGTAACGCC CGCTTCCACT TCACCCACAC CATCCAGCAG  
1601 AAGAACCCTT TCACCCTCAA GGTCCTCACC ACCCGAGGAG TTGCAGAAAG  
1651 AACACCAAGC TTCATGTATC CCCAGGGCAC CGCGAGCAGC CAGATGGTGC  
1701 TTCGTGGCAT GGACCTCCTG CTGGAATGCA TCGCCTCCGG GGTCCCAACA  
1751 CCAGACATCG CATGGTACAA GAAAGGTGGG GACCTCCCAT CTGATAAGGC  
1801 CAAGTTTGAG AACTTTAATA AGGCCCTGCG TATCACAAAT GTCTCTGAGG  
1851 AAGACTCCGG GGAGTATTTC TGCCTGGCCT CCAACAAGAT GGGCAGCATC  
1901 CGGCACACGA TCTCGGTGAG AGTAAAGGCT GCTCCCTACT GGCTGGACGA  
1951 ACCCAAGAAC CTTATTCTGG CTCCTGGCGA GGATGGGAGA CTGGTGTGTC  
2001 GAGCCAATGG AAACCCCAAA CCCACTGTCC AGTGGATGGT GAATGGGGAA  
2051 CCTTTGCAAT CGGCACCACC TAACCCAAAC CGTGAGGTGG CCGGAGACAC  
2101 CATCATCTTC CGGGACACCC AGATCAGCAG CAGGGCTGTG TACCAGTGCA  
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2151 ACACCTCCAA CGAGCATGGC TACCTGCTGG CCAACGCCTT TGTCAGTGTG  
2201 CTGGATGTGC CGCCTCGGAT GCTGTCGCCC CGGAACCAGC TCATTCGAGT  
2251 GATTCTTTAC AACCGGACGC GGCTGGACTG CCCTTTCTTT GGGTCTCCCA  
2301 TCCCCACACT GCGATGGTTT AAGAATGGGC AAGGAAGCAA CCTGGATGGT  
2351 GGCAACTACC ATGTTTATGA GAACGGCAGT CTGGAAATTA AGATGATCCG  
2401 CAAAGAGGAC CAGGGCATCT ACACCTGTGT CGCCACCAAC ATCCTGGGCA  
2451 AAGCTGAAAA CCAAGTCCGC CTGGAGGTCA AAGACCCCAC CAGGATCTAC  
2501 CGGATGCCCG AGGACCAGGT GGCCAGAAGG GGCACCACGG TGCAGCTGGA  
2551 GTGTCGGGTG AAGCACGACC CCTCCCTGAA ACTCACCGTC TCCTGGCTGA  
2601 AGGATGACGA GCCGCTCTAT ATTGGAAACA GGATGAAGAA GGAAGACGAC  
2651 TCCCTGACCA TCTTTGGGGT GGCAGAGCGG GACCAGGGCA GTTACACGTG  
2701 TGTCGCCAGC ACCGAGCTAG ACCAAGACCT GGCCAAGGCC TACCTCACCG  
2751 TGCTAGCTGA TCAGGCCACT CCAACTAACC GTTTGGCTGC CCTGCCCAAA  
2801 GGACGGCCAG ACCGGCCCCG GGACCTGGAG CTGACCGACC TGGCCGAGAG  
2851 GAGCGTGCGG CTGACCTGGA TCCCCGGGGA TGCTAACAAC AGCCCCATCA  
2901 CAGACTACGT CGTCCAGTTT GAAGAAGACC AGTTCCAACC TGGGGTCTGG  
2951 CATGACCATT CCAAGTACCC CGGCAGCGTT AACTCAGCCG TCCTCCGGCT  
3001 GTCCCCGTAT GTCAACTACC AGTTCCGTGT CATTGCCATC AACGAGGTTG  
3051 GGAGCAGCCA CCCCAGCCTC CCATCCGAGC GCTACCGAAC CAGTGGAGCA  
3101 CCCCCCGAGT CCAATCCTGG TGACGTGAAG GGAGAGGGGA CCAGAAAGAA  
3151 CAACATGGAG ATCACGTGGA CGCCCATGAA TGCCACCTCG GCCTTTGGCC  
3201 CCAACCTGCG CTACATTGTC AAGTGGAGGC GGAGAGAGAC TCGAGAGGCC  
3251 TGGAACAACG TCACAGTGTG GGGCTCTCGC TACGTGGTGG GGCAGACCCC  
3301 AGTCTACGTG CCCTATGAGA TCCGAGTCCA GGCTGAAAAT GACTTCGGGA  
3351 AGGGCCCTGA GCCAGAGTCC GTCATCGGTT ACTCCGGAGA AGATTTACCC  
3401 AGTGCCCCTA GGCGTTTCCG AGTCCGGCAG CCCAACCTGG AGACAATCAA  
3451 CCTGGAATGG GATCATCCTG AGCATCCAAA TGGGATCATG ATTGGATACA  
3501 CTCTCAAATA TGTGGCCTTT AACGGGACCA AAGTAGGAAA GCAGATAGTG  
3551 GAAAACTTCT CTCCCAATCA GACCAAGTTC ACGGTGCAAA GAACGGACCC  
3601 CGTGTCACGC TACCGCTTTA CCCTCAGCGC CAGGACGCAG GTGGGCTCTG  
2651 GGGAAGCCGT CACAGAGGAG TCACCAGCAC CCCCGAATGA AGCTACTCCA  
3701 ACCGCAGCTC CTCCCACATT GCCCCCGACT ACCGTGGGTG CGACGGGCGC  
3751 TGTGAGCAGT ACCGATGCTA CTGCCATTGC TGCCACCACC GAAGCCACAA  
3801 CAGTCCCCAT CATCCCAACT GTCGCACCTA CCACCATCGC CACCACCACC  
3851 ACCGTCGCCA CAACTACTAC AACCACTGCT GCCGCCACCA CCACCACGGA  
3901 GAGTCCTCCC ACCACCACCT CCGGGACTAA GATACACGAA TCCGCCCCTG  
3951 ATGAGCAGTC CATATGGAAC GTCACGGTGC TCCCCAACAG TAAATGGGCC  
4001 AACATCACCT GGAAGCACAA TTTCGGGCCC GGAACTGACT TTGTGGTTGA  
4051 GTACATCGAC AGCAACCATA CGAAAAAAAC TGTCCCAGTT AAGGCCCAGG  
4101 CTCAGCCTAT ACAGCTGACA GACCTCTATC CCGGGATGAC ATACACGTTG  
4151 CGGGTTTATT CCCGGGACAA CGAGGGCATC AGCAGTACCG TCATCACCTT  
4201 TATGACCAGT ACAGCTTACA CCAACAACCA AGCAGACATC GCCACCCAGG  
4251 GCTGGTTCAT TGGGCTTATG TGCGCCATCG CCCTCCTGGT GCTGATCCTG  
4301 CTCATCGTCT GTTTCATCAA GAGGAGTCGC GGCGGCAAGT ACCCAGTACG  
4351 AGAAAAGAAG GATGTTCCCC TTGGCCCTGA AGACCCCAAG GAAGAGGATG  
4401 GCTCATTTGA CTATAGTGAT GAGGACAACA AGCCCCTGCA GGGCAGTCAG  
4451 ACATCTCTGG ACGGCACCAT CAAGCAGCAG GAGAGTGACG ACAGCCTGGT  
4501 GGACTATGGC GAGGGTGGCG AGGGTCAGTT CAATGAAGAC GGCTCCTTCA  
4551 TCGGCCAGTA CACGGTCAAA AAGGACAAGG AGGAAACAGA GGGCAACGAA  
4601 AGCTCAGAGG CCACGTCACC TGTCAATGCT ATCTACTCTC TGGCCTAAGA  
4651 ATTCAGTGGA TCCACTAGTA ACGGCCGCCA GTGTGCTGGA ATTAATTCGC  
6701 TGTCTGCGAG GGCCAGCTGT TGGGGTGAGT ACTCCCTCTC AAAAGCGGGC  
4751 ATGACTTCTG CGCTAAGATT GTCAGTTTCC AAAAACGAGG AGGATTTGAT  
4801 ATTCACCTGG CCCGCGGTGA TGCCTTTGAG GGTGGCCGCG TCCATCTGGT  
4851 CAGAAAAGAC AATCTTTTTG TTGTCAAGCT TGAGGTGTGG CAGGCTTGAG  
4901 ATCTGGCCAT ACACTTGAGT GACAATGACA TCCACTTTGC CTTTCTCTCC  
4951 ACAGGTGTCC ACTCCCAGGT CCAACTGCAG GTCGAGCATG CATCTAGGGC  
5001 GGCCAATTCC GCCCCTCTCC CTCCCCCCCC CCTAACGTTA CTGGCCGAAG  
5051 CCGCTTGGAA TAAGGCCGGT GTGCGTTTGT CTATATGTGA TTTTCCACCA  
5101 TATTGCCGTC TTTTGGCAAT GTGAGGGCCC GGAAACCTGG CCCTGTCTTC  
5151 TTGACGAGCA TTCCTAGGGG TCTTTCCCCT CTCGCCAAAG GAATGCAAGG  
5201 TCTGTTGAAT GTCGTGAAGG AAGCAGTTCC TCTGGAAGCT TCTTGAAGAC  
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5251 AAACAACGTC TGTAGCGACC CTTTGCAGGC AGCGGAACCC CCCACCTGGC  
5301 GACAGGTGCC TCTGCGGCCA AAAGCCACGT GTATAAGATA CACCTGCAAA  
5351 GGCGGCACAA CCCCAGTGCC ACGTTGTGAG TTGGATAGTT GTGGAAAGAG  
5401 TCAAATGGCT CTCCTCAAGC GTATTCAACA AGGGGCTGAA GGATGCCCAG  
5451 AAGGTACCCC ATTGTATGGG ATCTGATCTG GGGCCTCGGT GCACATGCTT  
5501 TACATGTGTT TAGTCGAGGT TAAAAAAACG TCTAGGCCCC CCGAACCACG  
5551 GGGACGTGGT TTTCCTTTGA AAAACACGAT GATAAGCTTG CCACAACCCG  
5601 GGATAATTCC TGCAGCCAAT ATGGGATCGG CCATTGAACA AGATGGATTG  
5651 CACGCAGGTT CTCCGGCCGC TTGGGTGGAG AGGCTATTCG GCTATGACTG  
5701 GGCACAACAG ACAATCGGCT GCTCTGATGC CGCCGTGTTC CGGCTGTCAG  
5751 CGCAGGGGCG CCCGGTTCTT TTTGTCAAGA CCGACCTGTC CGGTGCCCTG  
5801 AATGAACTGC AGGACGAGGC AGCGCGGCTA TCGTGGCTGG CCACGACGGG  
5851 CGTTCCTTGC GCAGCTGTGC TCGACGTTGT CACTGAAGCG GGAAGGGACT  
5901 GGCTGCTATT GGGCGAAGTG CCGGGGCAGG ATCTCCTGTC ATCTCACCTT  
5951 GCTCCTGCCG AGAAAGTATC CATCATGGCT GATGCAATGC GGCGGCTGCA  
6001 TACGCTTGAT CCGGCTACCT GCCCATTCGA CCACCAAGCG AAACATCGCA  
6051 TCGAGCGAGC ACGTACTCGG ATGGAAGCCG GTCTTGTCGA TCAGGATGAT  
6101 CTGGACGAAG AGCATCAGGG GCTCGCGCCA GCCGAACTGT TCGCCAGGCT  
6151 CAAGGCGCGC ATGCCCGACG GCGATGATCT CGTCGTGACC CATGGCGATG  
6201 CCTGCTTGCC GAATATCATG GTGGAAAATG GCCGCTTTTC TGGATTCATC  
6251 GACTGTGGCC GGCTGGGTGT GGCGGACCGC TATCAGGACA TAGCGTTGGC  
6301 TACCCGTGAT ATTGCTGAAG AGCTTGGCGG CGAATGGGCT GACCGCTTCC  
6351 TCGTGCTTTA CGGTATCGCC GCTCCCGATT CGCAGCGCAT CGCCTTCTAT  
6401 CGCCTTCTTG ACGAGTTCTT CTGAGGGGAT CAATTCTCTA GAGCTCGCTG  
6451 ATCAGCCTCG ACTGTGCCTT CTAGTTGCCA GCCATCTGTT GTTTGCCCCT  
6501 CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCCAC TGTCCTTTCC  
6551 TAATAAAATG AGGAAATTGC ATCGCATTGT CTGAGTAGGT GTCATTCTAT  
6601 TCTGGGGGGT GGGGTGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA  
6651 ATAGCAGGCA TGCTGGGGAT GCGGTGGGCT CTATGGCTTC TGAGGCGGAA  
6701 AGAACCAGCT GGGGCTCGAG TGCATTCTAG TTGTGGTTTG TCCAAACTCA  
6751 TCAATGTATC TTATCATGTC TGTATACCGT CGACCTCTAG CTAGAGCTTG  
6801 GCGTAATCAT GGTCATAGCT GTTTCCTGTG TGAAATTGTT ATCCGCTCAC  
6851 AATTCCACAC AACATACGAG CCGGAAGCAT AAAGTGTAAA GCCTGGGGTG  
6901 CCTAATGAGT GAGCTAACTC ACATTAATTG CGTTGCGCTC ACTGCCCGCT  
6951 TTCCAGTCGG GAAACCTGTC GTGCCAGCTG CATTAATGAA TCGGCCAACG  
7001 CGCGGGGAGA GGCGGTTTGC GTATTGGGCG CTCTTCCGCT TCCTCGCTCA  
7051 CTGACTCGCT GCGCTCGGTC GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC  
7101 TCAAAGGCGG TAATACGGTT ATCCACAGAA TCAGGGGATA ACGCAGGAAA  
7151 GAACATGTGA GCAAAAGGCC AGCAAAAGGC CAGGAACCGT AAAAAGGCCG  
7201 CGTTGCTGGC GTTTTTCCAT AGGCTCCGCC CCCCTGACGA GCATCACAAA  
7251 AATCGACGCT CAAGTCAGAG GTGGCGAAAC CCGACAGGAC TATAAAGATA  
7301 CCAGGCGTTT CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT GTTCCGACCC  
7351 TGCCGCTTAC CGGATACCTG TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG  
7401 CTTTCTCAAT GCTCACGCTG TAGGTATCTC AGTTCGGTGT AGGTCGTTCG  
7451 CTCCAAGCTG GGCTGTGTGC ACGAACCCCC CGTTCAGCCC GACCGCTGCG  
7501 CCTTATCCGG TAACTATCGT CTTGAGTCCA ACCCGGTAAG ACACGACTTA  
7551 TCGCCACTGG CAGCAGCCAC TGGTAACAGG ATTAGCAGAG CGAGGTATGT  
7601 AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC GGCTACACTA  
7651 GAAGGACAGT ATTTGGTATC TGCGCTCTGC TGAAGCCAGT TACCTTCGGA  
7701 AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA CAAACCACCG CTGGTAGCGG  
7751 TGGTTTTTTT GTTTGCAAGC AGCAGATTAC GCGCAGAAAA AAAGGATCTC  
7801 AAGAAGATCC TTTGATCTTT TCTACGGGGT CTGACGCTCA GTGGAACGAA  
7851 AACTCACGTT AAGGGATTTT GGTCATGAGA TTATCAAAAA GGATCTTCAC  
7901 CTAGATCCTT TTAAATTAAA AATGAAGTTT TAAATCAATC TAAAGTATAT  
7951 ATGAGTAAAC TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT  
8001 ATCTCAGCGA TCTGTCTATT TCGTTCATCC ATAGTTGCCT GACTCCCCGT  
8051 CGTGTAGATA ACTACGATAC GGGAGGGCTT ACCATCTGGC CCCAGTGCTG  
8101 CAATGATACC GCGAGACCCA CGCTCACCGG CTCCAGATTT ATCAGCAATA  
8151 AACCAGCCAG CCGGAAGGGC CGAGCGCAGA AGTGGTCCTG CAACTTTATC  
8201 CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT  
8251 CGCCAGTTAA TAGTTTGCGC AACGTTGTTG CCATTGCTAC AGGCATCGTG  
8301 GTGTCACGCT CGTCGTTTGG TATGGCTTCA TTCAGCTCCG GTTCCCAACG  
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8351 ATCAAGGCGA GTTACATGAT CCCCCATGTT GTGCAAAAAA GCGGTTAGCT  
8401 CCTTCGGTCC TCCGATCGTT GTCAGAAGTA AGTTGGCCGC AGTGTTATCA  
8451 CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA TGCCATCCGT  
8501 AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT  
8551 AGTGTATGCG GCGACCGAGT TGCTCTTGCC CGGCGTCAAT ACGGGATAAT  
8601 ACCGCGCCAC ATAGCAGAAC TTTAAAAGTG CTCATCATTG GAAAACGTTC  
8651 TTCGGGGCGA AAACTCTCAA GGATCTTACC GCTGTTGAGA TCCAGTTCGA  
8701 TGTAACCCAC TCGTGCACCC AACTGATCTT CAGCATCTTT TACTTTCACC  
8751 AGCGTTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG CAAAAAAGGG  
8801 AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT  
8851 ATTATTGAAG CATTTATCAG GGTTATTGTC TCATGAGCGG ATACATATTT  
8901 GAATGTATTT AGAAAAATAA ACAAATAGGG GTTCCGCGCA CATTTCCCCG  
8951 AAAAGTGCCA CCTGACGTC  
 
7.1.9 Thy-1 insert sequence 
   1 ATGAACCTGG CCATCAGCAT CGCTCTCCTG CTAACAGTCT TGCAGGTCTC  
  51 CCGAGGGCAG AAGGTGACCA GCCTAACGGC CTGCCTAGTG GACCAGAGCC  
 101 TTCGTCTGGA CTGCCGCCAT GAGAATACCA GCAGTTCACC CATCCAGTAC  
 151 GAGTTCAGCC TGACCCGTGA GACAAAGAAG CACGTGCTCT TTGGCACTGT  
 201 GGGGGTGCCT GAGCACACAT ACCGCTCCCG AACCAACTTC ACCAGCAAAT  
 251 ACAACATGAA GGTCCTCTAC TTATCCGCCT TCACTAGCAA GGACGAGGGC  
 301 ACCTACACGT GTGCACTCCA CCACTCTGGC CATTCCCCAC CCATCTCCTC  
 351 CCAGAACGTC ACAGTGCTCA GAGACAAACT GGTCAAGTGT GAGGGCATCA  
 401 GCCTGCTGGC TCAGAACACC TCGTGGCTGC TGCTGCTCCT GCTCTCCCTC  
 451 TCCCTCCTCC AGGCCACGGA TTTCATGTCC CTGTGA 
7.1.10 pIRESneo-Thy-1 (pIRESneo with a Thy-1 insert) 
   1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTCGACTCT CAGTACAATC  
  51 TGCTCTGATG CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT  
 101 GGAGGTCGCT GAGTAGTGCG CGAGCAAAAT TTAAGCTACA ACAAGGCAAG  
 151 GCTTGACCGA CAATTGCATG AAGAATCTGC TTAGGGTTAG GCGTTTTGCG  
 201 CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT GATTATTGAC  
 251 TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA  
 301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG  
 351 CCCAACGACC CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT  
 401 AACGCCAATA GGGACTTTCC ATTGACGTCA ATGGGTGGAC TATTTACGGT  
 451 AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC  
 501 CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA  
 551 CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA  
 601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA  
 651 TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA  
 701 TGGGAGTTTG TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA  
 751 ACAACTCCGC CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG  
 801 GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG  
 851 GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTTGGTACC  
 901 GAGCTCGGAT CGATATCTGC GGCCGCATGA ACCTGGCCAT CAGCATCGCT  
 951 CTCCTGCTAA CAGTCTTGCA GGTCTCCCGA GGGCAGAAGG TGACCAGCCT  
1001 AACGGCCTGC CTAGTGGACC AGAGCCTTCG TCTGGACTGC CGCCATGAGA  
1051 ATACCAGCAG TTCACCCATC CAGTACGAGT TCAGCCTGAC CCGTGAGACA  
1101 AAGAAGCACG TGCTCTTTGG CACTGTGGGG GTGCCTGAGC ACACATACCG  
1151 CTCCCGAACC AACTTCACCA GCAAATACAA CATGAAGGTC CTCTACTTAT  
1201 CCGCCTTCAC TAGCAAGGAC GAGGGCACCT ACACGTGTGC ACTCCACCAC  
1251 TCTGGCCATT CCCCACCCAT CTCCTCCCAG AACGTCACAG TGCTCAGAGA  
1301 CAAACTGGTC AAGTGTGAGG GCATCAGCCT GCTGGCTCAG AACACCTCGT  
1351 GGCTGCTGCT GCTCCTGCTC TCCCTCTCCC TCCTCCAGGC CACGGATTTC  
1401 ATGTCCCTGT GAAATTCAGT GGATCCACTA GTAACGGCCG CCAGTGTGCT  
1451 GGAATTAATT CGCTGTCTGC GAGGGCCAGC TGTTGGGGTG AGTACTCCCT  
1501 CTCAAAAGCG GGCATGACTT CTGCGCTAAG ATTGTCAGTT TCCAAAAACG  
1551 AGGAGGATTT GATATTCACC TGGCCCGCGG TGATGCCTTT GAGGGTGGCC  
1601 GCGTCCATCT GGTCAGAAAA GACAATCTTT TTGTTGTCAA GCTTGAGGTG  
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1651 TGGCAGGCTT GAGATCTGGC CATACACTTG AGTGACAATG ACATCCACTT  
1701 TGCCTTTCTC TCCACAGGTG TCCACTCCCA GGTCCAACTG CAGGTCGAGC  
1751 ATGCATCTAG GGCGGCCAAT TCCGCCCCTC TCCCTCCCCC CCCCCTAACG  
1801 TTACTGGCCG AAGCCGCTTG GAATAAGGCC GGTGTGCGTT TGTCTATATG  
1851 TGATTTTCCA CCATATTGCC GTCTTTTGGC AATGTGAGGG CCCGGAAACC  
1901 TGGCCCTGTC TTCTTGACGA GCATTCCTAG GGGTCTTTCC CCTCTCGCCA  
1951 AAGGAATGCA AGGTCTGTTG AATGTCGTGA AGGAAGCAGT TCCTCTGGAA  
2001 GCTTCTTGAA GACAAACAAC GTCTGTAGCG ACCCTTTGCA GGCAGCGGAA  
2051 CCCCCCACCT GGCGACAGGT GCCTCTGCGG CCAAAAGCCA CGTGTATAAG  
2101 ATACACCTGC AAAGGCGGCA CAACCCCAGT GCCACGTTGT GAGTTGGATA  
2151 GTTGTGGAAA GAGTCAAATG GCTCTCCTCA AGCGTATTCA ACAAGGGGCT  
2201 GAAGGATGCC CAGAAGGTAC CCCATTGTAT GGGATCTGAT CTGGGGCCTC  
2251 GGTGCACATG CTTTACATGT GTTTAGTCGA GGTTAAAAAA ACGTCTAGGC  
2301 CCCCCGAACC ACGGGGACGT GGTTTTCCTT TGAAAAACAC GATGATAAGC  
2351 TTGCCACAAC CCGGGATAAT TCCTGCAGCC AATATGGGAT CGGCCATTGA  
2401 ACAAGATGGA TTGCACGCAG GTTCTCCGGC CGCTTGGGTG GAGAGGCTAT  
2451 TCGGCTATGA CTGGGCACAA CAGACAATCG GCTGCTCTGA TGCCGCCGTG  
2501 TTCCGGCTGT CAGCGCAGGG GCGCCCGGTT CTTTTTGTCA AGACCGACCT  
2551 GTCCGGTGCC CTGAATGAAC TGCAGGACGA GGCAGCGCGG CTATCGTGGC  
2601 TGGCCACGAC GGGCGTTCCT TGCGCAGCTG TGCTCGACGT TGTCACTGAA  
2651 GCGGGAAGGG ACTGGCTGCT ATTGGGCGAA GTGCCGGGGC AGGATCTCCT  
2701 GTCATCTCAC CTTGCTCCTG CCGAGAAAGT ATCCATCATG GCTGATGCAA  
2751 TGCGGCGGCT GCATACGCTT GATCCGGCTA CCTGCCCATT CGACCACCAA  
2801 GCGAAACATC GCATCGAGCG AGCACGTACT CGGATGGAAG CCGGTCTTGT  
2851 CGATCAGGAT GATCTGGACG AAGAGCATCA GGGGCTCGCG CCAGCCGAAC  
2901 TGTTCGCCAG GCTCAAGGCG CGCATGCCCG ACGGCGATGA TCTCGTCGTG  
2951 ACCCATGGCG ATGCCTGCTT GCCGAATATC ATGGTGGAAA ATGGCCGCTT  
3001 TTCTGGATTC ATCGACTGTG GCCGGCTGGG TGTGGCGGAC CGCTATCAGG  
3051 ACATAGCGTT GGCTACCCGT GATATTGCTG AAGAGCTTGG CGGCGAATGG  
3101 GCTGACCGCT TCCTCGTGCT TTACGGTATC GCCGCTCCCG ATTCGCAGCG  
3151 CATCGCCTTC TATCGCCTTC TTGACGAGTT CTTCTGAGGG GATCAATTCT  
3201 CTAGAGCTCG CTGATCAGCC TCGACTGTGC CTTCTAGTTG CCAGCCATCT  
3251 GTTGTTTGCC CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC  
3301 CACTGTCCTT TCCTAATAAA ATGAGGAAAT TGCATCGCAT TGTCTGAGTA  
3351 GGTGTCATTC TATTCTGGGG GGTGGGGTGG GGCAGGACAG CAAGGGGGAG  
3401 GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG GCTCTATGGC  
3451 TTCTGAGGCG GAAAGAACCA GCTGGGGCTC GAGTGCATTC TAGTTGTGGT  
3501 TTGTCCAAAC TCATCAATGT ATCTTATCAT GTCTGTATAC CGTCGACCTC  
3551 TAGCTAGAGC TTGGCGTAAT CATGGTCATA GCTGTTTCCT GTGTGAAATT  
3601 GTTATCCGCT CACAATTCCA CACAACATAC GAGCCGGAAG CATAAAGTGT  
3651 AAAGCCTGGG GTGCCTAAGA GTGAGCTAAC TCACATTAAT TGCGTTGCGC  
3701 TCACTGCCCG CTTTCCAGTC GGGAAACCTG TCGTGCCAGC TGCATTAATG  
3751 AATCGGCCAA CGCGCGGGGA GAGGCGGTTT GCGTATTGGG CGCTCTTCCG  
3801 CTTCCTCGCT CACTGACTCG CTGCGCTCGG TCGTTCGGCT GCGGCGAGCG  
3851 GTATCAGCTC ACTCAAAGGC GGTAATACGG TTATCCACAG AATCAGGGGA  
3901 TAACGCAGGA AAGAACATGT GAGCAAAAGG CCAGCAAAAG GCCAGGAACC  
3951 GTAAAAAGGC CGCGTTGCTG GCGTTTTTCC ATAGGCTCCG CCCCCCTGAC  
4001 GAGCATCACA AAAATCGACG CTCAAGTCAG AGGTGGCGAA ACCCGACAGG  
4051 ACTATAAAGA TACCAGGCGT TTCCCCCTGG AAGCTCCCTC GTGCGCTCTC  
4101 CTGTTCCGAC CCTGCCGCTT ACCGGATACC TGTCCGCCTT TCTCCCTTCG  
4151 GGAAGCGTGG CGCTTTCTCA ATGCTCACGC TGTAGGTATC TCAGTTCGGT  
4201 GTAGGTCGTT CGCTCCAAGC TGGGCTGTGT GCACGAACCC CCCGTTCAGC  
4251 CCGACCGCTG CGCCTTATCC GGTAACTATC GTCTTGAGTC CAACCCGGTA  
4301 AGACACGACT TATCGCCACT GGCAGCAGCC ACTGGTAACA GGATTAGCAG  
4351 AGCGAGGTAT GTAGGCGGTG CTACAGAGTT CTTGAAGTGG TGGCCTAACT  
4401 ACGGCTACAC TAGAAGGCAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG  
4451 TTACCTTCGG AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC  
4501 GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG CAGCAGATTA CGCGCAGAAA  
4551 AAAAGGATCT CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC  
4601 AGTGGAACGA AAACTCACGT TAAGGGATTT TGGTCATGAG ATTATCAAAA  
4651 AGGATCTTCA CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT  
4701 CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA  
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4751 GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC  
4801 TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG  
4851 CCCCAGTGCT GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT  
4901 TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT  
4951 GCAACTTTAT CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAGCTAG  
5001 AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG CAACGTTGTT GCCATTGCTA  
5051 CAGGCATCGT GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC  
5101 GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCCATGT TGTGCAAAAA  
5151 AGCGGTTAGC TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG  
5201 CAGTGTTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC TCTTACTGTC  
5251 ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC  
5301 ATTCTGAGAA TAGTGTATGC GGCGACCGAG TTGCTCTTGC CCGGCGTCAA  
5351 TACGGGATAA TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT  
5401 GGAAAACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG  
5451 ATCCAGTTCG ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT  
5501 TTACTTTCAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC  
5551 GCAAAAAAGG GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT  
5601 CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG  
5651 GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCCGCGC  
5701 ACATTTCCCC GAAAAGTGCC ACCTGACGTC 
 
